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Abstract
The single-humped Arabian camel (Camelus dromedarius) thrives in the hot
arid Arabian desert. Many unique adaptations permit it to accomplish this. Camel
erythrocytes or red blood cells (RBCs) have a peculiar elliptical shape and are
amenable to large variations in physical conditions resulting from dehydration and
rehydration cycles. The oxygen transport protein hemoglobin is found abundantly in
RBCs and is also believed to behave differently in camels. While several
physiological and biochemical studies have been performed on camel hemoglobin,
very little is known about genetic and structural adaptions in this protein. The camel
genome harbors several unique variations which are being investigated for the
treatment of several disorders such as diabetes, cancer, and hepatitis. In this study,
several

aspects

of

camel

hemoglobin

were

investigated

from

genetic,

pharmacological and molecular modeling perspectives. Genetic analysis of camel
hemoglobin revealed that camels harbor a unique variation in the region of
hemoglobin that harbors a peptide called hemorphin. Hemorphins are endogenous
bioactive peptides produced during proteolytic cleavage of hemoglobin and are
highly conserved among mammals. Several therapeutic properties of mammalian
hemorphins have been reported. However, their precise molecular binding behavior
remain elusive. This study extensively investigated the binding behavior and
pharmacologic effects of human and camel hemorphins, with angiotensin-converting
enzyme (ACE), mu-opioid receptor (MOR), and insulin-regulated aminopeptidase
(IRAP) receptor using in silico and in vitro approaches. Camel hemorphins produced
more potent activity, better binding affinity, and more stable interactions with critical
residues of ACE, MOR and IRAP receptors when compared to human hemorphins.
This study also identified, for the first time, a G protein-coupled receptor angiotensin
II type 1 receptor (AT1R) that is a target of hemorphins. In silico and in vitro data
demonstrated that LVV-hemorphin-7 binds to the intracellular side of AT1R and
allosterically potentiated the potency of AngII as well as its downstream signaling.
Lastly, 1000 nanosecond (ns) comparative molecular dynamics (MD) simulations
were performed using camel and human hemoglobin protein structures to see how
these molecules differ in varying conditions of osmolarity and temperature. Camel

viii
hemoglobin demonstrated limited fluctuations, especially near the heme binding
regions at higher salt and temperature conditions, compared to human hemoglobin.
Additionally, the binding pose, energetics and interaction stability of oxygen-affinity
determining

energy

molecules,

adenosine

triphosphate

(ATP)

and

2,3-

bisphosphoglycerate (2,3-BPG) were determined in silico. 2,3-BPG is abundantly
present in erythrocytes and plays a significant role in the unloading of oxygen
molecules in peripheral tissues, compared to ATP. In simulations, 2,3-BPG formed
more stable interactions with camel hemoglobin at severe dehydrated conditions
compared to human hemoglobin. In summary, this study provides insights into the
overall stability of camel hemoglobin as well as the binding behavior of ATP and
2,3-BPG at different dehydrated conditions, along with pharmacological and
therapeutic activity of the hemoglobin derived hemorphin peptides.

Keywords: Camel, Hemoglobin, Hemorphins, Molecular docking, Molecular
dynamics, Molecular biological techniques.
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)Title and Abstract (in Arabic

تقيم اإلختالفات الجينية والبنائية في بروتين الهيموجلوبين المستخلص من الجمال
الملخص

ينمو الجمل العربي وحيد السنام ( )Camelus dromedariusفي الصحراء العربية القاحلة
الحارة حيث يتميز بالعديد من الخصائص الفريدة التي تسمح لهم بالعيش في ظل هذه الظروف
المناخية القاهرة .خاليا الدم الحمراء لهذا الجمل أو كريات الدم الحمراء لها شكل بيضاوي فريد
وهي قابلة للتغيرات الكبيرة في ظل الظروف الفيزيائية الناتجة عن دورات الجفاف ودورات
معالجة الجفاف .وتم العثور على بروتين الهيموجلوبين الناقل األساسي لألكسجين في كريات
ضا أنه يعمل بطريقة مختلفة في اإلبل .في حين أنه تم إجراء العديد من
الدم الحمراء ويعتقد أي ً
الدراسات الفسيولوجية والكيميائية الحيوية على بروتين الهيموجلوبين في اإلبل ،إلى اآلن ال
يُعرف سوى القليل جدًا عن التكيفات الوراثية والهيكلية في هذا البروتين .تحتوي المعلومات
الجينية في اإلبل على العديد من االختالفات المميزة التي يتم دراستها لعالج العديد من
األمراض.
في هذه الدراسة ،تم دراسة الهيموجلوبين في اإلبل من جوانب مختلفة كالنمذجة الوراثية
والدوائية والجزيئية .أظهر التحليل الجيني للهيموجلوبين في اإلبل أنه يحتوي على اختالف فريد
في منطقة الهيموجلوبين وبالتحديد في ببتيد يسمى الهيمورفين .الهيمورفين هوعبارة عن ببتيدات
نشطة بيولوجيًا يتم إنتاجها أثناء االنقسام البروتيني للهيموجلوبين وهي موجودة بشكل متشابه في
جميع الثدييات كما تم التأكد من العديد من الخصائص العالجية للهيمورفين في الثدييات .ومع
ذلك ،فإن ترابط بيبتيد الهيمورفين الجزئي مبهما إلى اآلن.
توصلت هذه الدراسة إلى نتائج تخص التأثيرات العالجية و سلوك الترابط الجزئي لببتيد
الهيمورفين في األبل والبشر ،وارتباطه مع إنزيم المحول لألنجيوتنسين ( ،)ACEومستقبالت
ميو أفيونيد ( ،)MORومستقبالت أمينوببتيداز ( )IRAPالتي ينظمها األنسولين ()IRAP
باستخدام تقنيات مختبرية ( )in vitroو تقنيات معلوماتيه حيوية ( .)in silicoومن المثير
لالهتمام أن الهيمورفين في اإلبل أظهر نشا ً
طا أكثر فاعلية ،وارتباط أفضل تماسكا ،وتفاعالت
أكثر ثباتًا مع مستقبالت  ACEو  MORو  IRAPعند مقارنتها بالهيمورفين البشري .كما
ضا ،وألول مرة ،مستقبالت األنجيوتنسين  2من النوع األول ()AT1R
حددت هذه الدراسة أي ً

x

المقترنة ببروتين  Gوالتي تستهدف الهيمورفين .أظهرت البيانات باستخدام تقنيات مختبرية ( in
 )vitroو تقنيات معلوماتيه حيوية ( )in silicoأن  LVV-hemorphin-7يرتبط بالجانب
أخيرا ،تم إجراء محاكاة
الداخلي من  AT1Rويقوي فاعلية اإلشارات الحيوية ل .AngII
ً
 1000نانوثانية للحركة الجزيئية ( )MDباستخدام هياكل بروتين الهيموجلوبين البشري واإلبل
لمعرفة كيفية إختالف هذه الجزيئات في ظروف مختلفة من األسموزية ودرجة الحرارة.
ومن المثير لالهتمام ،أن الهيموجلوبين في اإلبل أظهر تقلبات محدودة ،خاصة بالقرب من
مناطق ارتباط الحديد في ظروف ارتفاع الملح ودرجة الحرارة ،مقارنة بالهيموجلوبين البشري.
عالوة على ذلك  ،تم تحديد شكل االرتباط  ،وتقارب االرتباط ،واستقرار تفاعل جزيئات الطاقة
التي تحدد تقارب األكسجين  ،وثالثي فوسفات األدينوزين ( )ATPو -3،2بيسفوسفوجليسيرات
( )BPG-3،2باستخدام التقنيات المعلوماتيه الحيوية .وفي نموذج المحاكاة ،أظهر BPG-3،2
تفاعالت مستقرة مع هيموجلوبين األبل في ظل الظروف الجافة مقارنتا بالهيموجلوبين البشري.
وفي الختام  ،هذا البحث تحقق من استقرارية بروتين الهيموجلوبين في األبل ،إضافة الى سلوك
ارتباطه مع ال  ATPو  BPG-3،2في حاالت الجفاف المختلفة ،إلى جانب النشاط الدوائي

والعالجي لببتيدات الهيمورفين المشتقة من الهيموجلوبين.

مفاهيم البحث الرئيسية :األبل ،الهيموجلوبين ،اإلرتباط الجزئي ،الحركة الجزئية ،الدراسات
الجزئية الحيوية.

xi

Acknowledgements
I would like to extend thanks to the many people, who so generously
contributed to the work presented in this dissertation.
Special mention goes to my enthusiastic supervisor Dr Ranjit Vijayan for
the useful comments, detailed discussions, remarks and engagement through the
learning process of this doctoral dissertation. You have been a tremendous mentor
for me. I would like to thank you for introducing me to the exciting field of
computational biology and drug design.
I would like to thank my committee for their guidance, support, and
assistance throughout my preparation of this dissertation, especially Dr Mohamed
Akli Ayoub. I would like to thank the chair and members of the Department of
Biology at the United Arab Emirates University for assisting me during my studies
and research.
Special thanks go to my parents, wife, brothers, and sisters who helped me
along the way. I am sure they suspected it was endless. In addition, special thanks
are extended to Bincy Baby, Amna Harib and my PhD batch mates for their
assistance and friendship.

xii

Dedication

To my beloved parents and family

xiii

Table of Contents
Title………..… ................................................................................................................... i
Declaration of Original Work ............................................................................................ii
Copyright………... ...........................................................................................................iii
Advisory Committee ......................................................................................................... iv
Approval of the Doctorate Dissertation ............................................................................. v
Abstract…… ....................................................................................................................vii
Title and Abstract (in Arabic) ........................................................................................... ix
Acknowledgements ........................................................................................................... xi
Dedication. … ..................................................................................................................xii
Table of Contents ............................................................................................................xiii
List of Tables..................................................................................................................xvii
List of Figures ...............................................................................................................xviii
List of Abbreviations.....................................................................................................xxiii
Chapter 1: Introduction ...................................................................................................... 1
1.1 Overview .......................................................................................................... 1
1.1.1 Unique physiological characteristics of camels........................................ 2
1.1.2 Unique genetic characteristics of camels .................................................. 3
1.1.3 The model protein, camel hemoglobin ..................................................... 5
1.2 Relevant literature ............................................................................................ 7
1.2.1 Camel hemoglobin .................................................................................... 9
1.2.2 Hemorphins ............................................................................................ 11
1.2.3 Therapeutic properties of hemorphins .................................................... 13
1.2.4 Molecular mechanism of the interaction of hemorphins and
their targets ...................................................................................................... 18
1.3 Statement of the problem ............................................................................... 20
1.4 Hypothesis and objectives .............................................................................. 22
Chapter 2: Methods .......................................................................................................... 24
2.1 Ethical approval ............................................................................................. 24
2.2 Sample collection and storage condition ....................................................... 24
2.3 DNA extraction .............................................................................................. 24
2.4 Primers ........................................................................................................... 25
2.5 PCR amplification and purification ............................................................... 26
2.6 DNA sequencing and analysis ....................................................................... 27
2.7 Multiple sequence alignment of hemoglobin  protein ................................. 28

xiv
2.8 Generation of homology model ..................................................................... 28
2.9 Protein structure pre-processing..................................................................... 29
2.10 Ligand preparation ....................................................................................... 29
2.11 Active site identification and grid generation .............................................. 30
2.12 Peptide and ligand docking .......................................................................... 30
2.13 Analysis of docking results and binding free energy calculation ................ 31
2.14 Molecular dynamics (MD) simulations ....................................................... 31
2.14.1 Simulation of membrane bound proteins.............................................. 32
2.14.2 Simulation of non-membrane bound proteins ...................................... 33
2.15 In vitro ACE inhibition assay....................................................................... 34
2.16 cDNA constructs and ligands ....................................................................... 35
2.17 Cell culture and transfection ........................................................................ 35
2.18 Dose–response BRET assay......................................................................... 36
2.19 Real-time BRET kinetic assay ..................................................................... 36
2.20 IP1 accumulation assay ................................................................................ 37
2.21 Data presentation and statistical analysis ..................................................... 38
Chapter 3: Insights into the Interaction of Hemorphin and its Targets ............................ 39
3.1 Results ............................................................................................................ 39
3.1.1 Multiple sequence alignment of hemoglobin  protein
sequences ................................................................................................ 39
3.1.2 Structure-based homology modeling of -type opioid
receptor ................................................................................................... 41
3.1.3 Molecular docking .................................................................................. 42
3.1.4 -opioid receptor .................................................................................... 42
3.1.5 Insulin-regulated aminopeptidase ........................................................... 51
3.1.6 Molecular dynamics simulations ............................................................ 56
3.1.7 Simulations of camel and non-camel LVV-hemorphin-7
bound to MOR ........................................................................................ 57
3.1.8 Simulations of camel and non-camel LVV-hemorphin-7
bound to IRAP ........................................................................................ 62
3.2 Discussion ...................................................................................................... 69
Chapter 4: In silico and In vitro Comparison of the Angiotensin-I
Converting Enzyme Inhibitory Activity of Camel and other
Mammalian Hemorphins ............................................................................ 73
4.1 Results ............................................................................................................ 73
4.1.1 Molecular docking .................................................................................. 73
4.1.2 Docking of non-camel and camel LVV-hemorphin-7 to ACE............... 73
4.1.3 Docking of non-camel and camel hemorphin-7 to ACE ........................ 83
4.1.4 Molecular dynamics simulations ............................................................ 89
4.1.5 Simulations of different peptides of non-camel and camel
hemorphins bound to ACE ..................................................................... 89
4.1.6 In vitro ACE inhibition assay ................................................................. 98

xv
4.1.7 Determination of ACE inhibitory potential of non-camel
and camel hemorphin peptides ............................................................... 98
4.1.8 Comparison of the ACE inhibitory activity of different
hemorphin peptides............................................................................... 101
4.2 Discussion .................................................................................................... 103
Chapter 5: Pharmacological Action of LVV-Hemorphin-7 on Angiotensin
II Type 1 Receptor ...................................................................................... 109
5.1 Results .......................................................................................................... 109
5.1.1 Weak agonistic effect of LVV–Hemorphin-7 on AT1R ...................... 109
5.1.2 Positive allosteric effects of LVV–hemorphin-7 on AT1R .................. 113
5.1.3 Confirmation of the positive allosteric effects of
LVV–hemorphin-7 on AT1R ............................................................... 116
5.1.4 Activation of AT1R by LVV-hemorphin-7 .......................................... 121
5.1.5 Effects of LVV–hemorphin-7 on AT1R-mediated
downstream signaling ........................................................................... 122
5.1.6 Molecular docking and molecular dynamics studies ............................ 125
5.1.7 LVV-hemorphin-7 binds to an intracellular site of AT1R ................... 126
5.1.8 Binding of LVV-H7 to AT1R potentiated the binding of
AngII..................................................................................................... 131
5.2 Discussion .................................................................................................... 142
Chapter 6: Structural and Genetic Changes of Camel Hemoglobin ............................. 151
6.1 Results .......................................................................................................... 151
6.1.1 Hemoglobin α and β genes sequences .................................................. 151
6.1.2 Molecular dynamics (MD) simulation of camel and human
hemoglobin ........................................................................................... 155
6.1.3 Molecular docking of 2,3-BPG and ATP with camel
hemoglobin ........................................................................................... 165
6.1.4 Molecular docking of 2,3-BPG and ATP with human
hemoglobin ........................................................................................... 166
6.1.5 Molecular dynamics (MD) simulations of 2,3-BPG and
ATP bound to camel and human hemoglobin ...................................... 169
6.1.6 MD simulations of camel and human hemoglobin bound to
2,3-BPG at different salt concentrations............................................... 170
6.1.7 MD simulations of camel and human hemoglobin bound to
2,3-BPG at different temperature conditions ........................................ 176
6.1.8 MD simulations of ATP bound to camel and human
hemoglobin at different salt conditions ................................................ 181
6.1.9 MD simulations of ATP bound to camel and human
hemoglobin at different temperature conditions ................................... 186
6.2 Discussion .................................................................................................... 191
Chapter 7: Conclusion .................................................................................................... 198

xvi
Chapter 8: Future Prospects ........................................................................................... 199
References.. ............................................................................................................ ..…..200
List of Publications ........................................................................................................ 216

xvii

List of Tables
Table 1: Sequence of hemorphin peptides. ................................................................ 13
Table 2: Primer sets used in PCR to amplify hemoglobin  and  genes. ................ 26
Table 3: Interacting residues of the best pose of non-camel (LVVYPWTQRF)
and camel (LVVYPWTRRF) hemorphin with MOR, and IRAP. .............. 44
Table 4: List of interactions formed by the top binding pose of
LVVYPWTQRF, LVVYPWTRRF, YPWTQRF, and
YPWTRRF hemorphin peptides with ACE. ............................................... 75
Table 5: Log EC50 values of LVV-hemorphin-7 and AngII. ................................... 112
Table 6: Percentage Emax values of AngII in the various BRET assays. .................. 120
Table 7: AT1R residues that interacted with the best docked pose of
LVV-H7 and AngII. .................................................................................. 128
Table 8: List of coding and non-coding variations observed in hemoglobin
genes of different breeds of camel. ........................................................... 153
Table 9: MD simulation conditions used for simulating complex systems of
camel and human hemoglobin. ................................................................. 156
Table 10: Interacting residues of camel and human hemoglobin with
2,3-BPG and ATP. ................................................................................... 168
Table 11: MD simulation conditions used for simulating complex systems
of 2,3-BPG and ATP with camel and human hemoglobin. ..................... 169

xviii

List of Figures
Figure 1: Three dimensional structure of camel hemoglobin ...................................... 7
Figure 2: Classification of camels................................................................................ 8
Figure 3: Proposed pharmacological action of hemorphinson different
opioid receptors and its regulation of signaling pathways leading
to analgesia. ................................................................................................ 15
Figure 4: Therapeutic targets of hemorphins and the molecular mechanism
of action…………………………………………………………………..20
Figure 5: Sequence alignment of hemoglobin  protein sequences
of closely related mammals ........................................................................ 40
Figure 6: Ramachandran plot of the human mu opioid receptor model. ................... 41
Figure 7: 3D structure of modeled active human MOR. ........................................... 47
Figure 8: Interactions of hemorphin peptides with MOR. ......................................... 48
Figure 9: Interactions of non-camel LVV-hemorphin-7 residues
with mu-opioid receptor. ............................................................................ 49
Figure 10: Interactions of camel LVV-hemorphin-7 residues
with mu-opioid receptor. .......................................................................... 50
Figure 11: 3D structure of IRAP.. .............................................................................. 53
Figure 12: Interactions of hemorphin peptide with IRAP. ......................................... 54
Figure 13: Interactions of non-camel LVV-hemorphin-7 residues with IRAP.......... 55
Figure 14: Interactions of camel LVV-hemorphin-7 residues with IRAP. ................ 56
Figure 15: RMSD and RMSF plots of triplicate 100 ns simulations of MOR. .......... 59
Figure 16: The average percentage of equilibrium simulation time
during which residues of MOR maintained contact with
LVVYPWTQRF peptide in triplicate 100 ns simulations. ...................... 60
Figure 17: The average percentage of equilibrium simulation time
during which residues of MOR maintained contact with
LVVYPWTRRF peptide in triplicate 100 ns simulations. ...................... 61
Figure 18: Histograms of the percentage of simulation time where a
MOR residue maintains contact with the hemorphin peptide in
triplicate simulations. ................................................................................ 62
Figure 19: RMSD and RMSF plots of triplicate 100 ns simulations of IRAP.. ......... 65
Figure 20: The average percentage of equilibrium simulation time during
which residues of IRAP maintain contact with LVVYPWTQRF
peptide from triplicate 100 ns simulations. .............................................. 66

xix
Figure 21: The average percentage of equilibrium simulation time
during which residues of IRAP maintain contact with
LVVYPWTRRF peptide from triplicate 100 ns simulations. .................. 67
Figure 22: Histograms of the percentage of simulation time where an
IRAP residue maintains contact with the hemorphin peptide in
triplicate simulations. ............................................................................... 68
Figure 23: The active site of Angiotensin-I converting enzyme (ACE)
shown in red circle and a closer look at the interaction of
LVV-hemorphin-7 in the active site of ACE. ......................................... 77
Figure 24: Closer view of the docked pose of LVVYPWTQRF
peptide and the hydrogen bond interactions it forms with
ACE shown as black dashed lines. ........................................................... 78
Figure 25: Closer view of the docked pose of LVVYPWTRRF peptide
and the hydrogen bond interactions it forms with ACE shown
as black dashed lines ................................................................................ 79
Figure 26: Interactions of human hemorphin (LVVYPWTQRF) with ACE. ............ 80
Figure 27: Interactions of camel hemorphin (LVVYPWTRRF) with ACE. ............. 81
Figure 28: Closer view of the docked pose of YPWTQRF peptide and the
hydrogen bond interactions it forms with ACE shown as black
dashed lines. ............................................................................................. 85
Figure 29: Closer view of the docked pose of YPWTRRF peptide and
the hydrogen bond interactions it forms with ACE shown as
black dashed lines. ................................................................................... 86
Figure 30: Interactions of human hemorphin (YPWTQRF) with ACE. .................... 87
Figure 31: Interactions of camel hemorphin (YPWTRRF) with ACE. ..................... 88
Figure 32: RMSD plots of Cα atoms of ACE protein extracted from
triplicate 200 ns simulations of hemorphin-ACE complex.. .................... 91
Figure 33: RMSF plots of Cα atoms of ACE protein extracted from
triplicate 200 ns simulations of hemorphin-ACE complex.. .................... 92
Figure 34: The average percentage of equilibrium simulation time during
which ACE residues retain interaction with human hemorphin
(LVVYPWTQRF) peptides from triplicate 200 ns simulations.. ............. 93
Figure 35: The average percentage of equilibrium simulation time during
which ACE residues retain interaction with camel hemorphin
(LVVYPWTRRF) peptides from triplicate 200 ns simulations. .............. 94
Figure 36: The average percentage of equilibrium simulation time
during which ACE residues retain interaction with human
hemorphin (YPWTQRF) peptides from triplicate 200 ns

xx
simulations. .............................................................................................. 96
Figure 37: The average percentage of equilibrium simulation time during
which ACE residues retain interaction with camel hemorphin
(YPWTRRF) peptides from triplicate 200 ns simulations. ...................... 97
Figure 38: Dose-response curves of different hemorphin peptides. ........................ 100
Figure 39: IC50 of different hemorphin peptides. ................................................... 102
Figure 40: LVV-hemorphin-7’s action on AT1R. ................................................... 111
Figure 41: Positive allosteric modulation of LVV-hemorphin-7 on
AT1R activation demonstrated by dose-response BRET
technique. ................................................................................................ 115
Figure 42: Positive allosteric modulation of LVV-hemorphin-7 on
AT1R activation demonstrated by dose-response BRET
technique. ................................................................................................ 116
Figure 43: Positive allosteric modulation of LVV-hemorphin-7 on
AT1R activation demonstrated by real-time BRET kinetic
analysis. ................................................................................................. 119
Figure 44: AT1R-selective antagonist (irbesartan) inhibited both
AngII- and LVV-hemorphin-7-mediated BRET potentiation. ............... 122
Figure 45: Positive allosteric modulation of LVV-hemorphin-7 on
AT1R-mediated IP1 production. ............................................................. 124
Figure 46: Structure of AT1R with the docked peptide. .......................................... 129
Figure 47: 2D ligand interaction diagram of LVV-hemorphin-7 with
AT1R. ..................................................................................................... 130
Figure 48: Plots of RMSD and RMSF of protein Cα atoms extracted from
three independent 500 ns simulations of AT1R complexes. .................. 131
Figure 49: Binding pose of AngII with AT1R in the presence and
absence of LVV-H7. .............................................................................. 133
Figure 50: 2D ligand interaction diagram of AngII with AT1R .............................. 134
Figure 51: 2D ligand interaction diagram of AngII with
AT1R-LVV-hemorphin-7.. ..................................................................... 135
Figure 52: Average percentage of simulation time from three 500 ns
runs during which AT1R residues maintain contact with
LVV-H7. ................................................................................................ 137
Figure 53: Average percentage of simulation time from three 500 ns
runs during which AT1R residues maintain contact with
AngII in the absence of LVV-H7. .......................................................... 138
Figure 54: Average percentage of simulation time from three 500 ns

xxi
runs during which AT1R residues maintain contact with
AngII in the presence of LVV-H7. ......................................................... 139
Figure 55: Histograms of the percentage of simulation time where an
AT1R residue maintained contact with a peptide. ................................. 140
Figure 56: Chromatograms of camel samples. ......................................................... 152
Figure 57: Root mean square standard deviation (RMSD) and
root mean square fluctuation (RMSF) of protein Cα atoms
obtained from a 1000 ns run of camel and human hemoglobin
simulation at different salt conditions. ................................................... 160
Figure 58: Root mean square standard deviation (RMSD) and
root mean square fluctuation (RMSF) of protein Cα atoms
obtained from a 1000 ns run of camel and human hemoglobin
simulation at different temperature conditions.. .................................... 164
Figure 59: Docked pose of 2,3-BPG and ATP with camel and
human hemoglobin. ................................................................................ 167
Figure 60: Root mean square standard deviation (RMSD) and
root mean square fluctuation (RMSF) of protein Cα atoms
obtained from a 200 ns run of 2,3-BPG bound camel and
human hemoglobin simulations at different salt conditions. ................ 173
Figure 61: The percentage of simulation time during which different
residues of camel hemoglobin interacted with 2,3-BPG. ....................... 175
Figure 62: The percentage of simulation time during which different
residues of human hemoglobin interacted with 2,3-BPG. ..................... 176
Figure 63: Root mean square standard deviation (RMSD) and
root mean square fluctuation (RMSF) of protein Cα atoms
obtained from a 200 ns run of 2,3-BPG bound camel and human
hemoglobin simulations at different temperature conditions.. ............... 178
Figure 64: The percentage of simulation time during which different
residues of camel hemoglobin interacted with 2,3-BPG.. ...................... 180
Figure 65: The percentage of simulation time during which different
residues of human hemoglobin interacted with 2,3-BPG. ..................... 181
Figure 66: Root mean square standard deviation (RMSD) and
root mean square fluctuation (RMSF) of protein Cα atoms
obtained from a 200 ns run of ATP bound camel and human
hemoglobin simulations at salt conditions. ........................................... 183
Figure 67: The percentage of simulation time during which different
residues of camel hemoglobin interacted with ATP.. ............................ 185
Figure 68: The percentage of simulation time during which different

xxii
residues of human hemoglobin interacted with ATP. ............................ 186
Figure 69: Root mean square standard deviation (RMSD) and
root mean square fluctuation (RMSF) of protein Cα atoms
obtained from a 200 ns run of ATP bound camel and human
hemoglobin simulations at different temperature conditions. ................ 188
Figure 70: The percentage of simulation time during which different
residues of camel hemoglobin interacted with ATP.. ............................ 190
Figure 71: The percentage of simulation time during which different
residues of human hemoglobin interacted with ATP.. ........................... 191

xxiii

List of Abbreviations
ACE

Angiotensin Converting Enzyme

AKT/PKB

Protein Kinase B

AngII

Angiotensin II

ANOVA

Analysis of Variance

AT1R

Angiotensin II Type 1 Receptor

ATP

Adenosine Triphosphate

AT4R

Angiotensin Type 4 Receptor

AVP

Arginine Vasopressin

BBB

Blood Brain Barrier

BLAST

Basic Local Alignment Search Tool

BPG

Bisphosphoglycerol

BRET

Bioluminescence Resonance Energy Transfer

CYP450

Cytochrome P450

CNS

Central Nervous System

DAG

Diacylglycerol

DOR

Delta Opioid Receptor

DMEM

Dulbecco Modified Eagle Medium

DMSO

Dimethyl Sulfoxide

dNTPs

Deoxynucleoside triphosphates

DPP4

Dipeptidyl Peptidase

xxiv
DPPC

Dipalmitoylphosphatidylcholine

DNA

Deoxyribonucleic acid

ECL

Extracellular Loop

EDTA

Ethylene Diamine Acetate

ERK

Extracellular Signal-Regulated Kinase

FDA

Food and Drug Administration

GC

Guanine Cytocine

GLP

Glucagon Like Peptidase

GLUT4

Glucose Transporter Type 4

GPCR

G-Protein Coupled Receptor

GPI

Glucose Phosphate Isomerase

Hb

Hemoglobin

HBB

Hemoglobin Beta

HCAbs

Heavy Chain Antibodies

H7

Hemorphin-7

HEK293

Human Embryonic Kidney 293 Cells

IC50

The Half Maximal Inhibitory Concentration

ICL

Intracellular Loop

IP1

Inositol Phosphate

IR

Immune Response

IRAP

Insulin Regulated Aminopeptidase

KOR

Kappa Opioid Receptor

xxv
KKS

Kallikrein Kinnin System

MD

Molecular Dynamics

MHC

Major Histocompatibility Complex

MM-GBSA

Molecular Mechanics-Generalized Born Surface Area

mM

Millimolar

MOR

Mu Opioid Receptor

NCBI

National Center for Biotechnology Information

NFAT

Nuclear Factor of Activation T Cell

nM

Nanomolar

NPT

Number of particles, Pressure and Temperature

OPLS

Optimized Potentials for Liquid Simulations

PAR1

Protease Activated Receptor 1

PBS

Phosphate Buffer Saline

PBST

Phosphate Buffer Saline Tween

PCR

Polymerase Chain Reaction

PDB

Protein Data Base

PI3K

Phosphoinositide 3-kinases

PLC

Phospholipase-C

RAS

Renin Angiotensin System

RAAS

Renin Angiotensin Aldosterone System

RBCs

Red Blood Cells

xxvi
RESPA

Reference System Propagator Algorithm

RMSD

Root Mean Square Deviation

RMSF

Root Mean Square Fluctuation

SNPs

Single Nucleotide Polymorphisms

SP

Standard Precision

SPC

Single Point Charge

SDS-PAGE

Sodium Dodecyl Phosphate Polyacrylamide Gel
Electrophoresis

SEM

Standard Error of the Mean

SPSS

Statistical Package for the Social Sciences

TCR

T-Cell Receptor

TK

Tyrosine Kinase

TM

Transmembrane

XP

Extra Precision

YPET

Yellow Fluorescent Protein

1

Chapter 1: Introduction
1.1 Overview
Camels play a vital role in the survival of mankind, particularly those living
in arid regions, due to their versatile role and unique capability to acclimatize to
these extreme environmental conditions (Beuzen, Stear, & Chang, 2000; Burger,
2016; Soman & Tinson, 2016). Despite the huge economic, cultural, and biological
significance, the genetic architecture of camels has not been extensively studied to
gain a deeper understanding of the molecular biology that underlies these unique
adaptations. The camel genome contains approximately 20,000 genes and is roughly
2.38 gigabases in size (Jirimutu et al., 2012). The genetic architecture of camels has a
profound impact that enables them to survive under extreme conditions (Andersson
& Georges, 2004; Wu et al., 2014). Variations in the genome and proteome of the
camel are also being explored for the treatment of a number of disorders (Agrawal,
Jain, Shah, Chopra, & Agarwal, 2011; Jirimutu et al., 2012; Muyldermans et al.,
2009).

Camels harbor numerous unique traits that permit them to live and thrive in
distant areas, scorched lands, and high mountains (Jirimutu et al., 2012). They have
an inherent ability to endure thirst and hunger for longer period of times in extremely
harsh environmental conditions. Studies focused on the camel genome have
demonstrated the contribution of numerous genes that permit them to acclimatize to
severe ecological conditions (Elmahdi, Sallmann, Fuhrmann, von Engelhardt, &
Kaske, 1997; Jirimutu et al., 2012; Kasahara et al., 2007; Muyldermans, 2001).
Additionally, multiple studies have assessed the therapeutic potential of camel
products in the management of several human ailments (Agrawal et al., 2011; Fitak,
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Mohandesan, Corander, & Burger, 2016; Jirimutu et al., 2012; Muyldermans et al.,
2009).

1.1.1 Unique physiological characteristics of camels

Camels harbor unique attributes that permit them to survive in extreme desert
conditions. Previous studies have shown that camels store energy in their humps in
the form of fat which permits them to survive without food and water for a longer
period of time when compared to other closely related mammals (Emmanuel &
Nahapetian, 1980). The body temperature of camels fluctuate between 34 to 41°C
within the day (Schmidt-Nielsen, Schmidt-Nielsen, Jarnum, & Houpt, 1956). Camels
have the ability to lose water up to 25% of its body weight (Macfarlane, Morris, &
Howard, 1963). Another study revealed that camels could lose water up to 30% of its
body weight in severe dehydrated conditions. Compared to this, other closely related
mammals will not be able to withstand such drastic changes and will probably die
because of circulatory failure when the water loss surpasses 12% of their body
weight (McKinley, McBurnie, & Mathai, 2001). Several factors are involved in
regulating the body water balance including tissue osmolality and particularly blood
osmolality (Andersson, Olsson, & Rundgren, 1980).

Camel kidneys are primarily involved in the conservation of water by raising
the osmolarity of urine. The camel kidney has the ability to reabsorb more water and
produce highly concentrated urine compared to other mammals. Furthermore, unlike
other mammals, a camel’s intestine has the unique capability to reabsorb water and
water loss via feces is extremely low (Davidson, 2014). Surprisingly, camels can
withstand high blood glucose level (twofold than other ruminants) without exhibiting
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any signs of diabetes. Camels can also ingest approximately eight times more salt
compared to other mammals without demonstrating any signs of hypertension (AlAli, Husayni, & Power, 1988; Jirimutu et al., 2012).

1.1.2 Unique genetic characteristics of camels

Although camels have huge economic, cultural, and biological significance,
very little is reported about the camel genome and the evolutionary preferences it
confers. Camels along with other domestic animals and livestock, possess unique
attributes and genetic variations (Andersson & Georges, 2004). The camel genome is
nearly 2.38 gigabases and encodes around 20,821 genes (Jirimutu et al., 2012).

Recent genomic and transcriptomic studies have unlocked the characteristics
of the unique adaptations in camels (Jirimutu et al., 2012; Wu et al., 2014).
Researchers have explored the importance of ‘rapidly evolving genes’ in species
differentiation and adaptation in camels (Kasahara et al., 2007; Ming et al., 2017;
Muyldermans et al., 2009). Fast divergence of protein-coding genes are typically
estimated by a high ratio of non-synonymous-to-synonymous substitutions (dN/dS)
(Jirimutu et al., 2012). Jirimutu et al. (2012) reported approximately 2,730 notably
faster evolving genes in camels compared its adjacent cattle orthologs. Importantly,
these genes were augmented in metabolic pathways such as lipid and carbohydrate
metabolism, adipocytokine signaling pathways, and insulin signaling pathways.
They suggested that these genes might have assisted the camel to enhance their
energy storage and production in the desert.

Camels are ruminant herbivores with a large forestomach. Nevertheless, they
have significantly higher blood glucose levels (6–8 mmol/l) compared to other
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mammals. Cytochrome 2E (CYP2E) and cytochrome 2J (CYP2J) genes, which
belong to a set rapidly evolving genes, could be associated with type II diabetes
mellitus (Jirimutu et al., 2012). Phosphoinositide 3-kinases (PI3K) and protein kinase
(PKB) are two crucial genes in the insulin signaling pathway that has seen rapid
divergence in camels and could have altered their sensitivity to insulin (Ming et al.,
2017). This reinforces earlier findings that a higher glucose blood level in camels is
primarily due to their high insulin resistance (Kaske, Elmahdi, Engelhardt, &
Sallmann, 2001). Additionally, cytochrome P450 (CYP450) genes distribution has
also be reported to be different in camels compared to other mammals. CYP genes
are principally involved in arachidonic acid metabolism. Interestingly, an analysis of
the Bactrian camel genome revealed more copies of CYP450 genes. For instance,
camels have eleven copies of CYP2J gene and two copies of CYP2E gene compared
to other mammals including humans. However, copies of CYP4A and CYP4F genes
were found to be lower in camels in comparison to other mammals (Jirimutu et al.,
2012). CYP2E and CYP2J support to convert arachidonic acid into 19(S)-hydroxyeicosatetraenoic acid [19(S)-HETE], while CYP4F and CYP4A convert it into 20HETE (Wu et al., 2014). 19(S)-HETE is a strong vasodilator of renal preglomerular
vessels that potentiate water reabsorption and is particularly important for its survival
in deserts (Carroll et al., 1996). Several copies of CYP2J genes enable them to
withstand high amount of salt without exhibiting hypertension (Wu et al., 2014). The
prime activity of CYP2J2 gene is controlled by high-salt diet and the inhibition of
this gene can lead to high blood pressure (Zhao, Pollock, Inscho, Zeldin, & Imig,
2003). The impact of extreme desert conditions results in substantial increase in
sodium levels of serum, urea, creatinine, and plasma arginine vasopressin (AVP)
levels while plasma aldosterone level was not significantly changed (Al-Ali et al.,
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1988). These findings support earlier studies that demonstrated that renin-angiotensin
system is vital for the regulation of water balance during dehydration. Additionally,
studies have also shown an upsurge of serum creatinine and serum urea levels in
dehydration (Finberg, Yagil, & Berlyne, 1978; Siebert & Macfarlane, 1971). Camels
also have the inherent ability to survive starvation while maintaining a consistent
nitrogen level via urea-nitrogen recycling (Mousa, Ali, & Hume, 1983).

Camels are comparatively more resistant to many infectious diseases,
compared to other mammals residing in the same terrestrial area. However, the
immunogenome of camel remains elusive (Burger, 2016; Muyldermans et al., 2009;
Wernery & Kaaden, 2004). The camel’s immune system comprises of a unique
heavy chain antibody homodimer. More importantly, camels are the only mammals
that possess heavy-chain antibodies (HCAbs) that is devoid of the light chain
(Hamers-Casterman et al., 1993; Tillib, Vyatchanin, & Muyldermans, 2014).
However, very little is known about the major histocompatibility complex (MHC)
region of the camel genome (Antczak, 2013). The immune response (IR) genes that
demonstrate a critical role in host–pathogen interactions are present in the genomic
MHC region (Janeway, Travers, Walport, & Shlomchik, 2001).

1.1.3 The model protein, camel hemoglobin

The protein hemoglobin is abundantly present in red blood cells (RBCs) or
erythrocytes. Hemoglobin is the oxygen carrying protein that gives the typical red
color to blood. Adult vertebrate hemoglobin is composed of four protein chains, two
 chains and two  chains. These chains were produced as a result of gene
duplication (Storz, 2016). A ferrous ion (Fe2+) contained in the heme group present
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in each chain acts as a cofactor for this tetrameric protein. Oxygen is transported in
blood by reversibly binding to these Fe2+ ions. Structurally, hemoglobin chains retain
the classic globin fold, which is shared by several proteins. Myoglobin, for example,
a monomer, retains the same fold albeit with just around 25% sequence identity to
hemoglobin.

Camel hemoglobin contains more charged amino acid residues and are more
hydrophilic than hemoglobins of other mammalian species (Bogner, Csutora,
Cameron, Wheatley, & Miseta, 1998). The availability of a three dimensional X-ray
crystal structure of the camel hemoglobin molecule now permits structural
comparisons of this molecule with that of several other well-studied species
including humans, rats and mice (Balasubramanian, Moorthy, Neelagandan, &
Ponnuswamy, 2009) (Figure 1).

7

Figure 1: Three dimensional structure of camel hemoglobin (PDB ID: 3GDJ) with 
chains shown in red and  chains shown in green. The heme group is shown in blue
stick representation.

1.2 Relevant literature
Camels play an important role in less economically compromised parts of
Asian, Arabian, and African deserts. Camels have been used as a source food, for
transportation, and for protection for a very long time. Currently, they are
enormously vital in various parts of the scorched world as sustainable livestock
species (Burger, 2016). Camels belong to Camelidae family. The Camelidae family
could be traced back to North America approximately 35 million years ago during
the Eocene period (Reed, 1972). Camels are broadly classified into two major types –
small and large camels – which are further subdivided into Camelus, Lama, and
Vicugna genera. A distinct collective classification of camels is not present so far.
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Nevertheless, the most frequently used and known classification is given in Figure 2
(Wu et al., 2014). Irrespective of their classification, camels are usually differentiated
based on habitat, function, and color. Camels has roughly the same shape but deviate
in body size, color, and conformation (Al-Swailem et al., 2010). The large camelids
comprise of two domestic species: the single-humped dromedary camel Camelus
dromedarius, and the two-humped Bactrian camel Camelus bactrianus. Dromedary
camels are also referred to as Arabian camels and are predominantly found in the hot
and barren region between the northern part of Africa and east of Asia. The
domestication of dromedary camel first started around five thousand or six thousand
years ago in the Arabian peninsula (Almathen et al., 2016; Trinks, Burger, Beneke,
& Burger, 2012). Bactrian camels are primarily found in deserted areas of central
Asia and colder regions. The llama and the alpaca are the two members of small
camelids which are limited to South America.

Figure 2: Classification of camels.

9
1.2.1 Camel hemoglobin

Camel red blood cell (RBC) is a fascinating case study of adaptation to severe
environmental conditions (Oyewale et al., 2011). It has been well established that the
shape of the erythrocytes in all mammals is spherical or concave. However, camels
erythrocytes are extremely enucleated, ovaloid, small, flat, and circulates in large
numbers (Azwai, Abdouslam, Al-Bassam, Al Dawek, & Al-Izzi, 2007;
Goniakowska-Witalinska & Witalinski, 1976). This unique elliptical shape of camel
erythrocytes enables their flow in dehydrated conditions and permit them to cross
small capillaries (Eitan, Aloni, & Livne, 1976). Moreover, camel RBCs are
extremely resistant to osmotic hemolysis and has the ability to swell up to 240% of
their normal volume without rupturing (Oyewale et al., 2011). It is believed that this
could be because of different arrangement of membrane phospholipids in its
erythrocytes (Wardeh, 2004). There are several possible hypotheses on how the cells
could survive severe osmotic shock. This includes: (1) erythrocyte membrane
plasticity and its composition (Eitan et al., 1976); (2) variations in the cytoskeleton
molecules of camel erythrocyte including erythrocytic spectrin (Ralston, 1975); (3)
the water holding capacity of camel hemoglobin and its packaging inside the
erythrocyte (Bogner et al., 2005); (4) the concentration of energy rich compounds in
the

erythrocyte

cytosol,

including

adenosine

triphosphate

(ATP),

2,3-

bisphosphoglycerate (2,3-BPG) and cofactors such as chloride ions and its binding
affinity to hemoglobin in different stages of osmotic stress (Garby, Gerber, & De
Verdier, 1969).

Camels have inherent ability to survive without drinking water for longer
period of time. Camels can lose 30% of their body weight during dehydrated
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conditions. Studies have shown that a dehydrated camel can regain the lost water
(approximately 30 gallons) within 10 minutes. Notwithstanding, the high flow of
water into the bloodstream, camel’s erythrocytes remained intact (Perk, 1963).
However, in humans entry of only 600 ml of water into the blood circulation cause
hemoglobinuria (Perk, 1963). It has been suggested that the ability of camel
erythrocytes to resist high dilutions are due to higher binding capacity of camel
erythrocytes with water (Perk, 1963).

Studies have shown that 2,3-bisphosphoglycerate (2,3-BPG)

and ATP

interact with hemoglobin and substantially decreases its affinity for oxygen (Chu,
Breite, Ciraolo, Franco, & Low, 2008; Macdonald, 1977). The hemoglobin
oxygenation is critically controlled by the 2,3-BPG levels in the RBCs (Berg,
Tymoczko, & Stryer, 2002). 2,3-BPG is the most abundant phosphate compound
present in red blood cells and is generally formed from the rearrangement of 1,3
bisphosphoglycerate during glycolysis (Chen, Yu, Zulfajri, Lin, & Wang, 2017). The
presence of 2,3-BPG and ATP in erythrocytes promote the unloading of oxygen in
tissue capillaries and subtle changes in their levels could substantially affects the
release of oxygen. The molecular binding of 2,3-BPG and ATP with human
hemoglobin has been explored using in vitro and in silico studies (Gerber, Berger,
Jänig, & Rapoport, 1973; Lennon, Scott, Chapman, & Kuchel, 1994). However, the
stability of binding residues, especially critically important residues of human and
other mammalian hemoglobin, with these abundantly present co-factors under
different stresses have not been explored.
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1.2.2 Hemorphins

The cryptome is a part of the proteome that forms cryptic peptides with
important biological activities (Pimenta & Lebrun, 2007). The cryptome is naturally
incorporated in protein sequences and has the ability to form multiple biologically
active peptides called cryptides when exposed to proteolytic cleavage (Ivanov,
Karelin, Philippova, Nazimov, & Pletnev, 1997; Pimenta & Lebrun, 2007). Cryptides
produce similar or, entirely different biological activities, compared to the protein
from which it was excised. Lately, numerous cryptides have been reported and their
putative pharmacological activities in several diseases have been described (Fesenko
et al., 2019; Gaglione et al., 2019; Haines et al., 2019). Hemorphins are known
endogenous cryptides. They belong to the family of atypical opioid peptides and are
released during the serial degradation of hemoglobin proteins (Blishchenko et al.,
2005; Jinsmaa & Yoshikawa, 2002). Generally, opioid peptides are roughly divided
into typical and atypical opioid peptides. Typical opioid peptides include
enkephalins, betaendorphins and dynorphins. These bioactive peptides are formed by
the degradation of

proenkephalin, proopiomelanocortin and prodynorphin,

respectively, and possessed the same N-terminal amino acid sequence tyrosineglycine-glycine-phenylalanine (Goldstein, Tachibana, Lowney, Hunkapiller, &
Hood, 1979; Hughes et al., 1975). Sequential lysis of some proteins releases another
group of peptides known as atypical opioid peptides. Casomorphins, cytochrophins,
and hemorphins, produced from casein, cytochrome b, and hemoglobin, respectively,
belong to this group (Brantl et al., 1985). All atypical opioid peptides possess a
single common factor, which is an N-terminal tyrosine residue. Compared to typical
opioid peptides, further extension of the amino acid sequence beyond the tyrosine
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residue at the N terminal is possible in atypical opioid peptides (Teschemacher,
1993).

Hemorphins are 4–10 amino acid long bioactive peptides formed by the
sequential degradation of hemoglobin proteins (Brantl et al., 1985). The initial wellcharacterized hemoglobin-derived peptide was hemorphin-4 obtained from bovine
blood (Brantl et al., 1986). Afterwards, Glamsta and colleagues described longer
isoforms of hemorphins in the human pituitary (Glamsta et al., 1991). Serial cleavage
of hemoglobin generates a chain of biologically active peptides with overlapping
sequences. These endogenous peptides have been identified and produced from
several biological fluids such as brain, plasma, hypothalamic tissues, cerebrospinal
fluids, pituitary glands, peripheral and central nervous systems, and adrenal tissues
(Glamsta, Meyerson, Silberring, Terenius, & Nyberg, 1992). Studies have reported
the association of hemorphins to several physiological and pathological conditions
such as long distance running, inflammation, cancer, and cerebrovascular bleeding
(Glamsta et al., 1992; Sanderson, Andren, Caprioli, & Nyberg, 1996). These peptides
are also produced during alteration from usual behavior and the action of certain
enzymes in particular tissues (Ivanov et al., 1997). These bioactive short peptides
contain an essential tetrapeptide core - tyrosine-proline-tryptophan-threonine
(YPWT) (Nyberg, Sanderson, & Glamsta, 1997). Extended hemorphin peptides have
been produced in human and bovine tissues due to N- and C- terminal extensions of
this core sequence (Glamsta et al., 1992). Known hemorphin peptides of different
lengths are given in Table 1. Amongst all known hemorphins, LVV-hemorphin-7 and
VV-hemorphin-7 are considered to be the longest and most stable form of
hemorphins (Moeller et al., 1997). The relatively small size of hemorphins also
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enable them to cross the blood-brain barrier (BBB) (Glamsta et al., 1992). The
sequence of hemorphin is highly conserved among mammals. Several studies have
reported promising therapeutic potential of hemorphins in various disorders (Ali,
Baby, Soman, & Vijayan, 2019; Cheng, Tao, Cheng, & Huang, 2012). Nevertheless,
the detailed cellular and molecular mechanisms that trigger the interaction of
hemorphins and their targets remain elusive.

Table 1: Sequence of hemorphin peptides.
Name

Amino acid sequence

Hemorphin-4

Tyr-Pro-Trp-Thr (YPWT)

Hemorphin-5

Tyr-Pro-Trp-Thr-Gln (YPWTQ)

Hemorphin-6

Tyr-Pro-Trp-Thr-Gln-Arg (YPWTQR)

Hemorphin-7

Tyr-Pro-Trp-Thr-Gln-Arg-Phe (YPWTQRF)

LVV-hemorphin-4 Leu-Val-Val-Tyr-Pro-Trp-Thr (LVVYPWT)
LVV-hemorphin-5 Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln (LVVYPWTQ)
LVV-hemorphin-6 Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg (LVVYPWTQR)
VV-hemorphin-7

Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe(VVYPWTQRF)

LVV-hemorphin-7 Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe(LVVYPWTQRF)
1.2.3 Therapeutic properties of hemorphins

Hemorphin-4 (YPWT) was the first short hemorphin peptide obtained from
hemoglobin. This peptide was extracted from bovine blood that was subjected to a
mixture of gastrointestinal enzymes (Lau & Dunn, 2018). After that, a number of
other peptides, such as hemorphin-4 to -7 and LVV-hemorphin-4, -6, and -7, were
identified that also have the YPWT sequence (Dagouassat, Garreau, Sannier, Zhao,
& Piot, 1996; Moisan et al., 1998). These peptide are generally formed in the
cerebrospinal fluid, brain, plasma and spinal cord (Glamsta et al., 1992; Karelin,
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Philippova, Karelina, & Ivanov, 1994). Different lengths of hemorphins have been
associated with several biological activities such as pharmacological actions on
spatial learning, inflammation, analgesia and transient hypotension (Cheng et al.,
2012; Lee et al., 2004). Out of all hemorphins, LVV-hemorphin-7 (LVV-H7 or
LVVYPWTQRF) is the longest with 10 amino acids. Several reports have indicated
that LVV-hemorphin-7 is the most hydrophobic peptide and is abundantly present in
mammalian central nervous system (CNS) (Karelin et al., 1994; Moeller et al., 1997).

The existence and discovery of different opioid binding sites in the
mammalian brain started several studies to determine their precise natural ligands.
Met- and Leu-enkephalin were the earliest endogenous opioid peptides to be reported
(Hughes et al., 1975). After that, different bioactive peptides were reported that were
released from controlled cleavage of protein precursors. Classical opioid peptides
such as enkephalins, dynorphins, and -endorphins are produced by the lysis of
proenkephalin, prodynorphin and proopiomelanocortin, respectively. These are
mostly present in the CNS (Kakidani et al., 1982). Three opioid receptors namely ,
, and  have been investigated extensively. Several groups of peptides are produced
as a result of partial proteolysis of proteins. For example, cytochrophins are produced
from mitochondrial cytochrome b, casomorphins released from the milk protein casein, and hemorphins derived from hemoglobin (Karelin et al., 1994). Investigating
the agonistic activity of peptides to opioid receptors is of great importance as their
binding produces profound analgesia in inflamed tissue (Stein, Schäfer, &
Machelska, 2003). Studies have illustrated that hemorphins could also bind to opioid
receptors (Glamsta et al., 1992). Moreover, a study conducted on electrically
stimulated myenteric plexus/longitudinal muscle preparation of the guinea pig ileum,
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demonstrated that hemorphin-5, -6, and -7 possessed opioid-like activity. Glucose
phosphate isomerase (GPI) bioassay has shown agonistic opioid-like effects of
different hemorphins (Zadina, Kastin, Kersh, & Wyatt, 1992). Furthermore, opioid
receptor affinity of hemorphin was evaluated in membranes from rat brain and the
findings indicated IC50 values in the micromolar range (Yukhananov, Glämsta, &
Nyberg, 1994). Additionally, studies have also suggested that hemorphins mimic
opioid peptides in terms of their analgesic activities. A dose-dependent
antinociceptive response of hemorphins have also been reported in mice (Davis,
Gillespie, & Porreca, 1989). Chow and colleagues have also reported that intrathecal
doses of angiotensin IV (Ang IV) and LVV-hemorphin-7 causes anti-hyperalgesia in
rats (Chow et al., 2018). The proposed binding of hemorphins and canonical opioid
receptor signaling is given in Figure 3.

Figure 3: Proposed pharmacological action of hemorphinson different opioid
receptors and its regulation of signaling pathways leading to analgesia. Analgesic
effects of μ opioid receptor (MOR), κ opioid receptor (KOR), and δ opioid receptor
(DOR) are mainly correlated with Gi-protein signaling. Hemorphins exhibit its pain
killing effects by activating the MOR induced Gi-dependent signaling pathway. The
pharmacological action of hemorphin on DOR and KOR are remain elusive. +
represents activation and ? indicates that the mechanism is currently not known.
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Hypertension is considered to be one of the most significant health problems
that prevail globally. The mortality rate is highly dependent on its timely discovery
and management. Worldwide, approximately 13.5% of total deaths are associated
with hypertension (Lawes, Vander Hoorn, & Rodgers, 2008). Recent studies also
suggest that hypertension affects approximately 972 million adults and this number is
expected to further increase up to 1.56 billion by the year 2025 (Kearney et al.,
2005). Hypertension is also considered to be one of the major risk factors for
disorders related to the heart and contributes to over nine million deaths every year
(Sawicka et al., 2011). The pathophysiology of hypertension is extremely
complicated, and it involves various risk factors such as stress, smoking, and
consumption of alcohol, elevated sodium, genetics, obesity and some environmental
factors. Apart from these factors the activity of the renin-angiotensin system (RAS)
has also been observed to play a well-known role in the pathogenesis of hypertension
(Schütten, Houben, de Leeuw, & Stehouwer, 2017).

The zinc metallopeptidase angiotensin-I converting enzyme (ACE) is found
in many tissues and biological fluids and is one of an important player in regulating
RAS and kallikrein-kinnin system (KKS). ACE causes hypertension by two
mechanisms. Firstly, two amino acids are cleaved by ACE from the decapeptide
angiotensin I for producing the octapeptide angiotensin II which is a relatively
stronger vasoconstrictor. Secondly, ACE is associated with the degradation of
bradykinin which is considered a potent vasodilator (Ondetti, Rubin, & Cushman,
1977; Priyanto et al., 2015). ACE is linked closely to hypertension and is an
important target for discovering the anti-hypertensive drugs as a result of these
effects. Captopril and lisinopril are widely prescribed ACE inhibitors, and currently,
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these drugs are limited in their use because of well-documented side effects such as
angioedema, kidney problems, cough and allergic reactions (Yu et al., 2018). In
addition to that, increase in the incidence of cardiovascular diseases has led the
search for safer and novel alternatives. Endogenous or biologically active peptides
are a few of the alternatives that are being considered and explored due to their longterm regulation of tissue homeostasis, high bioavailability, and better safety profile
(Iwaniak, Minkiewicz, & Darewicz, 2014; Wang, Chen, Fu, Li, & Wei, 2017).

It has been demonstrated that hemorphins have beneficial effects in the
control of blood pressure. The observations also revealed that hemorphins can
significantly reduce blood pressure in hypertensive rats (Cejka, Zelezna, Velek,
Zicha, & Kunes, 2004). Additionally, it has been reported in various studies that antihypertensive effects are produced by hemorphins while inhibiting ACE, the key
component of RAAS (Fruitier-Arnaudin, Cohen, Bordenave, Sannier, & Piot, 2002;
Lantz, Glämsta, Talbäck, & Nyberg, 1991).

RAS in the brain is believed to be involved in processes other than
homeostatic control. It has been associated with neuronal differentiation, nerve
regeneration, learning and memory (Lee et al., 2004). Ang IV has been associated
with various physiological functions, including the facilitation of memory (Albiston
et al., 2004; Moeller et al., 1997). LVV-hemorphin-7 was recognized as an
endogenous high-affinity ligand of the presumed angiotensin IV receptor (AT4R)
(Moeller et al., 1997). Further studies characterize this putative receptor and
indicated that this protein was analogous to IRAP, a type II integral membrane
protein whose catalytic activity is inhibited by LVV-hemorphin-7 and Ang IV (Lee
et al., 2004; Ye, Chai, Lew, & Albiston, 2007). In vivo and in vitro studies revealed
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that LVV-hemorphin-7 could play a pivotal role in learning and memory. When an
intracerebral administration of LVV-hemorphin-7 was carried out, it enhanced the
spatial learning in rats and lessened the effects of scopolamine-induced learning
deficits in spatial learning tests and fear conditioning (Albiston et al., 2004). LVVhemorphin-7 has also been shown to modify the behavior of rats. Additionally, LVVhemorphin-7, reduced depression and increased locomotion in rats. However, this
depended on the activation of oxytocin receptors most likely due to changes in the
oxytocinase activity of AT4R (Da Cruz et al., 2017). It was presumed that by
inhibiting IRAP activity, LVV-hemorphin-7 protects the substrates of IRAP such as
oxytocin and vasopressin. These substrates play a key role in memory and learning
(Engelmann, Wotjak, Neumann, Ludwig, & Landgraf, 1996). In vivo microdialysis
showed that LVV-hemorphin-7 improved spatial working memory without a
significant increase in blood flow or hippocampal glucose uptake (De Bundel et al.,
2009).

1.2.4 Molecular mechanism of the interaction of hemorphins and their targets

Several in vitro studies have shown the high stability of hemorphins,
specifically LVV-hemorphin-7 in human plasma and tissue (Lantz et al., 1991;
Sanderson, Nyberg, & Khalil, 1998). Furthermore, in vivo studies have demonstrated
that peptidase enzyme present in extracellular fluid, especially amastatin-sensitive
amino peptidase, cleaves hemorphin peptide (Nydahl, Pierson, Nyberg, Caprioli, &
Andren, 2003). Nevertheless, LVV-hemorphin-7 has shown high stability in the
blood for longer periods of time when incubated with numerous proteolytic enzymes.
Notably, resistance of LVV-hemorphin-7 to proteolytic cleavage could be of major
importance to its pharmacological and biological activities (John, Schulz, &
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Forssmann, 2007; Sanderson et al., 1998). Hemorphins exist not only in blood, but
also in numerous organs and brain regions, such as adrenal, hypothalamus and
pituitary glands. Hemorphins have been reported to be involved in several cellular
and molecular mechanisms and determining the complex molecular interactions is a
challenging task. Based on previous reports, hemorphins have been revealed to
interact with opioid, RAS, immune and neuroendocrine and immune systems (Figure
4).

Ligand-dependent biased signaling is an interesting concept in the field of
GPCRs pharmacology where the same receptor could exhibit either Gi-dependent
signaling pathway or β-arrestin-dependent signaling pathway based on the bound
ligand.  opioid receptor (MOR) induced analgesia is correlated with Gi-dependent
signaling whereas β-arrestin-dependent signaling is linked with different side effects
such as constipation and respiratory. Hemorphins demonstrate their activities by
activating the Gi-dependent signaling of MOR. Nevertheless, MOR β-arrestin-2
associated activity of hemorphins are still unknown. The putative action of
hemorphins on KOR and DOR, however, remain elusive. Hemorphins may also
produce selective agonism through the recruitment of β-arrestin-2 and internalization
of receptors, and may produce anxiolytic and dysphoric activities via DOR and
KOR, respectively.
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Figure 4: Therapeutic targets of hemorphins and the molecular mechanism of action.
Blocked, dashed, and pointed, represent inhibition, release of ions, and activation of
target, respectively.
1.3 Statement of the problem
Hemoglobin is one of the well-characterized and widely studied protein
genetically, biochemically, and structurally. Studies have elucidated the structural
and genetic variations amongst the mammalian hemoglobin. However, camel
hemoglobin has not been greatly explored. Some physiological and biochemical
studies have been performed on camel hemoglobin. However, very little is known
from a structural perspective. Therefore, a comparative study principally focused on
structural and genetics aspects of camel hemoglobin will provide insights into how
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the camel hemoglobin behaves in varying conditions of osmolarity and temperature
that it is normally susceptible to in contrast to human hemoglobin.

The co-factors ATP and 2,3-BPG are abundantly present in RBCs and are
involved in the release of oxygen molecule during hypoxic and dehydrated
conditions. Several studies on different mammals including humans have shown that
ATP, and 2,3-BPG preferentially bind to β subunits of hemoglobin and helps in the
unloading of oxygen molecules into tissues. Despite the inherent ability of camel to
survive severe dehydrated conditions, the role of these energy molecules in camel
hemoglobin have not been studied yet. Hence, it would benefit from a comparative
investigation aimed at elucidating the molecular interactions of these molecules with
camel and human hemoglobin under different stress conditions such as different
conditions of temperature and salt concentrations in greater depth.

Several bioactive peptides are generally produced from proteolytic
degradation of precursors proteins including hemoglobin. Numerous studies have
identified the existence of several hemoglobin derived peptides such as hemorphins
from different mammals including humans and these have been shown to diverse
biological activities. However, functional and biological activities of camel
hemoglobin derived peptides remain elusive. Thus, it is important to identify the
genetic variations among these bioactive peptides in closely related mammals and
determine the impact of small variation on the overall functioning of the therapeutic
drug targets.
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1.4 Hypothesis and objectives
The physiological function of camel hemoglobin is not affected by sudden
changes in osmolarity and temperature. This is an evolutionary advantage for
dromedaries to endure the dehydration. The main hypothesis is that the extreme
adaptive features of camel hemoglobin could be attributed to its primary as well as
quaternary structures and its interaction with co-factors. The overreaching aim of this
study was to determine the structural and genetic variations of camel hemoglobin and
to identify the activity of hemoglobin-derived biologically active peptides. This
project adopted computational modeling and molecular approaches to investigate
several aspects of camel hemoglobin to address these issues.

The objectives of this study are to:

1) Study the behavior of camel hemoglobin protein under a range of osmolarity and
temperature variations using long time scale molecular dynamics (MD)
simulations under different salt and temperature conditions.

2) Compare the binding of ATP and 2,3-BPG in camel and other mammalian
hemoglobin structures using binding site analysis, molecular docking and MD
simulations to identify any mechanistic differences in the action of these
molecules.
3) Sequence and analyze  and  hemoglobin genes to identify SNPs in camels
belong to different breeds to identify SNPs that could potentially be correlated
with oxygen affinity.

23
4) Identify the most likely binding pose of human or other mammals and camel
LVV-hemorphin-7 with ACE, MOR and IRAP and to calculate the binding
affinity using molecular docking and MD simulations.

5) Investigate the binding and activation of AT1R by human and camel LVVhemorphin-7 by in silico approaches and in transfected human embryonic kidney
(HEK293) cells using bioluminescence resonance energy transfer technology
(BRET).
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Chapter 2: Methods
2.1 Ethical approval
Ethical approval was obtained from United Arab Emirates University to
collect blood samples. Ethical approval no: ERA_2017_5655, was granted on 24
January 2018.

2.2 Sample collection and storage condition
10 ml of whole blood was taken from three different breeds of camels (50
Sudani, 50 Omani, 50 Mixed breeds, and 20 dairy) into vacuum collection tubes
containing dipotassium EDTA (Ethylene Diamine Acetate) and transferred to the
Department of Biology, United Arab Emirates University, for further analysis. In
ordered to store them for longer period of time, all blood samples obtained in EDTA
tubes were stored at -50°C in the Molecular Biology Lab of the Department of
Biology.

2.3 DNA extraction
DNA was isolated from camel blood using Norgen blood DNA isolation kit
(Norgen Biotek, Canada) following manufacturer’s guidelines. Briefly, 20 µl of
proteinase K was added to the microcentrifuge tube and 200 µl of camel blood was
then added to the same tube. After that, 300 µl of lysis buffer B was added to the
tube containing blood and peoteinase K, and was vortexed for 10 seconds. After
mixing the reaction mixture, the centrifuge tubes were incubated for 10 minutes at
55ºC. After incubation, tubes were briefly spun and 110 µl of 96% ethanol was
added to each tube containing the samples and mixed well by vortexing for 10
seconds. Next, binding columns were assembled on the collection tubes provided
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with the kit. Reaction mixture from each tube was transferred to the column and
centrifuged for 1 minute at approximately 8,000 rpm. Flowthrough was discarded
and columns were reassembled again with the collection tube. After that, the column
was washed with washing buffer provided with the kit in two steps by adding 500 µl
of washing buffer in each step and centrifuged for 1 minute at 8000 rpm. After each
step of washing, the flowthrough was discarded and columns were assembled with
new collection tubes. In order to dry the columns, the columns were centrifuged for 2
minutes at 14000 rpm and collection tubes were discarded. Next, the columns were
placed into the elution tubes provided with the kit and approximately 200 µl of
elution buffer was added to each column. The elution tubes containing elution buffer
and column were incubated at room temperature for 1 minute. After incubation, the
elution tubes were centrifuged at 8000 rpm for 1 minute. After eluting the DNA, the
quality and quantity of DNA was measured by loading 1 µl of extracted DNA in
NanoDrop 2000/c (Thermo Fisher Scientific, USA) which is a microvolume
spectrophotometers. After that, the extracted DNA samples were stored at -20ºC.

2.4 Primers
The sequence of camel hemoglobin  and  genes were retrieved from
National Center for Biotechnology Information (NCBI) browser. Several overlapping
primers were designed using Primer-Basic Local Alignment Search Tool (BLAST)
to amplify the full genes of hemoglobin α and . Melting temperature and Guanine
Cytocine (GC) content of each primer were also determined. Designed primers were
purchased from Macrogen (Korea). The optimum conditions for the primers were
then determined experimentally. The list of primers and their optimal conditions are
given in Table 2.
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Table 2: Primer sets used in PCR to amplify hemoglobin  and  genes.
Forward (F) /
Reverse (R)

Sequence (5’- 3’)

F

GCACACTTCCGATCCTGACCTA

R

GCTTAACGGTATTTGGAGGTC

F

CCCATCATGGTGCTGTCTTCC

R

CGGTATTTGGAGGTCAGCACG

F

CTGGGCATAAAAGGAAGAGCAG

R

GCATAGGTGCCCTTGAGGTT

F

GGTGCTAAACTCCTTTGGTG

R

GACAGAGGCCAGATGCTCAA

F

CTCACATCAAGAGCAACCTC

R

GAGGTTGCTCTTGATGTGAG

F

ACCTTCTTGCCATGGGCCTTG

R

CAAGGCCCATGGCAAGAAGGT

Annealing
Time (sec)

Annealing
Temperature
(°C)

45

59

37

57

31

54

38

59

36

54

38

59

2.5 PCR amplification and purification
In this study a premixed ready-to-use solution called the Go Taq® Green
Master Mix (Promega, USA), was used. Go Taq® Green Master Mix comprises an
optimal concentration of dNTPs, Taq DNA polymerase, MgCl2 and reaction buffers.
A total reaction volume of 50 µl was prepared and used for each PCR run. For
amplification of hemoglobin genes, 2 µl of extracted DNA from each sample, 1.5 µl
of forward and reverse primers, 25 µl of green master mix, and 20 µl of deionize
water were added to each PCR tube. The following reaction conditions were used in
the Thermal Cycler: 1 cycle of pre-denaturation for 3 minutes at 95ºC for 3 minutes,
followed by 34 cycles of denaturation at 95ºC for 30 seconds, annealing at specific
temperature and time demonstrated in Table 3, and lastly final extension at 72ºC for
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one minute. After the amplification, amplified PCR products were visualized on
1.5% (w/v) agarose gel using electrophoresis. After visualization of PCR products,
the amplified PCR products were purified using the Norgen PCR purification kit
(Norgen Biotek, Canada) following the manufacturer’s guidelines. For this purpose,
the binding buffer provided in the kit was added in each PCR tube in 5:1 ratio to the
PCR product. After the addition of binding buffer, the PCR tubes were briefly
vortexed and pulse-spun. The mixture was then added into a column placed on the
tube provided in the kit and centrifugation was performed for 1 minute at 8000 rpm.
The flow-through was discarded and 500 µl of washing buffer (96-100% ethanol)
was added to the column and again centrifugated for 1 minute at 10,000 rpm. The
flow-through was discarded again and the spun for 2 minutes at 14,000 rpm in order
to dry the column. After that, the column was assembled with the 1.7 ml elution tube.
In order to obtain high concentration of DNA, 10 µl of elution buffer was added to
the center of the column bed and kept standing at room temperature for 1 minute.
After that, the column was centrifuged at 14, 000 rpm for 2 minutes. The last step of
purification was repeated one more time. Finally, the quantity and quality of the
purified amplified DNA was measured by loading 1 µl of purified DNA in
NanoDrop 2000/c (Thermo Fisher Scientific, USA) which is a microvolume
spectrophotometer.

2.6 DNA sequencing and analysis
Samples that fulfilled the quality and quantity required were sent for
sequencing to Macrogen, (Korea). The sequences and chromatograms were provided
by Macrogen which were then analyzed further. FinchTV chromatogram viewer
version 1.4.0 (Geospiza) was used to visualize the chromatograms. BioEdit Sequence
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Alignment Editor Version v7.0.5 (Tom Hall Ibis Therapeutics) as used to carry out
sequence alignment. Reference sequences for hemoglobin  (NCBI Accession:
105098415) and hemoglobin  genes (NCBI Accession: 105097953) were obtained
from NCBI RefSeq database.
2.7 Multiple sequence alignment of hemoglobin  protein
NCBI protein database was used to obtain the hemoglobin protein
sequences of Homo sapiens (NP_000509), Camelus dromedarius (XP_010988890),
Equus

caballus

(XP_001504239),

Bos

taurus

(NP_776342),

Sus

scrofa

(NP_001138313), Ovis aries (NP_001091117), Pan troglodytes (NC_036890) and
Oryctolagus cuniculus (NP_001075729). Multiple sequence alignment of these
sequences was carried out using ClustalW (Thompson, Higgins, & Gibson, 1994).

2.8 Generation of homology model
In order to dock the hemorphin peptides to the human MOR, a homology
model was developed using Schrödinger Prime. Briefly, a BLAST search of Protein
Data Bank (PDB) was carried out to determine homologous protein structures. The
X-ray crystallographic structure of the active MOR from Mus musculus (PDB ID:
5C1M) was used as the template, with an overall sequence identity of 72%, to
produce three-dimensional homology model of the active human MOR (UniProt
accession: P35372). Protein refinement modules of Schrödinger Prime were used to
refine the loops and the structure was minimized and optimized.
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2.9 Protein structure pre-processing
PDB was used to retrieve three dimensional structures of MOR (PDB ID:
5C1M), IRAP (PDB ID: 5MJ6), ACE (PDB ID: 2XY9), AT1R (PDB ID: 4ZUD),
and hemoglobin (PDB ID: 3GDJ, 2HHB) (Akif et al., 2011; Fermi et al., 1984; H.
Zhang et al., 2015a; H. Zhang et al., 2015b). Protein Preparation Wizard of
Schrödinger Suite 2016-4 was used to pre-process the protein structure retrieved
from PDB (Schrödinger, LLC, New York, NY). The preparation of protein involved
a number of steps including the proper assignment of bond orders, adjustment of
ionization states, orientation of disorientated groups, creation of disulphide bonds,
removal of water molecules, metal and co-factors, capping of terminus amide,
assignment of partial charges, and the addition of missing atoms and side chains.
Hydrogen atoms were integrated and protonation state at pH 7 was used. In order to
acquire a geometrically stable structure, optimization and minimization steps were
carried out (Sastry, Adzhigirey, Day, Annabhimoju, & Sherman, 2013).

2.10 Ligand preparation
Two dimensional structures of 2,3 BPG and ATP were retrieved from
PubChem. These two ligands were prepared and conformers were produced using
Schrödinger Ligprep (Schrödinger, LLC, New York, NY). Briefly, preparation of
ligands included conversion of 2D structures to 3D format, addition of hydrogen
atoms, generation of tautomer and ionization states, neutralization of charged groups,
structure filtration and finally geometry optimization of the molecule.
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2.11 Active site identification and grid generation
A receptor grid was created, by using default parameters, around the active
site of the prepared protein. Van der Waal’s scaling factor of 1 and a charge cutoff of
0.25 were used for this purpose. Lastly, a cubic search space was made which
focused specifically on the centroid of the active site residues of the studied drug
targets.

2.12 Peptide and ligand docking
In order to predict the binding pose of hemorphins in MOR, IRAP, ACE and
AT1R, as well as to measure the binding free energy, peptide docking was used. The
Schrödinger Peptide Docking version 2016-4 was used to perform peptide docking
with penalties for cis amide bonds (Schrödinger, LLC, New York, NY). All peptides
were docked into active sites of the MOR, IRAP, ACE, and hemoglobin by using
default parameters. Additionally, flexible ligand sampling was used to produce
diverse ligand conformations by the ConfGen algorithm (Watts et al., 2010). The
OPLS 2005 force field was used to describe the protein and peptide and post docking
minimization was also executed in the gridded protein field. The GlideScore
(GScore) scoring function was used to rank different poses (Friesner et al., 2006).
Finally, the lowest GScore value of the top docked pose was reported for each
peptide small ligands.

For predicting the binding pose, activity and affinity of 2,3-BPG and ATP
molecules with camel and human hemoglobin, ligand docking was carried out. Grid
based docking was performed using Schrödinger Glide version 2016-4 (Schrödinger,
LLC, New York, NY). Standard precision (SP) docking was carried out first
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followed by extra precision (XP) docking. To soften the potential of nonpolar parts
of ligands, the scaling factor for the ligand van der Waals radii was set in 0.80 with a
partial atomic charge of 0.15. In both SP and XP docking procedures, flexible ligand
sampling was used to generate various ligand conformations. No constraints were
used in the entire docking studies. Optimized Potentials for Liquid Simulations
(OPLS) 2005 force field was used and post docking minimization was also carried
out. Both 2,3-BPG and ATP were docked flexibly to camel and human hemoglobin
structures.

2.13 Analysis of docking results and binding free energy calculation
Schrödinger Maestro was used to visualize and interpret interactions such as
hydrogen bond interactions, π interactions and hydrophobic interactions involving
the top pose (Schrödinger, LLC, New York, NY). Binding free energy calculations
were performed using molecular mechanics-generalized born surface area (MMGBSA), in an implicit solvent model. These MM-GBSA based binding energies were
estimated using the OPLS 2005 force field and Schrödinger Prime employing the
VSGB 2.0 implicit solvent model (Li et al., 2011). For the purpose of MM-GBSA
binding energy estimations, the receptor was treated rigidly and the peptide was
minimized.

2.14 Molecular dynamics (MD) simulations
MD simulations were carried out to determine the protein dynamics and
interaction

stability

of

the

top

binding

pose

of

the

LVVYPWTQRF,

LVVYPWTRRF, YPWTQRF, YPWTRRF, 2,3-BPG, and ATP in the active site of
appropriate target receptor as explicitly detailed in the results section of each chapter.
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MD simulations of these ligand-protein complexes were carried out using Desmond
employing the OPLS 2005 force field (Bowers et al., 2006).

2.14.1 Simulation of membrane bound proteins

Different systems of human and camel hemorphin peptides docked to MOR,
and AT1R were prepared. Each of the peptide bound simulations were carried out
with different initial velocities in triplicates for 100 ns and 500 ns, respectively. The
complex structures of MOR and AT1R with hemorphin peptides were embedded into
a pre-equilibrated DPPC membrane in an orthorhombic box. Each prepared system
of hemorphin bound to MOR and AT1R were solvated using the single point charge
(SPC) water model with a water box, and a buffer distance of 10 Å was maintained.
In order to maintain a salt concentration of 0.15 mM NaCl, counterions and
appropriate number of ions were incorporated. Prior to conducting MD simulations,
each system was subjected to steepest descent minimization with Desmond’s default
protocol.

The default relaxation protocol for membrane proteins was used to initially
relax the prepared systems. Eight stages of relaxation procedure encompassed
minimization with constraint on solute heavy atoms, constraint free minimization,
simulation with heating from 0 K to 300 K heating, H2O barrier and gradual
constraining, simulation under constant number of particles, pressure and
temperature NPT equilibration with H2O barrier with heavy atoms restrained, NPT
equilibration of solvent and lipids, simulation in the presence of NPT ensemble with
protein heavy atoms constraint decreased from 10.0 to 2.0 kcal/mol, NPT
equilibration with Cα atoms constrained at 2 kcal/mol, and simulation with no
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constrains for 1.5 ns under the NPT ensemble. Finally, production simulation runs
were carried out for 100 ns or 500 ns each system of MOR and AT1R, respectively.

The simulation runs were carried out under NPT ensemble using the NoseHoover thermostat to maintain a temperature of 300 K and isotropic Martyna-TobiasKlein barostat to maintain the pressure at 1 atm (Martyna, Klein, & Tuckerman,
1992; Martyna, Tobias, & Klein, 1994). The short-range Coulombic interactions
were investigated with a cut-off value of 9.0 Å using the short-range approach
(Essmann et al., 1995). A time-reversible reference system propagator algorithm
(RESPA) integrator was used with a time step of 2.0 fs (Tuckerman, Berne, &
Martyna, 1992). For the purpose of analysis, the trajectories were saved at an interval
of 100 ps. When simulation runs were finished, RMSD, RMSF, and protein-ligand
contacts were evaluated.

2.14.2 Simulation of non-membrane bound proteins

Different systems of human and camel hemorphin peptides bound to ACE,
and IRAP were prepared and each of the peptide bound simulations were carried out
with different initial velocities in triplicates for 200 ns or 100 ns, respectively.
Additionally, complex systems of 2,3-BPG and ATP with human and camel
hemoglobin were prepared and simulated for 200 ns. Briefly, each complex system
was solvated in an orthorhombic box by using the SPC water model, and a buffer
distance of 10 Å was maintained (Schrödinger, LLC, New York, NY). In order to
maintain a salt concentration of 0.15 mM NaCl, counterions and appropriate number
of ions were incorporated. Prior to conducting MD simulations, each system was
subjected to steepest descent minimization with Desmond’s default protocol. The
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simulation runs were carried out under NPT ensemble using the Nose-Hoover
thermostat to maintain a steady temperature of 300 K and isotropic Martyna-TobiasKlein barostat to sustain the pressure at 1 atm (Martyna et al., 1992; Martyna et al.,
1994). The short-range Coulombic interactions were investigated with a cut-off value
of 9.0 Å using the short-range approach (Essmann et al., 1995). A time-reversible
reference system propagator algorithm (RESPA) integrator was used with a time step
of 2.0 fs (Tuckerman et al., 1992). For the purpose of analysis, the trajectories were
saved at an interval of 100 ps. Lastly, root mean square deviation (RMSD), root
mean square fluctuation (RMSF), and protein-ligand contacts of each complex
system was determined from the trajectories.

2.15 In vitro ACE inhibition assay
The inhibition of ACE was assessed using the ACE Kit WST (Dojindo
Laboratories, Mashiki-machi, Japan). Custom synthesized hemorphin peptides
(LVVYPWTQRF, LVVYPWTRRF, YPWTQRF, and YPWTRRF) were purchased
from New England Peptide (Gardner, MA, USA). Manufacturer’s instructions were
followed for preparing the indicator working solution and enzyme working solution.
From each hemorphin peptide, 10 µl of each dose was added to the wells of a 96well microplate. While, in blank 1 and blank 2, 20 µl and 40 µl of deionized water
were added, respectively. A volume of 20 µl of the substrate buffer was added to
each well. Next, 20 µl of enzyme working solution was added in all of the sample
wells and blank 1. The plate was then immediately incubated at 37°C for 1 h. After 1
h of incubation, 200 µl of indicator working solution was added to each well and
then incubated for 5 min at room temperature. After 5 min of room temperature
incubation, plate absorbance was determined at 450 nm using Glomax Discover
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Microplate Reader (Promega, Madison, WI, USA). Finally, the ACE inhibitory
activity was computed using the following equation: Inhibition rate (%) = (Ablank1 −
Asample) / (Ablank1 − Ablank2) × 100. From the obtained ACE inhibitory data, IC50 was
measured using Prism 7 (GraphPad, San Diego, CA, USA) from a non-linear
regression plot of ACE inhibition (%) against peptide concentration (µM).

2.16 cDNA constructs and ligands
The human protein-coding plasmids, AT1R-RlucII, yPET–β-arrestin 2, and
Venus-Gαq for the brief expression in HEK293 cells were generously provided by
Dr Stéphane Laporte (McGill University, Montréal, QC, Canada), Dr Mark Scott
(Cochin Institute, Paris, France), and Dr Nevin Lambert (Augusta University, GA,
USA), respectively. Irbesartan and AngII (Sigma, St. Louis, MO, USA) and LVV–
hemorphin-7 (LVVYPWTQRF) (New England Peptide, Gardner, MA, USA) were
used as ligands in this study.

2.17 Cell culture and transfection
HEK293 cells were kept at 37°C, 5% CO2 in complete medium (Dulbecco
modified Eagle medium (DMEM) containing 100 IU/ml of penicillin, 100 µg/ml of
streptomycin, and 0.3 mg/ml of glutamine), complemented with 10% fetal calf serum
(GIBCO BRL, Carlsbad, CA, USA). For bioluminescence resonance energy transfer
(BRET) measurements, brief transfections were performed in 96-well plates.
However, IP1 experiments were carried out in six-well plates using lipofectamine
2000 (Invitrogen). Precisely, for BRET experiments, in each 96-well plate, 50 ng of
either Venus-Gαq or yPET–β-arrestin 2 was mixed with 25 ng of AT1R-Rluc in 25
µl of serum-free DMEM and kept at room temperature for 5 min. Next, 25 µl of
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serum-free DMEM containing 0.5 µl of Lipofectamine 2000 was added in the
plasmid solution and kept at room temperature for 20 min. Finally, 96 well plates
were seeded with cells (105 in 150 µl/well) resuspended in DMEM complemented
with 10% fetal calf serum (FCS) were then kept with the final DNA-Lipofectamine
2000 mix (50 µl/well). All experiments were performed after 48 h transfection.

2.18 Dose–response BRET assay
For dose-response assays, BRET technology was used as mentioned earlier
(Ayoub et al., 2015). Briefly, cells were initially washed with 50 µl/well of
phosphate-buffered saline (PBS) and challenged at 37°C for 30 min with 40 µL of
PBS containing or not (vehicle) the designated doses of either LVV-hemorphin-7,
AngII (control), or AngII in the presence of the specified doses of LVV–hemorphin7. Immediately after treatment, 10 µl of coelenterazine h (Promega) in PBS was
incorporated to a final concentration of 5 µM, and BRET signals were measured
using the Tristar 2 multilabel plate reader (Berthold, Germany), permitting sequential
measurements of light emission at 480 and 540 nm. While, for the antagonist assays
using irbesartan, cells were initially incubated with 30 µl of irbesartan (10 µM) at
37°C for 15 min before their stimulation with 10 µl of LVV–hemorphin-7 (10 µM)
followed by the activation with 10 µl of AngII (10 nM) at 37°C for 30 min, and
BRET measurements were carried out as mentioned above.

2.19 Real-time BRET kinetic assay
Several protocols were adopted for the real-time BRET kinetics. For this,
cells were initially washed with 50 µl/well of PBS and resuspended in 40 µl/well of
PBS having coelenterazine h (5 µM), and BRET signals were determined in real time
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for approximately 5 min to estimate the baseline. While, in the direct protocol, 10
µl/well of PBS with or not (vehicle) either 10 µM of LVV–hemorphin-7, 10 nM of
AngII (control), or both, was added, after the baseline, and BRET reading were
measured for 50 min. However, for sequential protocol, after the baseline, BRET
readings were measured in real time upon two sequential treatments (T1 and then
T2). This comprises of 10 µl/well of PBS with or not (vehicle) 10 µM of LVV–
hemorphin-7 (T1) and BRET signals were measured for 10 min. Immediately after
that, 10 µl/well of PBS with or not (vehicle) 10 nM of AngII were added and BRET
signal were again measured for 25 min. Finally, the BRET measurements were also
performed in opposite order (10 nM of AngII followed by 10 µM of LVV–
hemorphin-7) as discussed in results section of Chapter 5.

2.20 IP1 accumulation assay
Analysis of IP1 accumulation was carried out in HEK293 cells briefly coexpressing either AT1R-Rluc with Venus-Gαq similar to previous BRET
experiments or only untagged AT1R (AT1R-WT) with the help of IP-One Tb kit
(Cisbio Bioassays, France) as per manufacturer’s instructions. For this set of
experiments, cells were initially incubated or not (control) with 10 µM of LVV–
hemorphin-7 at 37°C for 15 min before activated or not (vehicle) with the different
doses of AngII at 37°C for 30 min. After that, cells were lysed by using the available
assay reagents, and the assay was kept at room temperature for 1 h. Finally,
fluorescence emission was determined after excitation at 340 nm, at 620 nm and 665
nm, for 50 µs using the Tristar 2 multilabel plate reader (Berthold, Germany).
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2.21 Data presentation and statistical analysis
The data obtained from BRET experiments are given as the ratio of light
emission at 540 nm over 480 nm was initially transformed into “ligand-induced
BRET” signals by deducting the ratio obtained from vehicle-treated cells from the
same ratio obtained from AngII/LVV–hemorphin-7–treated cells. Next, for BRET
and IP1 experiments, % responses were obtained by taking the maximal AngIIinduced signal as 100% in the control condition in different assays. Additionally, the
kinetic and the sigmoidal dose–response curves were adjusted to appropriate
nonlinear regression equations using GraphPad Prism software (San Diego, CA,
USA). The data being measured was demonstrated as mean ± SEM (Standard Error
of the Mean). As appropriate, one- way or two-way analysis of variance (ANOVA)
was carried out and Tukey multiple-comparisons test or Sidak’s multiplecomparisons test was used to compare means for determining the degree of
significance between the different treatments statistically.
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Chapter 3: Insights into the Interaction of Hemorphin and its Targets
3.1 Results
Extensive computational approaches were employed to investigate the
binding mode and and binding stability of hemorphin peptides with MOR and IRAP.
3.1.1 Multiple sequence alignment of hemoglobin  protein sequences
The reference sequence of hemoglobin (HBB) proteins of closely related
mammals were obtained from NCBI Protein database. Multiple sequence alignment
was carried out using ClustalW to identify the similarities and differences in HBB
protein sequences (Clustal, Thompson, Higgins, & Gibson, 1994). LVV-hemorphin7 is a 10 amino acids long peptide, and its sequence is highly conserved among
mammals. It ranges from amino acid positions 32 to 41 in the HBB protein sequence
in human, chimpanzee, camel, pig, and rabbit. In the bovine and sheep protein, it lies
between amino acids positions 30 to 39, and in the horse, the LVV-hemorphin-7 is
positioned between amino acids 31 to 40. The multiple sequence alignment results
indicated a single amino acid substitution in the camel HBB protein at position 40,
where glutamine has been substituted with arginine (Q > R). The remaining residues
in this region are identical (Figure 5).

Figure 5: Sequence alignment of hemoglobin  protein sequences of closely related mammals - Homo sapiens (human), Pan troglodytes
(chimpanzee), Camelus dromedarius (camel), Oryctolagus cuniculus (rabbit), Sus scrofa (wild pig), Equus caballus (horse), Bos taurus (bovine),
and Ovis aries (sheep). Multiple sequence alignment showed a variation in camel hemoglobin at position 40, where glutamine was changed to
arginine. The hemorphin region of hemoglobin  protein is shown in green color and substituted residue is represented with red color.
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3.1.2 Structure-based homology modeling of -type opioid receptor
The X-ray crystallographic structure of MOR from Mus musculus (PDB ID:
5C1M) was used as a template to generate the three-dimensional (3D) homology
model of the active state of the human -type opioid receptor (MOR) (UniProt
accession: P35372) (Figure 7). The generated structural model of the active MOR’s
active conformation is similar to the conserved seven-transmembrane topology of G
protein-coupled receptors (GPCRs). Additionally, the Ramachandran plot indicated
that the produced model’s general stereochemical quality was good with nearly all
the residues are in the permissible and favorable regions (Figure 6).

Figure 6: Ramachandran plot of the human mu opioid receptor model.

42
3.1.3 Molecular docking

The binding mode of both non-camel (LVVYPWTQRF) and camel
(LVVYPWTRRF) LVV-hemorphin-7 peptides was determined through extensive
docking and free energy calculations. For each binding mode the binding free
energies were calculated with the help of molecular mechanics generalized Born and
surface area (MM-GBSA) method.
3.1.4 -opioid receptor
The docking of both LVVYPWTRRF and LVVYPWTQRF peptides with
MOR produced 10 models each. The top five docked poses of LVVYPWTQRF
peptide produced the GScore of -10.88 kcal/mol, -10.61 kcal/mol, -10.23 kcal/mol, 9.83 kcal/mol, -9.35 kcal/mol and the calculated MM-GBSA binding free energies
corresponding to these poses were -97.82 kcal/mol, -94.38 kcal/mol, -91.86 kcal/mol,
-87.91 kcal/mol, and -84.79 kcal/mol, respectively. The top five docked poses of
LVVYPWTRRF peptide produced the GScore of -10.65 kcal/mol, -10.53 kcal/mol, 10.35 kcal/mol, -10.23 kcal/mol, -9.96 kcal/mol and the calculated MM-GBSA
binding free energies corresponding to these poses were -108.35 kcal/mol, -115.07
kcal/mol, -101.61 kcal/mol, -94.73 kcal/mol, and -91.89 kcal/mol, respectively. The
list of interacting residues of the best pose of each peptide along with their respective
Gscore and MM-GBSA binding free energy are provided in Table 3. The top-docked
conformation of LVVYPWTQRF peptide demonstrated that the residues of the Nterminal of the peptide formed interactions with residues in transmembrane helices 5
and 6 (TM5 and TM6) present at the bottom of the binding site. The N-terminal
residues (Leu1-Val2-Val3) of LVVYPWTQRF formed multiple hydrophobic
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interactions with TM6 residues Ile298, Tyr301, Val302, Ala306, and Val308. A
hydrogen bond was formed between Leu1 and the backbone amino group of the
hydrophilic Asn232 located on TM5. Tyr4 of the peptide produced interactions with
Asp149 via a hydrogen bond and, along with Pro5, it exhibited hydrophobic
interactions with Ile146 and Tyr150 located on TM3. However, Pro5, Trp6, and Thr7
residues of LVVYPWTQRF formed interactions with Arg213, Ile217, Cys219,
Thr220, and Leu221 on the  sheet. The C-terminal residues (Thr7-Gln8-Arg9Phe10) of LVVYPWTQRF peptide formed hydrophobic interactions with Trp320,
His321, Ile324, and Tyr328 on TM7. His321 located on TM7 formed a π- π stacking
with Trp6 and a hydrogen bond with Gln8. Additionally, Gln8 also produced
hydrogen bonds with the side chain of the Glu312 situated on the third extracellular
loop and with Lys305 on TM5 (Figure 8A and Figure.9).

Table 3: Interacting residues of the best pose of non-camel (LVVYPWTQRF) and camel (LVVYPWTRRF) hemorphin with MOR, and IRAP.
Protein

Peptide

Glide docking MM-GBSA
score - GScore (kcal/mol)
(kcal/mol)

Residues forming
hydrogen bonds

MOR

LVVYPWTQRF

-10.88

-97.82 Gln126, Asn129,
Leu131, Asp149,
Asn232, Lys305,
Glu312, His321

MOR

LVVYPWTRRF

-10.53

-115.08 Asp149, Lys211,
Tyr212, Glu231,
Lys305, Ala306,
Glu312

Residues forming
hydrophobic
interactions

Residues
forming π-π
stacking

Leu58, Pro61, Pro65,
His321
Tyr77, Tyr130, Met132,
Ile146, Tyr150, Ile217,
Cys219, Leu221,
Trp228, Ile298, Tyr301,
Val302, Ala306,
Val308, Trp320, Ile324,
Tyr328
Ile146, Tyr150, Cys219,
Leu221, Phe223,
Trp228, Leu234, Ile236,
Val238, Ile298, Val302,
Ile303, Leu307, Val308,
Trp320, Ile324, Tyr328
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Table 3: Interacting residues of the best pose of non-camel (LVVYPWTQRF) and camel (LVVYPWTRRF) hemorphin with MOR, and IRAP
(Continued).
Protein

Peptide

Glide docking MM-GBSA
score - GScore (kcal/mol)
(kcal/mol)

Residues forming
hydrogen bonds

Residues forming
hydrophobic
interactions

IRAP

LVVYPWTQRF

-14.857

-148.038 Gly428, Glu441,
Lys460, Glu509,
Asp510, Glu541,
Glu818, Glu825,
Glu895

Tyr272, Pro296,
Ala427, Ala429,
Met430, Ala453,
Leu457, Ile461, Tyr495,
Ala514, Phe544,
Tyr549, Phe550,
Ala763, Leu769,
Ala822, Phe826, Tyr961

IRAP

LVVYPWTRRF

-13.653

-163.028 Gly428, Glu441,
Asp510, Glu541,
Glu818, Glu825,
Glu895

Tyr272, Pro296,
Ala427, Ala429,
Met430, Ala453,
Leu457, Ile461, Leu469,
Tyr495, Ala514,
Phe544, Tyr549,
Phe550, Ala822,
Phe826, Pro957, Tyr961

Residues
forming π-π
stacking
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The top pose of LVVYPWTRRF peptide exhibited a GScore of
−10.53 kcal/mol and MM-GBSA binding energy of −115.08 kcal/mol (Table 1).
Leu1, Val2, and Val3 residues of LVVYPWTRRF formed interactions with residues
located on TM5 (Glu231 and Ile236) and TM6 (Val302, Ile303, and Leu307). As
compared to LVVYPWTQRF, the Pro5 and Trp6 residues produced hydrogen bonds
with Tyr212 and Lys211, respectively, as well as showed hydrophobic interactions
with the β-sheet residues. However, the C-terminal residues of LVVYPWTRRF
peptide showed interactions with residues situated on TM3, TM5 and TM7. A
hydrogen bond was formed between Arg9 and Asp149 on TM3, while the substituted
arginine at position 8 exhibited a hydrogen bond with the side chain of Glu312
located on the third extracellular loop. Moreover, Val3, Tyr4 and Thr7 formed
hydrogen bonds with Glu231 (Figure 8B). A list of hydrophobic interactions that
were observed between LVVYPWTRRF and MOR are shown in Figure 10.

A

B

Figure 7: 3D structure of modeled active human MOR. (A) Side view of the binding pocket of MOR; (B) Top view of the binding pocket of
MOR. The MOR protein is shown with a sea green cartoon representation.
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A

B

Figure 8: Interactions of hemorphin peptides with MOR. (A) LVVYPWTQRF (non-camel hemorphin) docked in the binding pocket of MOR.
(B) LVVYPWTRRF (camel hemorphin) docked in the binding pocket of MOR. The MOR protein is shown with a sea green cartoon
representation. Hydrogen bonds are represented by black dotted lines and cation-π interactions are represented by red dotted lines.
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Figure 9: Interactions of non-camel LVV-hemorphin-7 residues with mu-opioid receptor.
49
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Figure 10: Interactions of camel LVV-hemorphin-7 residues with mu-opioid
receptor.
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3.1.5 Insulin-regulated aminopeptidase

Binding free energy calculations were performed for the different docking
conformations of LVVYPWTQRF and LVVYPWTRRF peptides. The top five
docked poses of LVVYPWTQRF peptide exhibited the GScore of -14.86 kcal/mol,
-13.91 kcal/mol, -13.33 kcal/mol, -12.73 kcal/mol, and -12.45 kcal/mol and the
calculated MM-GBSA binding free energies corresponding to these poses were 148.04 kcal/mol, -129.41 kcal/mol, -122.81 kcal/mol, -119.71 kcal/mol, and -114.88
kcal/mol, respectively. The top five docked poses of LVVYPWTRRF peptide
generated the GScore of -13.65 kcal/mol, -13.41 kcal/mol, -13.19 kcal/mol, -12.81
kcal/mol, -12.53 kcal/mol and the calculated MM-GBSA binding free energies
corresponding to these poses were -163.03 kcal/mol, -151.21 kcal/mol, -137.29
kcal/mol, -129.91 kcal/mol, and -119.44 kcal/mol, respectively. The list of
interacting residues of the best pose of each peptide along with their respective
Gscore and MM-GBSA binding free energy are provided in Table 3. The N-terminal
of LVVYPWTQRF and LVVYPWTRRF peptides occupied the S1 pocket, which is
adjacent to the binding pocket. Figure 12A displays the binding mode for
LVVYPWTQRF. In the reported binding mode, the N-terminal residues (Leu1, Val2,
and Val3) of LVVYPWTQRF occupied the S1 pocket and showed hydrogen bonds
with Leu541, Tyr549, and Gly428. These three N-terminal residues produced
hydrophobic interactions with residues in the S1 pocket - Tyr272, Pro296, Phe425,
Ala427, Ala429, Met430, Phe544, and Tyr961. Hydrogen bonds were formed
between aromatic residues Tyr4 and Trp6 of LVVYPWTQRF and Glu441 and
Lys460, respectively. They also interacted hydrophobically with Ala453, Leu457,
Ile461, Tyr495, Ala514, and Phe550. Gln8, Arg9, and Phe10 interacted
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hydrophobically with Ala763, Leu769, Phe770, Ala822, and Phe826. Thr7 exhibited
a hydrogen bond with Asp510, Gln8 showed hydrogen bonds with Glu509, and
Glu818 and Arg9 formed hydrogen bonds with the side chain of residues Glu825 and
Glu895 (Figures 12A, and 13). The interacting residues and binding scores are
shown in Table 3.

LVVYPWTRRF demonstrated a similar binding mode with the N-terminal
stabilized in the S1 pocket. The N-terminal residues (Leu1, Val2, and Val3) bound in
the S1 pocket and formed interactions hydrophobically with Tyr272, Pro296,
Ala427, Ala429, Met430, Phe544, Tyr549, Pro957, and Tyr961. Importantly, Val2
residue formed a hydrogen bond with the amino group of Gly428 of the GAMEN
loop (Gly428-Ala429-Met430-Glu431-Asn432). Tyr4, Pro5, and Trp6 residues of
LVVYPWTRRF peptide formed hydrophobic interactions with the active site
residues Leu457, Ile461, Tyr495, Ala514, and Phe550 and Trp6 produced a
hydrogen bond with Lys460. Arg8 formed hydrogen bonds with the side chain of
Glu825 and Glu895. However, Arg9 produced hydrogen bonds with Asp510 and
Glu818. The last three residues of C-terminal also formed hydrophobic interactions
with Leu769, Ala822, and Phe826 (Figures 12B and 14).

Figure 11: 3D structure of IRAP. (A) The active site of IRAP; (B) The enlarged view of the active site of IRAP in A. The hemorphin peptide
bound in the active site is shown in orange CPK representation, while GAMEN motif is shown in yellow CPK representation. The IRAP protein
is shown with a purple cartoon representation.
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A

B

Figure 12: Interactions of hemorphin peptide with IRAP. (A) LVVYPWTQRF (non-camel hemorphin) docked in the binding pocket of IRAP.
(B) LVVYPWTRRF (camel hemorphin) docked in the binding pocket of IRAP. The IRAP protein is shown with a purple cartoon representation.
Hydrogen bonds are represented by black dotted lines and cation-π interactions are represented by red dotted lines.
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Figure 13: Interactions of non-camel LVV-hemorphin-7 residues with IRAP.
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Figure 14: Interactions of camel LVV-hemorphin-7 residues with IRAP.
3.1.6 Molecular dynamics simulations

In order to investigate the stability and dynamics of the docked complexes,
all-atom MD simulations were carried out in triplicates using Desmond (Bowers et
al., 2006).
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3.1.7 Simulations of camel and non-camel LVV-hemorphin-7 bound to MOR
Three independent 100 ns all atom MD simulations of the LVVYPWTQRF
bound to modeled MOR structure embedded in a dipalmitoylphosphatidylcholine
(DPPC) membrane resulted in stable simulations with a protein Cα RMSD below 5 Å
(Figure 15A). The per-residue RMSF demonstrated that the third intracellular (ICL3) and extracellular loop (ECL-2) regions were the most flexible whereas the regions
that

were

membrane-embedded

were

the

least

flexible

(Figure

15B).

LVVYPWTQRF formed interaction with residues located on TM3 and TM7 during
MD simulations. Tyr4 and Trp6 produced sustained hydrogen bond and hydrophobic
interactions with Tyr150 and Asp149, respectively on TM3. Leu1 formed interaction
with the TM5 residue Glu231. Tyr4 residue showed interaction with Lys305 whereas
Val3, Trp6, and Arg9 residues formed sustained interactions with Trp320, Ile324 and
His321, respectively located on TM7 in the simulations. The average percentage of
equilibrated simulation period during which LVVYPWTQRF formed interactions
with MOR residues is shown in Figure 16. Contributions from each simulation are
given in Figure 18A.

In the case of LVVYPWTRRF peptide bound simulations, the protein
structure remained stable with RMSD below 4.5 Å in all three independent
simulations (Figure 15C). Figure 15E shows the distribution of the RMSD values
extracted from the LVVYPWTQRF and LVVYPWTRRF bound simulations. ECL-2
and ICL-3 regions demonstrated higher fluctuations. More importantly, ICL-3
produced higher fluctuations when compared to the MOR-LVVYPWTQRF complex
(Figure 15D). LVVYPWTRRF exhibited interactions with residues from TM2, TM3,
TM5, TM6, TM7 and the β-sheet. Arg9 showed interactions with Asp149 for the full
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duration of all three simulations, whereas Phe10 formed interaction with Tyr150
during the simulations. Additionally, LVVYPWTRRF peptide also formed
interaction with Glu231, Asn232, and Lys235 residues of TM5. Leu1 and Tyr4
residues formed consistent interactions with Ala306 and Lys305, respectively,
located on TM6 and the C-terminal residues showed interactions with Trp320, and
Tyr328 present on TM7. They also exhibited consistent interactions with Ile310 and
Glu312 on the third extracellular loop. The average percentage of equilibrated
simulation time during which the non-camel LVV-hemorphin-7 interacted with
MOR residues is given in Figure 17. Contributions from each simulation are shown
in Figure 18B.
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Figure 15: RMSD and RMSF plots of triplicate 100 ns simulations of MOR. Data
from the three independent runs are represented with red, blue, and green lines. (A)
RMSD of MOR-LVVYPWTQRF complex. (B) RMSF of MOR-LVVYPWTQRF
complex. (C) RMSD of MOR-LVVYPWTRRF complex. (D) RMSF of MORLVVYPWTRRF complex. (E) Density functions corresponding to the distribution of
RMSD values from three independent hemorphin-bound simulations.
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Figure 16: The average percentage of equilibrium simulation time during which
residues of MOR maintained contact with LVVYPWTQRF peptide in triplicate
100 ns simulations. To extract the equilibrium simulation data, the initial 50 ns of run
1 was removed, whereas the initial 30 ns of runs 2 and 3 were removed. Charged,
hydrophobic, and polar amino acids are shown with orange, green and blue color
respectively.
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Figure 17: The average percentage of equilibrium simulation time during which
residues of MOR maintained contact with LVVYPWTRRF peptide in triplicate
100 ns simulations. To extract the equilibrium simulation data, the initial 50 ns of run
1 was removed, whereas the initial 30 ns of runs 2 and 3 were removed. Charged,
hydrophobic, and polar amino acids are shown with orange, green and blue color
respectively.
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Figure 18: Histograms of the percentage of simulation time where a MOR residue
maintains contact with the hemorphin peptide in triplicate simulations. For
equilibrium simulation data, the first 50 ns of run 1 was discarded, while the first 30
ns of runs 2 and 3 were discarded. A) MOR-LVVYPWTQRF. B) MORLVVYPWTRRF.
3.1.8 Simulations of camel and non-camel LVV-hemorphin-7 bound to IRAP

100 ns molecular dynamics simulation runs in triplicates were used to
determine the binding stability of the bound peptide. In the case of LVVYPWTQRF
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bound simulations, the IRAP structure maintained stability with RMSD below 2.5 Å
(Figure 19A). Overall, simulations showed lower fluctuations in the protein residues
and the secondary structure was preserved during all simulations (Figure 19B). The
first three residues of the N-terminal of LVVYPWTQRF peptide were stabilized in
the S1 pocket by forming hydrogen bonds and hydrophobic interactions. Leu1, Val2,
and Val3 showed sustained hydrogen bonds with Tyr549 and Gly428 throughout the
simulations and also formed interactions with Phe544. Tyr4, Pro5, and Trp6 formed
consistent interactions with Glu441, Phe550, and Asn965. However, the C-terminal
residues sustained their interactions with Asp510, Asp513, Glu818, Gu825, and
Glu895 residues. Moreover, during the course of simulations, new contacts were
observed between the first three residues of LVVYPWTQRF and Trp6 with Arg929,
and Asn965. The average percentage of equilibrated simulation period during which
LVVYPWTQRF peptide formed interactions with IRAP residues is shown in Figure
20. Contributions from each simulation are shown in Figure 22A.

LVVYPWTRRF bound simulations showed stability with an RMSD below
2.75 Å (Figure 19C). Overall, LVVYPWTRRF bound simulations produced limited
fluctuations in IRAP residues (Figure 19D). The secondary structure was also
preserved during the simulations. Figure 19E shows the distribution of the RMSD
values extracted from the LVVYPWTQRF and LVVYPWTRRF bound simulations.
The first three residues of LVVYPWTRRF were stabilized in the S1 pocket of IRAP
by forming hydrogen bonds and hydrophobic interactions. Val2 residue formed a
sustained hydrogen bond with Gly428 in the GAMEN loop throughout the
simulation runs. The N-terminal residues (Leu1, Val2, and Val3) also formed
sustained hydrophobic interactions with Ala429, Phe544, Tyr549, and Tyr961. Pro5
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showed consistent interactions with Lys460, whereas Trp6 formed interaction with
Asp513. The mutated Arg8 demonstrated sustained hydrogen bonds with the
negatively charged residues Glu509, Asp510 and Glu818. Lastly, Arg9 and Phe10
residues of LVVYPWTQRF also formed consistent interactions with Lys517,
Phe770, Glu825 and Glu895. The average percentage of equilibrated simulation
period during which LVVYPWTRRF interacted with IRAP residues is shown in
Figure 21. Contributions from each simulation are given in Figure 22B.
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Figure 19: RMSD and RMSF plots of triplicate 100 ns simulations of IRAP. Data
from the three independent runs are represented with red, blue, and green lines. (A)
RMSD of IRAP-LVVYPWTQRF complex. (B) RMSF of IRAP-LVVYPWTQRF
complex. (C) RMSD of IRAP-LVVYPWTRRF complex. (D) RMSF of IRAPLVVYPWTRRF complex. (E) Density functions corresponding to the distribution of
RMSD values from three independent hemorphin-bound simulations.

66

Figure 20: The average percentage of equilibrium simulation time during which
residues of IRAP maintain contact with LVVYPWTQRF peptide from triplicate
100 ns simulations. The initial 30 ns of each of the 3 simulations were removed to
extract the equilibrium simulation data. Charged, hydrophobic and polar amino acids
are shown with orange, green and blue color respectively.
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Figure 21: The average percentage of equilibrium simulation time during which
residues of IRAP maintain contact with LVVYPWTRRF peptide from triplicate
100 ns simulations. The initial 30 ns of each of the 3 simulations were removed to
extract the equilibrium simulation data. Charged, hydrophobic and polar amino acids
are shown with orange, green and blue color respectively.
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Figure 22: Histograms of the percentage of simulation time where an IRAP residue
maintains contact with the hemorphin peptide in triplicate simulations. For
equilibrium simulation data, the first 30 ns of each run were discarded. A) IRAPLVVYPWTQRF. B) IRAP-LVVYPWTRRF.
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3.2 Discussion
The therapeutic potential of hemorphins has already been demonstrated by
multiple in vivo and in vitro studies (Cheng et al., 2012; Fruitier-Arnaudin et al.,
2002; J. Lee et al., 2004). Understanding the binding mode and activity of these
peptides at the molecular level is important as LVV-hemorphin-7 binds to several
proteins with high affinity. Computational molecular modeling and simulation
studies often supplements experimental studies. In this study, extensive
computational methods were used to explore the precise binding mode of both camel
and non-camel LVV-hemorphin-7 with MOR, and IRAP to elucidate how the
peptide interacts with these structurally and functionally different.

In MOR, camel and non-camel LVV-hemorphin-7 adopted distinct poses.
The critical residues involved in the binding are in agreement with prior theoretical
and experimental data (Cui, Yeliseev, & Liu, 2013). Asp149, an acidic residue of
MOR, was found to make a hydrogen bond with both camel and non-camel LVVhemorphin-7 (Figures 8A, and 8B). Interestingly, camel LVV-hemorphin-7 showed
sustained interaction for the full duration of the three simulations, whereas the same
interaction was consistent for an average of 90% of the three non-camel LVVhemorphin-7 simulations. These results complement several site directed
mutagenesis studies and structural models that showed the vital role played by
Asp149 (Asp147 in murine MOR) in opioid ligand recognition and the interaction
with several opioid ligands (Li et al., 1999; Spivak et al., 1997; Xu et al., 1999). This
critical interaction therefore should be given special consideration while designing
future novel MOR ligands. Camel LVV-hemorphin-7 formed interactions
hydrophobically with Tyr328, which is in agreement with a prior study that showed
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that hemorphins interact with Tyr326 of mouse MOR49,( Li et al., 1999).
Additionally, Trp320 residue of TM7 formed interactions with hemorphins and is
also in agreement with earlier studies (Eguchi, 2004; Noori, Mucksch, & Urbassek,
2014). Interestingly, camel LVV-hemorphin-7 formed interactions with essential
residues in the active site for a longer duration than non-camel hemorphin (Figure
18).

LVVYPWTRRF formed more stable interactions with Thr220, Glu231, and
Tyr328 residues when compared to LVVYPWTQRF in the human MOR model. The
equivalent residues in the murine MOR – Thr200, Glu299, and Tyr326 – have been
shown to form interactions with agonists (Cui et al., 2013; Noori et al., 2014).
Moreover, RMSF values were observed to be higher for ICL-3 residues when bound
to camel LVVYPWTRRF. Camel LVV-hemorphin-7 mostly formed interactions
with TM3, TM6, and TM7 of MOR, which has been proposed to contain the ionic
lock important for GPCR activation (Huang et al., 2015). As observed, the peptidebound simulations increased the ICL-3 region’s flexibility, which is consistent with
downstream protein complex interactions and signaling pathways stimulated by
receptor agonists (Waldhoer, Bartlett, & Whistler, 2004). The simulations of MOR
bound to camel LVV-hemorphin-7 demonstrated a lower RMSD than non-camel
LVV-hemorphin-7 (Figure 15). ECL-2 exhibited limited fluctuations upon binding to
both LVVYPWTRRF and LVVYPWTQRF peptides. This could support the binding
and selectivity of peptides. This is also in agreement with several mutagenesis
studies that established the role of ECL-2 in ligand orthosteric and allosteric
activation (Huang et al., 2015; Venkatakrishnan et al., 2013; Wheatley et al., 2012).
Furthermore, Trp320 and Tyr328 residues are essential in regulating biased MOR
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signaling and are vital in effector coupling (Hothersall et al., 2017). Interestingly,
LVVYPWTRRF formed interactions with both residues, whereas LVVYPWTQRF
interacted with only Trp320. Therefore, due to ligand bias, it is conceivable that
camel LVV-hemorphin-7 could produce its effect on MOR.

In the case of IRAP, both LVVYPWTRRF and LVVYPWTQRF
demonstrated analogous binding interactions. The binding pose of both camel and
non-camel hemorphin peptides showed that their N-terminal residues were stabilized
in the S1 pocket by forming sustained hydrogen bonds with Gly428 and Tyr549
(Figure 12). Studies have shown that Tyr549 is an essential residue for binding and
stabilizing the catalytic transition state and is extremely conserved in the M1 family
of metalloproteases (Wong, Zhou, & Rini, 2012). Moreover, it also interacted with
Phe544 and Tyr961 in the active site. Importantly, the interaction with Phe544 was
earlier demonstrated as an essential interaction for substrate and ligand binding
(Albiston et al., 2010). HEXXH Zn2+ binding motif and the GXMEN exopeptidase
motif are two conserved motifs present in the catalytic domain of IRAP. Mutagenesis
studies of these motifs revealed that Gly428, Ala429, and Asn432 are critical for
binding both inhibitors and peptide substrates, and also indicated that peptide
inhibitors of IRAP competitively bind to its catalytic site (Ye et al., 2007). In the
present study, the N-terminal residues of LVVYPWTRRF peptide formed
interactions with the GAMEN loop residues Gly428 and Ala429, whereas
LVVYPWTQRF interacted with only Gly428 (Figs. 21 and 22). Particularly, Val2 of
LVVYPWTRRF exhibited interactions with Gly428 and Ala429 (Figure 10B).
However, Val3 of both LVVYPWTRRF and LVVYPWTQRF peptides showed
interactions with Tyr549. Val3 is critical for hemorphins binding to IRAP; exclusion
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of Val3 residue results in the annihilation of binding to IRAP (Lee et al., 2003). Tyr4
and Trp6 residues formed interactions with Glu441 and Phe550. It has been
suggested that monosubstitutions of Tyr4 and Trp6 with alanine leads to a 10-fold
reduction in binding affinity (Lee et al., 2003). Additionally, the N-terminal residues
of hemorphins are essential for the inhibition of IRAP by forming sustained
interactions with key IRAP residues. It has been reported that the removal of Cterminal residues of LVV-hemorphin-7, such as Thr7, Gln8, Arg9, and Phe10 did not
substantially alter their binding affinity for IRAP. However, a moderate reduction in
affinity was demonstrated with the removal of Arg9 residue in cerebellar
membranes. Interestingly, during MD simulations, LVVYPWTQRRF residues Arg8
and Arg9 were noticed to form consistent interactions with charged residues Lys456,
Glu509, Asp510, Asp513, and Glu818 in relation to LVVYPWTQRF bound
simulations (Figures 22A, and 22B). These sustained interactions could lead to a
better affinity of LVVYPWTRRF peptide in the IRAP catalytic pocket.
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Chapter 4: In silico and In vitro Comparison of the Angiotensin-I
Converting Enzyme Inhibitory Activity of Camel and other
Mammalian Hemorphins

4.1 Results
In silico and in vitro studies were performed to determine the ACE inhibitory
activities of both camel and non-camel hemorphins.
4.1.1 Molecular docking

Molecular docking and binding free energy calculations methods were used
to identify the binding pose of human hemorphins LVVYPWTQRF and YPWTQRF
and camel hemorphins LVVYPWTRRF and YPWTRRF. The docked poses of each
peptide obtained from peptide docking were examined using the GScore scoring
function (Friesner et al., 2006).

4.1.2 Docking of non-camel and camel LVV-hemorphin-7 to ACE

The binding score and residues of ACE that formed interactions with
LVVYPWTQRF, LVVYPWTRRF, YPWTQRF, and YPWTRRF peptides are listed
in Table 4. The active site of ACE is comprised of three subsites, which are also
essential for ACE inhibition, termed S1, S2, and S1′. These subsites contain residues
that form interactions with potential inhibitors (Abdelhedi et al., 2018; Priyanto et
al., 2015). Ala354, Glu384, and Tyr523 comprise the S1 subsite; Gln281, His353,
Lys511, His513, and Tyr520 comprise the S2 subsite, and Glu162 constitutes the S1′
subsite (Ma et al., 2018). These hemorphin peptides interacted with important
residues in the active site of ACE. LVVYPWTQRF and LVVYPWTRRF peptides
exhibited an extensive network of interactions including hydrogen bonds,
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hydrophobic and electrostatic interactions with ACE as demonstrated by the two
dimensional ligand in interaction diagram (Figures 24 and 25).

Table 4: List of interactions formed by the top binding pose of LVVYPWTQRF, LVVYPWTRRF, YPWTQRF, and YPWTRRF hemorphin
peptides with ACE.
Glide
docking
MMResidues forming
Peptide
scoreGBSA
hydrogen bonds
GScore
(kcal/mol)
(kcal/mol)
Asn70, Glu123,
Arg124, Glu162,
-14.045
-134.860
LVVYPWTQRF
Thr282, Ala354,
Ala356, Glu384,
Tyr523
Trp59, Glu123,
Glu162, Thr166,
-18.824
-147.566 Trp220, Ala354,
LVVYPWTRRF
Ala356, Glu384,
Asp415, Tyr523
Glu123, Glu162,
Asn277, Ala354,
-15.955
-112.525
YPWTQRF
Ala356, Asn377,
Glu384
Lys118,Glu162,
Gln281,Ala354,
Ala356,Tyr360,
-17.202
YPWTRRF
-130.392
Asn377,Glu384,
Arg402,Asp415,
Tyr523

Residues forming hydrophobic
interactions
Tyr51, Trp59, Tyr62,Ala63, Ile88, Ala89,
Val119, Leu122, Ala125, Leu139, Leu140,
Cys352, Trp357, Tyr360, Cys370, Val379,
Val380, Phe391, Tyr394, Ala418, Phe457,
Phe512, Val518, Tyr520, Phe527

Residues
forming ππ stacking
or cation-π
interaction
His410

Tyr62, Ala63, Ile88, Leu139, Leu161,
Ala204, Ala207, Ala216, Met223, Trp279,
Val379, Val380, Phe391,Tyr394, Pro407,
Phe457, Phe512, Val518, Pro519, Phe527
Tyr62, Ala63, Trp279, Cys352, Trp357,
Phe359, Tyr360, Cys370, Val379, Val380,
Phe391, Tyr394, Pro407, Phe457, Phe512,
Tyr520, Phe527
Tyr62, Ala63, Ile88, Trp279, Trp357,
Cys370, Val379, Val380, Phe391, Tyr394,
Pro407,Phe457, Phe512, Val518, Phe527

Trp59,
His410

Trp59,
His410
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The top binding pose of LVVYPWTQRF peptide exhibited a GScore and an
MM-GBSA binding energy of −14.045 kcal/mol and −134.860 kcal/mol,
respectively (Table 4). The C-terminal residue Phe10 of LVVYPWTQRF formed a
hydrogen bond and hydrophobic interactions with Thr282 and Phe527 of ACE.
Phe10 also formed a polar interaction with the S2 subsite residue Gln281 and three
electrostatic interactions with residues Glu376, His383, and Asp453. A hydrogen
bond was formed between Glu162 residue of S1′ subsite and the sidechain of Arg9.
Moreover, it also exhibited an electrostatic interaction with Lys454, and three
hydrophobic interactions with Cys352, Val379, and Val380. LVVYPWTQRF
residues Thr7, and Gln8 were situated in the S1 and S2 subsites of ACE. A hydrogen
bond was formed between the sidechain of Gln8 and Glu384, Thr7 formed hydrogen
bonds with Ala354 and Tyr523 residues of ACE. Additionally, Gln8 residue of the
peptide also exhibited electrostatic and polar interactions with Glu411, Lys511, and
His513 and two hydrophobic interactions with Phe457, and Tyr520. A cation-π
interaction was observed between His410 and Trp6. A hydrogen bond was also
formed between the backbone amino group of Trp6 and Ala356. LVVYPWTQRF
peptide residues Tyr4, Pro5, and Trp6 formed interactions hydrophobically with
Leu139, Leu140, Trp357, Phe391, Tyr394, and Pro407, and electrostatically with
Glu143, Asp358, Lys368, Glu403, and Arg522. The N-terminus residues (Leu1,
Val2, and Val3) of LVVYPWTQRF formed hydrophobic interactions with ACE
residues Tyr51, Trp59, Tyr62, Ala63, Ile88, Ala89, Val119, and Leu122. Hydrogen
bonds were formed between the sidechain amino group of Leu1 and sidechain
carboxyl group of Val3 with Glu123 and Arg124, respectively (Figures 24, and 26).

Figure 23: The active site of Angiotensin-I converting enzyme (ACE) shown in red circle and a closer look at the interaction of LVVhemorphin-7 in the active site of ACE.
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Figure 24: Closer view of the docked pose of LVVYPWTQRF peptide and the hydrogen bond interactions it forms with ACE shown as black
dashed lines. The ACE protein is shown with a green cartoon representation and its interacting residues are highlighted in pink stick
representation; the docked ligand is shown as orange sticks, and hydrogen bonds are represented as black dashed lines.
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Figure 25: Closer view of the docked pose of LVVYPWTRRF peptide and the hydrogen bond interactions it forms with ACE shown as black
dashed lines. The ACE protein is shown with a green cartoon representation and its interacting residues are highlighted in pink stick
representation; the docked ligand is shown as orange sticks, and hydrogen bonds are represented as black dashed lines.
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Figure 26: Interactions of human hemorphin (LVVYPWTQRF) with ACE. Colored
circles represent amino acids that form interaction with bound ligand. Red circles
indicate negatively charged amino acids, dark blue colors indicate positively charged
amino acids, light blue circles indicate polar amino acids, and green circles indicate
hydrophobic amino acids. Hydrogen bonds are shown with purple arrows – dashed
arrows for hydrogen bonds involving amino acid side chain and regular arrows for
hydrogen bonds involving amino acid backbone. π–π interactions are represented
with green lines.
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Figure 27: Interactions of camel hemorphin (LVVYPWTRRF) with ACE. Colored
circles represent amino acids that form interaction with bound ligand. Red circles
indicate negatively charged amino acids, dark blue colors indicate positively charged
amino acids, light blue circles indicate polar amino acids, and green circles indicate
hydrophobic amino acids. Hydrogen bonds are shown with purple arrows – dashed
arrows for hydrogen bonds involving amino acid side chain and regular arrows for
hydrogen bonds involving amino acid backbone. π–π interactions are represented
with green lines.
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The binding mode of LVVYPWTRRF peptide was observed to be slightly
different from that of LVVYPWTQRF. Precisely, the C-terminus residues binding
and positioning in the S1 and S2 subsites of the active site along with the orientation
of the N-terminus residues were different. The GScore and an MM-GBSA binding
energy calculated for the top binding pose was −18.824 kcal/mol and −147.566
kcal/mol (Table 4). The C- terminal residue Phe10 exhibited polar interactions with
S2 subsite residues such as Asn277, Gln281, Thr282, and Asn285. Phe10 also
formed two electrostatic interactions with Glu376 and Asp453, and two hydrophobic
interactions with Val379 and Val380. LVVYPWTRRF residues Thr7, Arg8, and
Arg9 engrossed the S1, S2, and S1' subsites. The backbone functional groups of
Arg9 such as amino groups formed hydrogen bonds with S1′ subsite residue Glu162
and with S2 subsite residue His353, whereas its sidechain amino group showed a
hydrogen bond with Thr166. Additionally, Arg9 also produced two hydrophobic
interactions with Leu161 and Trp279. The backbone and sidechain amino groups of
Arg8 exhibited hydrogen bonds with S1 subsite residue Glu384 and Asp415. Arg8
also interacted electrostatically with His383 and Glu411, and hydrophobically with
Phe457 and Phe527. LVVYPWTRRF residue Thr7 showed two hydrogen bonds
with the S1 subsite residues Ala354 and Tyr523. However, Trp6 exhibited a
hydrogen bond and a cation-π interaction with Ala356 and His410, respectively.
Trp6 also formed two polar interactions with His387 and His513. Moreover,
LVVYPWTRRF residues Pro5 and Trp6 interacted electrostatically with Trp357,
Asp358, Tyr394, Glu403, and Pro407. Tyr4 formed a hydrogen bond with Trp59 and
a π-π stacking with Tyr360. The backbone of N-terminal residues Leu1 and Val2
produced hydrogen bonds with Glu123 and Trp220, respectively. Additionally, Leu1,
Val2, and Val3 of LVVYPWTRRF peptide also interacted hydrophobically with
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Leu139, Ile204, Ala207, Met223, Val518, and Pro519, and electrostatically with
Arg124 (Figures 25 and 27).

4.1.3 Docking of non-camel and camel hemorphin-7 to ACE

The GScore and MM-GBSA binding energy calculated for the top binding
pose of YPWTQRF peptide with ACE were −15.955 kcal/mol and M −112.525
kcal/mol, respectively (Table 4). The first residue of YPWTQRF, Tyr1 showed a
hydrogen bond and π-π stacking with Glu123 and Trp59 of ACE, respectively. The
N-terminal residues of YPWTQRF, Tyr1 and Pro2 interacted hydrophobically with
Tyr62, Ala63, Trp357, Tyr360, and Val380. The backbone functional groups of Trp3
such as amino and carboxyl groups, exhibited hydrogen bonds with Ala356, while
the sidechain of Trp3 produced a cation-π interaction with His410. Moreover,
YPWTQRF peptide residues Thr4 and Gln5 occupied the S1 and S2 subsites. The
backbone and sidechain functional groups of Thr4 produced hydrogen bonds with
two ACE residues Ala354 and Tyr523. Gln5 exhibited a hydrogen bond with
Glu384. Additionally, Thr4 and Gln5 residues also interacted hydrophobically with
Phe359, Tyr394, Phe457, Phe512, and Tyr520. The C-terminal residues Arg6 and
Phe7 exhibited hydrogen bonds with S1′ subsite residue Glu162, and Asn277. A
hydrogen bond was also formed between Arg6 and Asn377. Additionally, Arg6
produced three polar interactions with Gln369, Thr371, and Thr372, and also
interacted hydrophobically with Cys352 and Cys370. Phe7 residue of YPWTQRF
peptide formed four polar interactions with Thr166, Gln281, Thr282, and Asn285,
and also interacted electrostatically with Glu376, His383, Asp415, and Lys511
(Figures 28 and 30).
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On the other hand, YPWTRRF peptide produced a slightly different binding
pose, specifically the N-terminus residues (Tyr1 and Pro2) and the C-terminus
residues (Arg5 and Phe7). The C-terminus residue Phe7 produced a hydrogen bond
with S2 subsite residue Gln281. Phe7 also exhibited interactions with Thr282,
Glu376, Asp453, Lys454, and Phe457. Arg6 showed hydrogen bonds with Asn377,
and the S1′ subsite residue Glu162. Arg6 also formed five polar interactions with
Thr166, Asn285, Gln369, Thr371, and Thr372 residues of ACE. The substituted
residue of YPWTRRF peptide, Arg5 formed a hydrogen bond with S1 subsite
residue Glu384 and Asp415. Arg5 showed a polar interaction with S2 subsite residue
His353 and also interacted hydrophobically with Phe527. However, the Trp3 and
Thr4 residues of both YPWTRRF and YPWTQRF peptides produced similar
interactions with ACE. Moreover, Pro2 produced interactions with Trp357, Val518,
and Asn66. Hydrogen bonds were formed between the backbone amino and
sidechain hydroxyl groups of Tyr1 and with Lys118, Tyr360, and Arg402. Tyr1 also
interacted electrostatically with Glu403 and hydrophobically with Tyr62, Ala63,
Val399, and Phe512. Additionally, the first residue of YPWTRRF also exhibited π-π
stacking with Trp59 (Figures 29 and 31). Finally, a GScore and a MM-GBSA
binding energy calculated for the top binding pose of YPWTRRF peptide with ACE
was -17.202 kcal/mol and -130.392 kcal/mol, respectively (Table 4).

Figure 28: Closer view of the docked pose of YPWTQRF peptide and the hydrogen bond interactions it forms with ACE shown as black dashed
lines. The ACE protein is shown with a green cartoon representation and its interacting residues are highlighted in pink stick representation; the
docked ligand is shown as orange sticks, and hydrogen bonds are represented as black dashed lines.
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Figure 29: Closer view of the docked pose of YPWTRRF peptide and the hydrogen bond interactions it forms with ACE shown as black dashed
lines. The ACE protein is shown with a green cartoon representation and its interacting residues are highlighted in pink stick representation; the
docked ligand is shown as orange sticks, and hydrogen bonds are represented as black dashed lines.
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Figure 30: Interactions of human hemorphin (YPWTQRF) with ACE. Colored
circles represent amino acids that form interaction with bound ligand. Red circles
indicate negatively charged amino acids, dark blue colors indicate positively charged
amino acids, light blue circles indicate polar amino acids, and green circles indicate
hydrophobic amino acids. Hydrogen bonds are shown with purple arrows – dashed
arrows for hydrogen bonds involving amino acid side chain and regular arrows for
hydrogen bonds involving amino acid backbone. π–π interactions are represented
with green lines.
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Figure 31: Interactions of camel hemorphin (YPWTRRF) with ACE. Colored circles
represent amino acids that form interaction with bound ligand. Red circles indicate
negatively charged amino acids, dark blue colors indicate positively charged amino
acids, light blue circles indicate polar amino acids, and green circles indicate
hydrophobic amino acids. Hydrogen bonds are shown with purple arrows – dashed
arrows for hydrogen bonds involving amino acid side chain and regular arrows for
hydrogen bonds involving amino acid backbone. π–π interactions are represented
with green lines.

89
4.1.4 Molecular dynamics simulations
In order to determine the stability and dynamics of the nteractions between
ACE and hemorphin peptides, all-atom MD simulations were run in triplicate using
Desmond (Bowers et al., 2006).
4.1.5 Simulations of different peptides of non-camel and camel hemorphins
bound to ACE
The results of MD simulations showed that both LVVYPWTQRF-ACE and
LVVYPWTRRF-ACE complex systems remained stable for the full duration of 200
ns simulations. The RMSD of ACE was stabilized at approximately 2.0 Å for both
LVVYPWTQRF and LVVYPWTRRF peptide bound structures (Figures 32A and
32B).

Both LVVYPWTQRF and LVVYPWTRRF peptide bound simulations

demonstrated that most protein residues exhibited lower fluctuations, but for loop
regions (Figures 33A and 33B), and the secondary structures were maintained
throughout the simulations. Gln8, Arg9, and Phe10 residues of the C-terminal of
LVVYPWTQRF peptide were bound stably in S1, S2, and S1′ subsites by forming
hydrophobic and hydrogen interactions. Precisely, Glu162, Gln281, Glu384, Asp453,
Lys511, His513, and Tyr523 residues of ACE retained interactions with Gln8, Arg9,
and Phe10 residues during simulations. The analysis of the MD trajectory showed
that Arg9 formed stable interaction with S1′ subsite residue Glu162, and S2 subsite
residue Gln281. Thr7 and Gln8 residues were situated in the S1 and S2 subsites and
formed consistent interactions with Ala354, Glu384, Lys511, His513, and Tyr523.
The first three residues of LVVYPWTQRF peptide interacted with Glu123, Arg124,
and Tyr360 (Figure 34).
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Additionally, LVVYPWTQRF peptide maintained interactions with Trp59,
Glu143, His353, Glu411, Arg522, and Phe527. Similar to LVVYPWTQRF peptide,
the last three residues of LVVYPWTRRF peptide occupied subsites of ACE active
site (S1, S2, and S1′) and showed consistent interactions with the essential residues
of these subsites. Arg9 residue maintained sustained interaction with S1′ subsite
residue Glu162. Phe10 residue exhibited sustained interactions with Asn277,
Gln281, and Phe457. Notably, the mutated Arg8 residue of LVVYPWTRRF
demonstrated consistent interactions with Glu384, Glu411, Asp415, and Ser526,
which were not observed in the LVVYPWTQRF-bound simulations (Figure 35).
Pro5, Trp6 and Thr7 residues of LVVYPWTRRF interacted consistently with
His353, Ala354, Ala356, His410, His513, and Tyr523. Moreover, the first three
residues of LVVYPWTRRF peptide interacted with Lys118, Trp220, Glu123,
Arg124, Glu403, Ser517, and Arg522 during the simulation time. Figures 34 and 35
demonstrate the average (from three runs) percentage of the equilibrated simulation
time during which several residues of the LVVYPWTQRF and LVVYPWTRRF
interacted with different amino acids of ACE.
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Figure 32: RMSD plots of Cα atoms of ACE protein extracted from triplicate 200 ns
simulations of hemorphin-ACE complex. Data extracted from three independent runs
are shown with red, green, and blue. A) Simulation results of LVVYPWTQRF
peptide bound to ACE; B) Simulation results of LVVYPWTRRF peptide bound to
ACE; C) Simulation results of YPWTQRF peptide bound to ACE; D) Simulation
results of YPWTRRF peptide bound to ACE.
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Figure 33: RMSF plots of Cα atoms of ACE protein extracted from triplicate 200 ns
simulations of hemorphin-ACE complex. Data extracted from three independent runs
are shown with red, green, and blue. A) Simulation results of LVVYPWTQRF
peptide bound to ACE; B) Simulation results of LVVYPWTRRF peptide bound to
ACE; C) Simulation results of YPWTQRF peptide bound to ACE; D) Simulation
results of YPWTRRF peptide bound to ACE.
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Figure 34: The average percentage of equilibrium simulation time during which ACE
residues retain interaction with human hemorphin (LVVYPWTQRF) peptides from
triplicate 200 ns simulations. To extract the equilibrium simulation data, the initial
30 ns of each of the 3 simulations were removed. Charged, hydrophobic, and polar
amino acids are shown with orange, green and blue color respectively.
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Figure 35: The average percentage of equilibrium simulation time during which ACE
residues retain interaction with camel hemorphin (LVVYPWTRRF) peptides from
triplicate 200 ns simulations. To extract the equilibrium simulation data, the initial
30 ns of each of the 3 simulations were removed. Charged, hydrophobic, and polar
amino acids are shown with orange, green and blue color respectively.

The best docked complexes of YPWTQRF and YPWTRRF bound to ACE
were also simulated for 200 ns in triplicates. The protein RMSD stabilized at
approximately 2.5 Å in YPWTQRF-bound simulations (Figure 32C). The secondary
structure composition was preserved during the simulations and protein residues
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exhibited lower fluctuations, except loop regions (Figure 33C). Arg6 and Phe7 were
bound stably in the S1′ and S2 subsites, respectively, by producing consistent
interactions with ACE residues Glu162, Gln281, His353, Lys511, and Tyr523. Gln5
formed sustained interactions with Glu384 and Asp415 during the simulation runs.
Thr4 formed interaction with Ala354 and Glu411 residues of the S1 subsite. Tyr1,
Pro2, and Trp3 residues at the N-terminus interacted with Asn66, Ala356, Trp357,
Tyr360, and Glu403 (Figure 36). Similar to YPWTQRF, Arg6 and Phe7 residues of
YPWTRRF engrossed the S1′ and S2 subsites, respectively, by exhibiting consistent
interactions with Glu162, Gln281, and His513 (Figure 37). They also retained
consistent interactions with Asn277, Asn374, Glu376, and Phe457. Glu162 residue
of S1′ pocket formed interaction with Arg6 for the full duration of simulations. Arg5
of YPWTRRF peptide exhibited consistent interactions with Glu411, Asp415,
Lys51, and Ser526. It also produced sustained interactions with the S1 subsite
residues Ala354 and Glu384. His353 and Tyr523 residues of ACE interacted with
Thr4. Moreover, Tyr1, Pro2, and Trp3 residues at the N-terminus displayed
consistent interactions with Ala356, Trp357, His387, Phe391, Glu403, and Ser516
(Figures 36 and 37).
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Figure 36: The average percentage of equilibrium simulation time during which ACE
residues retain interaction with human hemorphin (YPWTQRF) peptides from
triplicate 200 ns simulations. To extract the equilibrium simulation data, the initial
30 ns of each of the 3 simulations were removed. Charged, hydrophobic, and polar
amino acids are shown with orange, green and blue color respectively.
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Figure 37: The average percentage of equilibrium simulation time during which ACE
residues retain interaction with camel hemorphin (YPWTRRF) peptides from
triplicate 200 ns simulations. To extract the equilibrium simulation data, the initial
30 ns of each of the 3 simulations were removed. Charged, hydrophobic, and polar
amino acids are shown with orange, green and blue color respectively.
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The RMSD of the protein Cα atoms stabilized at approximately 2 Å in
YPWTRRF-bound simulations, and the protein structure displayed structural stability
for the full duration of simulations (Figure 32D). Overall, ACE residues exhibited
fewer fluctuations except from loop regions and, the secondary structure remained
preserved throughout the simulations (Figure 32D). Figures 33 and 34 demonstrate
the average percentage of equilibrated simulation time during which several residues
of ACE interacted with two peptides.

4.1.6 In vitro ACE inhibition assay

The data obtained from the molecular docking and MD simulation indicated
that LVVYPWTRRF and YPWTRRF had more hydrogen bonds, electrostatic and
hydrophobic interactions with critical amino acids in the active site that are essential
for ACE inhibitory activity than LVVYPWTQRF and YPWTQRF, respectively. On
the basis of this, it was hypothesized that camel LVVYPWTRRF and YPWTRRF
peptides could demonstrate lower IC50 than non-camel LVVYPWTQRF and
YPWTQRF. To investigate this, the ACE inhibitory activity of all four peptides was
studied with the help of an in vitro ACE inhibition assay.

4.1.7 Determination of ACE inhibitory potential of non-camel and camel
hemorphin peptides
Firstly, longer hemorphin peptides (LVVYPWTQRF and LVVYPWTRRF)
of both camel and human were investigated for their ACE inhibitory activity at
different doses. ACE inhibitory activity was observed at all tested doses (Figure
38A). Both camel and human peptides demonstrated saturation at 200 µM.
Importantly, the experimental data exhibited a nice left shift in the dose-response
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curve of camel LVVYPWTRRF peptide at all tested doses, relative to
LVVYPWTQRF peptide (Figure 38A). Notably, this shift was statistically
significant (p < 0.0001, n = 3) at 10 µM, as demonstrated in Figure 38A.
Additionally,

dose-response

experiments

established

the

left

shift

of

LVVYPWTRRF. This suggests that LVVYPWTRRF peptide exhibited a more
potent

in

vitro

inhibitory

action

on

ACE.

Both

LVVYPWTQRF

and

LVVYPWTRRF peptides demonstrated a dose-dependent inhibitory activity on ACE
and IC50 values were in the micromolar range (Figure 39). IC50 of LVVYPWTRRF
peptide (6.601 µM) was significantly lower than LVVYPWTQRF peptide (12.649
µM) (p < 0.05, n = 3).

Moreover, the ACE inhibitory potential of both YPWTRRF and YPWTQRF
was also determined at different doses. Similarly, dose-response data showed that
YPWTRRF peptide exhibited a left shift at all tested doses, in comparison to
YPWTQRF peptide (Figure 38B). Moreover, this left shift was especially significant
at 10 µM, 50 µM, and 100 µM concentrations (p < 0.05, n = 3). Interestingly,
YPWTRRF exhibited significantly lower IC50 (9.310 µM) when compared to
YPWTQRF (25.894 µM) (p < 0.001, n = 3), as demonstrated in the (Figure 39).
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Figure 38: Dose-response curves of different hemorphin peptides. Per dose ACE
inhibitory activity is demonstrated in percentage. (A) Comparison of ACE inhibitory
activity of LVVYPWTRRF with LVVYPWTQRF at different doses; (B)
Comparison of ACE inhibitory activity of YPWTRRF with YPWTQRF at different
doses; (C) Comparison of ACE inhibitory activity of LVVYPWTRRF with
YPWTRRF at different doses; (D) Comparison of ACE inhibitory activity of
LVVYPWTQRF with YPWTQRF. The dose response comparisons were carried out
using statistical analysis. For this, two-way ANOVA and Sidak’s multiplecomparisons test was used to determine the degree of significance among different
peptides. Data are shown as mean ± SEM of three independent experiments.
**** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 and ns p > 0.05.
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4.1.8 Comparison of the ACE inhibitory activity of different hemorphin
peptides
Next, the ACE inhibitory role of the N-terminus residues (Leu1, Val2, and
Val3) of both LVVYPWTQRF and LVVYPWTRRF peptides were assessed. For
this, the ACE inhibition potential of LVVYPWTRRF with YPWTRRF and
LVVYPWTQRF with YPWTQRF was evaluated (Figure 10C and 10D). The IC50 of
LVVYPWTRRF (6.601 µM) was observed to be lower when compared YPWTRRF
(9.310 µM) (Figure 39).

A comparison of the ACE inhibitory potential of LVVYPWTQRF and its
shorter isoform YPWTQRF peptide showed that LVVYPWTQRF demonstrated
substantially lower ACE inhibitory potential than YPWTQRF at 10 µM, 50 µM, and
100 µM (Figure 38D). Interestingly, LVVYPWTQRF peptide exhibited significantly
lower IC50 (12.649 µM) than YPWTQRF (25.894 µM) (Figure 39). This clearly
indicated a positive role of the N-terminus residues (LVV-) of both LVVYPWTQRF
and LVVYPWTRRF peptides in the binding and inhibition of ACE.
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Figure 39: IC50 of different hemorphin peptides. IC50 values are shown in micro
molar (µM) units, and comparisons of IC50 was carried out using one-way ANOVA
and Sidak’s multiple-comparisons test to determine statistical significance between
different peptides of hemorphin. Data are shown as mean ± SEM of three
independent experiments. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05,
and ns p > 0.05.
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4.2 Discussion
Hemorphins are a class of bioactive opioid peptides released during
proteolytic cleavage of hemoglobin. Their therapeutic potential has been highlighted
in various studies (Cejka et al., 2004; Fruitier-Arnaudin et al., 2002; Lee et al., 2004).
Molecular binding behavior and binding stability of both camel and non-camel LVVhemorphin-7 on several targets have also been described in earlier work (Ali et al.,
2019). Here, extensive in silico approaches and an in vitro ACE inhibition assay
were employed to determine the precise binding and ACE inhibitory activity of four
different human and camel hemorphin peptides.

Results showed that

LVVYPWTRRF and YPWTRRF peptides bind more stably to vital residues in the
ACE active site, in comparison to LVVYPWTQRF and YPWTQRF, respectively.
The in vitro ACE inhibition assay also supported this finding.

A vital role is played by ACE, which is a membrane-bound zinc
metallopeptidase in the regulation of blood pressure by catalyzing the conversion of
angiotensin I into angiotensin II, which is a well-known vasoconstrictor (Fleming,
2006). A zinc ion binding motif is present in ACE, coordinated by His383, His387,
and Glu411, which is essential for the formation of the ACE-inhibitor complex.
Moreover, the active site of ACE is comprised of three subsites, which are also
essential for ACE inhibition, termed S1, S2, and S1′. These subsites contain residues
that form interactions with potential inhibitors (Abdelhedi et al., 2018; Priyanto et
al., 2015). Ala354, Glu384, and Tyr523 comprise the S1 subsite; Gln281, His353,
Lys511, His513, and Tyr520 comprise the S2 subsite, and Glu162 constitutes the S1′
subsite (Ma et al., 2018).
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By using extensive molecular docking and simulations, the binding mode of
each peptide with ACE was determined. Overall, all studied hemorphins stably
interacted with the active site residues of ACE. The last three residues at the Cterminus of each peptide encompassed all three active subsites of ACE (Figures 24,
25, 28, and 29). Arg9 and Phe10 residues of LVVYPWTQRF anchored the peptide
in the S2 and S1′ pockets by producing hydrogen bonds with Glu162, Gln281, and
Asp453. LVVYPWTQRF peptide residues Thr7 and Gln8 inhabited the S1 and S2
subsites by producing hydrogen bonds with Ala354, Lys511, His513, Tyr520, and
Tyr523. They also exhibited consistent interactions with His383, and Glu411 (Figure
34). The positioning of LVVYPWTRRF peptide in the active site of ACE was
observed to be slightly different. LVVYPWTRRF was observed to be deeply seated
in the active site of ACE. LVVYPWTRRF was stabilized by Arg9 and Phe10 due to
the formation of hydrogen bonds with Glu162, Asn277, Thr282, Asn374, and
Glu376. Arg9 and Phe10 residues also exhibited polar interaction with Gln281
(Figures 25 and 27). LVVYPWTRRF residues Thr7 and Arg8 showed consistent
interactions with vital S1 and S2 subsite residues during the simulation runs. In
addition to this, Arg8 of LVVYPWTRRF also showed consistent interactions with
Glu411, Asp415, and Ser526, compared to LVVYPWTQRF (Figures 34 and 35).
YPWTQRF and YPWTRRF displayed dissimilar binding modes. Particularly, the
positioning of Tyr1 and Pro2 residues of the N-terminus, and Arg5, and Phe7
residues of the C-terminus (Figures 28 and 29). Importantly, YPWTRRF showed
strong interactions with all vital residues of ACE, such as Glu162, Ala354, Ala356,
His387, Glu411, Glu415, Lys511, and Tyr523 during the simulations, in comparison
to YPWTQRF (Figures 36 and 37).
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FDA approved and widely prescribed ACE inhibitors such as captopril and
lisinopril formed interaction with Glu162, His353, Ala354, Glu384, His387, Glu411,
Lys511, His513, Tyr520, and Tyr523 of ACE (Natesh, Schwager, Evans, Sturrock,
& Acharya, 2004; Wang, Wu, Xu, Xie, & Guo, 2011). However, clinically used ACE
inhibitor enalaprilat, does not form any interaction with Glu162. This could be a
reason for the lower affinity of enalaprilat when compared to lisinopril (Wang et al.,
2011). These amino acids are important for designing prospective ACE inhibitors.
Amongst all the hemorphins investigated in this study, only camel hemorphin-7
interacted with His387. Apart from His387 and Tyr520 residues, all the other
hemorphins interacted with all of the essential residues, in the active site of ACE.

In silico data showed that LVVYPWTRRF and YPWTRRF possessed higher
affinity in comparison to LVVYPWTQRF and YPWTQRF, respectively. For
validating this, an ACE inhibition assay was carried out to determine the IC 50 of
these peptides. LVVYPWTRRF and YPWTRRF demonstrated IC50 values of 6.601
µM and 9.310 µM, respectively (Figure 39). Interestingly, the IC50 of
LVVYPWTRRF and YPWTRRF peptides were considerably lower than
LVVYPWTQRF (12.649 µM) and YPWTQRF (25.894 µM). This clearly showed
that LVVYPWTRRF and YPWTRRF demonstrated more potent ACE inhibitory
activity in comparison to LVVYPWTQRF and YPWTQRF. Nevertheless, the
difference between camel hemorphins did not prove to be substantial (Figure 39).
The results of non-camel hemorphin peptides were in agreement with the prior
studies that were carried out to determine the ACE inhibition potential of hemorphins
(Lantz et al., 1991; Zhao & Piot, 1997). Prior studies showed that LVVYPWTQRF
has a significantly better ACE inhibitory activity when compared to shorter
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hemorphins, such as YPWTQRF (Zhao & Piot, 1997). The results also demonstrated
the significance of the hydrophobic N-terminus leucine-valine-valine residues for
enhanced ACE inhibition. Moreover, the removal of leucine residue from the Nterminus of LVVYPWTQRF substantially decreased the ACE inhibitory potential of
VVYPWTQRF when compared to LVVYPWTQRF. LVVYPWTQRF being a more
potent inhibitor of ACE as compared to VVYPWTQRF has also been reported in
another comparative study as well (Ali et al., 2019). These results indicate the
importance of N-terminus in ACE inhibition.

From the perspective of structural activity, it has been demonstrated through
various comparative studies that the ACE inhibition potential of a peptide is
dependent on the presence of particular residues at N- and C-termini (Iwaniak et al.,
2014). At the N-terminus of a peptide, the presence of hydrophobic residues, in
particular leucine, valine, isoleucine and glycine, showed substantially higher ACE
inhibitory activity, whereas at the C-terminus, aromatic amino acids, such as
phenylalanine, proline, tryptophan, and tyrosine are important (Silvestre et al., 2012).
In addition, the presence of charged residues, particularly arginine and lysine, near
the C-terminus were also reported to be important to the peptide's inhibitory potential
for ACE (Sun et al., 2017). Furthermore, a number of studies have already illustrated
this phenomenon, which showed that by the elongation of the N-terminus, the ACE
inhibitory potential of certain peptides could be enhanced (Kohmura et al., 1989; Liu
et al., 2014). The results from in silico and in vitro techniques showed that both
LVVYPWTRRF and LVVYPWTQRF formed more stable interactions with the
active site residues of ACE and showed higher inhibition in comparison to shorter
hemorphin-7 peptides. Residues from the N-terminus (leucine-valine-valine) were
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found to bind to residues outside ACE's active site. This indicates that this part of the
molecule does not appear to have any direct interactions with the active site residues,
despite the ACE inhibitory effect. The peptide’s substantially enhanced ACE
inhibitory activity with the LVV- sequence may be attributed to the peptide's more
stable binding in the presence of this sequence. Moreover, the comparative analysis
of LVVYPWTRRF and LVVYPWTQRF revealed that LVVYPWTRRF to be a
more potent ACE inhibitory peptide as compared to LVVYPWTQRF (Figure 38A).
More importantly, the N-terminus residues of LVVYPWTRRF revealed more
consistent interactions with Tyr62, Lys118, Glu123, Arg124, Trp220, Glu403,
Arg522, and Ser517, whereas an arginine substitution at position 8 exhibited more
consistent interactions with Glu411, Glu415, and Ser526 in comparison to
LVVYPWTQRF (Figures 34 and 35). Such a binding mode of the mutated arginine
residue demonstrated that residues from the N-terminus had been pulled deeper into
the binding pocket. Hence, this could be one of the reasons for the higher ACE
inhibition potential of camel LVVYPWTRRF. These results are in agreement with
prior studies, that stated the significance of leucine and valine at the N-terminus and
arginine near the C-terminus for enhanced inhibition of ACE (Sun et al., 2017; Zhao,
Sannier, Garreau, Guillochon, & Piot, 1994). Furthermore, for the non-competitive
inhibition of ACE, studies have shown that the binding of peptide residues outside
the ACE active site, especially with Tyr62 and Asn70, also play an important role
(Ni, Li, Liu, & Hu, 2012). Apart from that, a novel dual inhibitor inhabiting both the
primary and secondary sites has also been described (Akif et al., 2011). The
secondary binding site residues of ACE were found to be Lys118, Glu123, Arg124,
Trp220, Glu403, and Arg522. This demonstrates the plasticity of ACE active site in
accommodating different types of potent inhibitors (Akif et al., 2011). A similar
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pattern was observed when LVVYPWTRRF was compared to the shorter camel
hemorphin peptide (YPWTRRF) (Figures 36, and 37). MD simulations also showed
that consistent interactions were produced by the N-terminus residues of
LVVYPWTQRF with Glu123, Arg124, and Glu143 along with active site residues of
ACE, compared to YPWTQRF (Figures 34 and 36). Likewise, comparative analysis
of shorter camel (YPWTRRF) and non-camel (YPWTQRF) peptides showed that
YPWTRRF exhibited substantially lower IC50 and more consistent interactions with
ACE active site residues as compared to YPWTQRF (Figures 38B and 39).
Moreover, interactions of the mutated arginine with Glu411, Asp415, and Ser526
placed the peptide more stably in the active site, compared to human hemorphin-7.
Importantly, prior studies that investigated the ACE inhibitory activities of peptides
have already positively linked the presence of arginine near the C-terminus with
higher ACE inhibition (Sun et al., 2017).
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Chapter 5: Pharmacological Action of LVV-Hemorphin-7 on Angiotensin
II Type 1 Receptor

5.1 Results
In silico and in viro assays were performed to determine the pharmacological
action and appropriate binding mode of LVV-hemorphin-7 on AT1R.
5.1.1 Weak agonistic effect of LVV–Hemorphin-7 on AT1R

BRET technology in HEK293 cells was used to determine the
pharmacological effects of camel and human LVV-hemorphin-7 on the functional
AT1R-Gαq coupling and β-arrestin 2 recruitment to AT1R, in real time and live
cells, as described in earlier studies (Ayoub et al., 2015). The activation of Gαqmediated IP1 production, as an important AT1R downstream signaling pathway, was
also examined. In this study, for the measurement of BRET assays in HEK293 cells,
AT1R-Rluc was used as the BRET donor, co-expressed with either mini Gαq (mGsq)
probe consisting of the GTPase domain of Gαq fused to Venus, as BRET acceptor
(Wan et al., 2018), or yPET–β-arrestin 2. BRET experiments were carried out in the
presence or absence of treatment of cells with different doses of AngII, camel LVV–
hemorphin-7 or human LVV-hemorphin-7. The results indicated that AngII
potentiated the BRET signals in a dose dependent manner between AT1R-Rluc and
both Venus-Gαq and yPET–β-arrestin 2 (Figures 40A and 40B) (Table 5).
Nevertheless, a partial effect on AT1R-Gαq coupling and β-arrestin 2 recruitment
was observed only at high doses of camel and human LVV–hemorphin-7 (10–100
µM) (Figures 40A and 40B). This also suggested that both camel and human LVV–
hemorphin-7 did not produce strong pharmacological effects on AT1R at reasonable
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doses. Since, both camel and human LVV-hemorphin-7 produced similar potency,
therefore human LVV-hemorphin-7 was used for further studies.

Figure 40: LVV-hemorphin-7’s action on AT1R. BRET experiments were performed on human embryonic kidney (HEK293) cells briefly coexpressing AT1R-Rluc (as BRET donor) and either Venus-Gαq or yPET-β-arrestin 2 (as BRET acceptors) simulated or not with either AngII,
LVV-hemorphin-7 or both. For the purpose of BRET measurements, HEK293 cells co-expressing AT1R-Rluc and either Venus-Gαq (A) or
yPET-β-arrestin 2 (B) were simulated with different doses of AngII or LVV-hemorphin-7 at 37°C for 30 minutes and BRET measurements were
determined. Data are represented as means ± SEM of 5 independent experiments carried out in triplicate.
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Table 5: Log EC50 values of LVV-hemorphin-7 and AngII. Two-way ANOVA and Tukey multiple-comparisons test was performed to measure
the statistical significance between different treatment conditions.
Transfections

Log EC50 AngII (BRET)

AT1R-Rluc
+
Venus-Gq

Control

AT1R-Rluc
+
Ypet--arrestin 2

Control

LVVhemorphin-7

-7.68  0.17

-7.75  0.23

Log EC50 AngII (IP1)

-8.78  0.14
(p<0.001, n=6)

Control

LVV-hemorphin-7

-7.57  0.19

-8.93  0.17
(p<0.0001, n=7)

-5.41  0.29
(n=5)

LVV-hemorphin-7
-8.91  0.19
(p<0.01, n=5)

ND

Control
AT1R-WT

Log EC50
LVV-hemorphin-7
(BRET)

-5.48  0.35
(n=5)

LVV-hemorphin-7

ND

ND
-8.15  0.03

-9.55  0.03
(p<0.0001, n=3)
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5.1.2 Positive allosteric effects of LVV–hemorphin-7 on AT1R

Multiple dose–response and real-time kinetic BRET assays were performed
to determine the possible pharmacological action of LVV–hemorphin-7 on AngIImediated AT1R activation. In order to measure the effects of dose–response
experiments, cells were initially incubated with different doses of LVV-hemorphin-7
for 15 min, after that BRET reading were calculated upon stimulation of AT1R with
different doses of AngII. Curves plotted from AngII BRET results between AT1RRluc and Venus-Gαq or yPET–β-arrestin demonstrated a substantial left shift (more
than one log, p < 0.001, n = 3), 2 in cells incubated with either 10 or 100 µM of
LVV–hemorphin-7 in comparison to control cells (Figures 41A and 41B). Moreover,
to obtain statistically significant data, these dose–response experiments were
repeated both in the presence of LVV–hemorphin-7 (10 µM) and absence (control).
The additional dataset supported the previous experiment results, and a left shift of
the AngII dose curves for BRET was observed between AT1R-Rluc and Venus-Gαq
(p < 0.001 for the whole dose curve, n = 6) or yPET–β-arrestin 2 (p < 0.001 for the
whole dose curve, n = 5) in cells pretreated with 10 µM of LVV–hemorphin-7 in
comparison to control cells (Figures 41C and 41D) (Table 5). These results for the
first time showed a positive pharmacological action of LVV–hemorphin-7 on AT1R
activation briefly expressed in HEK293 cells. On the basis of these results, where a
combination of 10 µM of LVV–hemorphin-7 and 10 nM of AngII, produced
approximately 25% of AT1R-mediated response was selected and used for further
BRET kinetics and functional assays.

In order to further confirm the positive pharmacological action of LVV–
hemorphin-7 on AT1R, dose-response experiments were carried out the other way
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around by either prior incubation of cells for 15 min or not in the presence of
different doses of LVV–hemorphin-7 and then cells were activated with 10 nM of
AngII for 20 min. The results clearly indicated that AngII-mediated BRET signals
between AT1R-Rluc and Venus-Gαq or yPET–β-arrestin 2 were substantially
increased by LVV–hemorphin-7 in a dose-dependent manner with EC50 in the
micromolar range (Table 5) (Figures 42A and 42B).

In this study, the thrombin receptor or protease-activated receptor 1 (PAR1)
was used as a negative control, and the pharmacological action of LVV–hemorphin-7
were also investigated on this GPCR. The results indicated that LVV-hemorphin-7
did not produce any noteworthy changes in the dose–response curves of thrombinmediated BRET increase between PAR1-Rluc and either Venus-Gαq or yPET–βarrestin2 (Figures 42C.and 42D).
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Figure 41: Positive allosteric modulation of LVV-hemorphin-7 on AT1R activation
demonstrated by dose-response BRET technique. For dose-response BRET analysis,
human embryonic kidney (HEK293) cells briefly co-expressing AT1R-Rluc and
either Venus-Gαq (A, and C) or yPET-β-arrestin 2 (B, and D) were used. In A and B,
HEK293 cells were initially incubated or not (control) with different doses of LVVhemorphin-7 for 15 minutes and then challenged with different doses of AngII for 30
minutes. In C and D, HEK293 cells were initially incubated or not (Control) with 10
µM of LVV-hemorphin-7 for 15 minutes and then cells were treated with different
doses of AngII for 30 minutes. Data are represented as means ± SEM of 5-6
independent experiments carried out in triplicate.
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Figure 42: Positive allosteric modulation of LVV-hemorphin-7 on AT1R activation
demonstrated by dose-response BRET technique. For dose-response BRET analysis,
human embryonic kidney (HEK293) cells briefly co-expressing AT1R-Rluc and
either Venus-Gαq (A) or yPET-β-arrestin 2 (B) were used. In A and B, HEK293 cells
were initially incubated with different doses of LVV-hemorphin-7 for 15 minutes
and then challenged with 10 nM of AngII for 30 minutes. Next, HEK293 cells briefly
co-expressing PAR1-Rluc and either Venus-Gαq (C) or yPET-β-arrestin 2 (D) were
initially incubated or not (control) with 10 µM of LVV-hemorphin-7 for 15 minutes
and then challenged with different doses of thrombin, as a negative control for 30
minutes. Data are represented as means ± SEM of 3 (C and D) or 5-6 independent
experiments carried out in triplicate.
5.1.3 Confirmation of the positive allosteric effects of LVV–hemorphin-7 on
AT1R
Several real-time BRET kinetics were performed to further observe the PAM
effects of LVV–hemorphin-7 on AT1R activation. For this, HEK293 cells briefly coexpressing AT1R-Rluc with either Venus-Gαq or yPET–β-arrestin 2 were used and
stimulated with different combinations of AngII and LVV–hemorphin-7 in different
protocols (Figures 43A, B, C, D, and F). Initially, BRET readings were measured in
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real time immediately after cells were stimulated or not with either LVV–hemorphin7 (10 µM), AngII (10 nM), or both. The results of real time kinetics experiments
demonstrated that the combination of LVV-hemorphin-7 and AngII substantially
increased the BRET signals within AT1R-Rluc/Venus-Gαq and AT1R-Rluc/yPET–
β-arrestin 2 pairs, in comparison to a single treatment of cells with AngII (Figure
39A and 39B) (Table 6). Additionally, LVV-hemorphin-7 also produced a partial
agonistic effect on BRET between AT1R-Rluc and yPET–β-arrestin 2 (Figure 43B).
However, this effect was observed to be very weak between AT1R-Rluc and VenusGαq (Figure 43A).

Next, sequential real-time kinetics experiments were carried out where BRET
readings were determined before the treatment of cells for 5 min, which formed the
baseline level. After 5 min, cells were treated with or not LVV–hemorphin-7 (10
µM) (treatment 1 or T1) for 10 min, and lastly cells were challenged or not with
AngII (10 nM) (treatment 2 or T2) for 25 min. The results of these kinetics
experiments demonstrated a very weak, approximately 10% potentiation of BRET
signals specifically in cells treated with LVV–hemorphin-7 only after 35 min of
measurements. Nevertheless, AT1R-Rluc/Venus-Gαq and AT1R-Rluc/yPET–βarrestin 2 pairs exhibited significantly higher AngII-induced BRET signals in cells
which were initially stimulated with LVV–hemorphin-7, in comparison to those
treated with vehicle (Figures 43C, and 43D) (Table 6). Moreover, BRET kinetics
experiments were also carried out in such a way that cells were initially challenged
with 10 nM of AngII for approximately15 to 20 min to initiate BRET potentiation
between AT1R-Rluc/Venus-Gαq and AT1R-Rluc/yPET–β-arrestin 2 pairs before
treating the cells with 10 µM of LVV–hemorphin-7 (Figures 43E and 43F). The
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results of these experiments demonstrated a substantial BRET increase beyond the
AngII-induced level in both cases signifying the positive allosteric effect of LVV–
hemorphin-7. This indicates that LVV-hemorphin-7 can also produce PAM effect
even after AngII binding to AT1R. Overall, these kinetic results were in agreement
with the dose–response tests as demonstrated in Figure 38 showing the PAM effect
of LVV–hemorphin-7 on AT1R activation.
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Figure 43: Positive allosteric modulation of LVV-hemorphin-7 on AT1R activation
demonstrated by real-time BRET kinetic analysis. For this, HEK293 cells briefly coexpressing AT1R-Rluc and either Venus-Gαq or yPET-β-arrestin 2 were used. In A
and B, BRET measurements were determined before (baseline) and upon cell
treatment (arrow) with either 10 nM AngII, 10 µM LVV-hemorphin-7, or both for 50
minutes. However, in C and D, BRET measurements were determined without any
treatment (baseline) for 5 minutes and then HEK293 cells were challenged or not
(vehicle) with 10 µM of LVV-hemorphin-7 (T1) for 10 minutes and then further
simulation or not (vehicle) with 10 nM of AngII (T2) for 25 minutes. While, in E and
F, HEK293 cells were initially treated with 10 nM of AngII and BRET readings were
calculated for approximately 20 minutes without any further treatment with 10 µM of
LVV-hemorphin-7 and additional BRET readings were determined for 25 minutes.
Data are represented as means ± SEM of 5-8 independent experiments carried out in
duplicate or triplicate.
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Table 6: Percentage Emax values of AngII in the various BRET assays. An
appropriate statistical analysis was performed to determine the degree of
significance. Kinetics 1 and 2 correspond to the data in Figure 39A/B and Figure
39C/D, respectively.
Transfections

AT1R-Rluc
+

Emax

Emax

Emax

(BRET doseresponse)

(BRET kinetics 1)

(BRET kinetics 2)

109  2

263  6

171  3

(p>0.05, n=9)

(p<0.0001, n=6)

(p<0.0001, n=8)

104  4

240  5

200  0.2

(p>0.05, n=8)

(p<0.0001, n=5)

(p<0.0001, n=5)

Venus-Gq

AT1R-Rluc
+
yPET-arrestin 2
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5.1.4 Activation of AT1R by LVV-hemorphin-7
In order to observe the effect of AT1R inhibition on both AngII and LVV–
hemorphin-7–mediated BRET potentiation, irbesartan was used as a selective AT1R
antagonist on cells briefly co-expressing AT1R-Rluc with either Venus-Gαq or
yPET–β-arrestin 2 (Figures 44A and 44B) challenged or not with either 10 µM of
LVV–hemorphin-7, or 10 nM of AngII, or both. These experiments results initially
established the substantial positive allosteric effects of LVV–hemorphin-7 on AngIIinduced BRET potentiation in both BRET case scenarios with AT1R-Rluc and either
Venus-Gαq or yPET–β-arrestin 2 (Figures 44A and 44B). Interestingly, a complete
inhibition of AngII-induced BRET signal was detected and their increase by LVV–
hemorphin-7 immediately after treatment with 10 µM dose of irbesartan (Figures
44A, and 44B). Indeed, these results clearly indicate that the PAM action of LVV–
hemorphin-7 encompasses the active conformation of AT1R.
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Figure 44: AT1R-selective antagonist (irbesartan) inhibited both AngII- and LVVhemorphin-7-mediated BRET potentiation. Before measuring BRET signals,
HEK293 cells briefly co-expressing AT1R-Rluc and either Venus-Gαq (A) or yPETβ-arrestin 2 (B) were initially stimulated or not (control using DMSO) with 10 µM of
irebesartan at 37ºC for 15 minutes. Next, cells were treated or not (basal) with either
10 nM of AngII, 10 µM of LVV-hemorphin-7, or both, at 37ºC for 30 minutes were
carried out. Data are represented as means ± SEM of 3 independent experiments
performed in duplicate.
5.1.5 Effects of LVV–hemorphin-7 on AT1R-mediated downstream signaling

In order to associate the BRET results with downstream signaling pathways
of AT1R, the pharmacological action of LVV–hemorphin-7 on AT1R-mediated IP1
production was determined as an indicator for Gαq/phospholipase C activation. To
measure this, experimental conditions similar to BRET experiments were used. For
this, initially HEK293 cells were used, briefly co-expressing Venus-Gαq and AT1RRluc. Initially, the assumed agonistic effect of LVV–hemorphin-7 was determined on
AT1R-mediated IP1 production in cells challenged with different doses of either
LVV-hemorphin-7 or AngII as control. As expected, LVV-hemorphin-7 did not
exhibit any notable effect on IP1 production even at 100 µM, while AngII nicely
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induced IP1 production in a dose-dependent manner and with the expected potency
(Figure 45A) (Table 6). Additionally, the positive allosteric effect of LVV–
hemorphin-7 was determined on AngII-mediated IP1 response by treating cells with
the different doses of AngII with or no pretreatment of cells for 15 min with 10 µM
of LVV–hemorphin-7. Similar to BRET experiments, LVV–hemorphin-7 potentiated
a noteworthy left shift of the AngII dose-dependent curve with a profound effect,
approximately 18.6-fold increase in AngII, EC50, relative to BRET data (Table 6)
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Figure 45: Positive allosteric modulation of LVV-hemorphin-7 on AT1R-mediated
IP1 production. For IP1 assays, HEK293 cells briefly co-expressing AT1R-Rluc with
Venus-Gαq or AT1R-WT was used (Figure A-D). For IP1 measurements in doseresponse experiments, cells were challenged or not with the different doses of either
AngII or LVV-hemorphin-7 or first pre-treated or not (Control) with 10 µM of LVVhemorphin-7 for 15 minutes and then stimulated for 30 minutes with different doses
of AngII (A-C). HEK293 cells expressing AT1R-WT were initially pre-treated or
untreated (control using DMSO) with 10 µM of AT1R antagonist (Irebesartan) at
37ºC for 15 minutes (D). After that, cells were treated or untreated (basal) with either
5 nM of AngII, 10 µM of LVV-hemorphin-7, or both, at 37ºC for 30 minutes, before
IP1 assays were carried out. IP1 data are represented as means ± SEM of 3-7
independent experiments carried out in duplicate or triplicate.
In order to rule out the possibility of any artifact in these experiments since
only AT1R-Rluc co-expressed with Venus-Gαq similar to BRET experiments.
Therefore, IP1 experiments were also carried out in HEK293 cells briefly expressing
the untagged AT1R (AT1R-WT). The results of these experiments indicated that
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AngII nicely promoted IP1 production in a dose–response manner, and combined
treatment of cells with LVV–hemorphin-7 (10 µM) substantially left shifted the
AngII dose-dependent curve with approximately 25-fold potentiation in AngII EC50
(Table 6). This also indicates the positive pharmacological effect of LVV–
hemorphin-7 on AT1R-mediated IP1 response.

Moreover, irbesartan, a selective antagonist of AT1R was used to investigate
its effect of AT1R inhibition, by using the same conditions and protocols as were
used for BRET assays. In these experiments, AT1R-WT expressed on HEK293 cells
was used treated or untreated with 10 µM dose of irbesartan, after that cells were
treated or not with LVV–hemorphin-7 dose of 10 µM, either individually or together
with a non-saturating dose of AngII (5 nM). Results clearly indicated that both
AngII-mediated IP1 formation and its substantial increase by LVV–hemorphin-7
were fully blocked by the treatment of irbesartan. These results are in agreement with
the BRET data as demonstrated in Figure 45.

Overall, the results of IP1 experiments in both AT1R-WT and AT1R-Rluc
validated the positive allosteric effect of LVV–hemorphin-7 on the activation of
AT1R and its downstream signaling pathways.

5.1.6 Molecular docking and molecular dynamics studies
In order to determine the stability and dynamics of the nteractions between
ACE and hemorphin peptides, all-atom MD simulations were run in triplicate using
Desmond (Bowers et al., 2006).
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5.1.7 LVV-hemorphin-7 binds to an intracellular site of AT1R
SiteMap analysis identified three potential binding sites in AT1R – two were
intracellular and the third was the extracellular orthosteric site. Since the in vitro data
indicated positive allosteric effects of LVV-hemorphin-7, two potential binding
cavities outside the orthosteric site were explored. LVV-hemorphin-7 was docked to
intracellular sites of AT1R identified by SiteMap. However, one of the intracellular
sites produced extremely poor docking results and was therefore excluded from
further studies. The best-docked pose of LVV-hemorphin-7-AT1R complex in the
other site produced a GScore of -11.05 kcal/mol. MM-GBSA based binding free was
estimated as -125.05 kcal/mol (Table 7). The docked conformation of LVVhemorphin-7 in this site interacted with intracellular loops 2 and 3, and the
cytoplasmic end of transmembrane helices 3 and 6 (TM3 and TM6) of AT1R. The
first three residues of the decapeptide formed hydrogen bonds with His132 and
Lys135, hydrophobic interaction with Tyr127, and an electrostatic interaction with
Arg137 (Figures 46 and 47).

The side chain of LVV-hemorphin-7 Tyr4 formed a

hydrogen bond with Val131 (Figures 4C and 46D). Pro5, Trp6 and Thr7 of LVVhemorphin-7 formed hydrophobic interactions with Ile130, Pro133, Met134 and
Ala221 of AT1R. Trp6 also formed and electrostatic interaction with Arg234. Cterminus residues Gln8, Arg9, and Phe10 of LVV-hemorphin-7 formed hydrogen
bonds with Lys60 and Arg126. They also exhibited hydrophobic interactions with
Val62, Ala129, Leu138, Met142, Ala225, Pro233 and Ile238, electrostatic
interactions with Lys230 and Lys232, and polar interactions with Thr61 and Asn235
(Table 7 and Figure 47).
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Five hundred nanosecond all-atom MD simulations of the docked system
embedded in a DPPC membrane were performed in triplicate to investigate the
binding dynamics and stability of the AT1R-LVV-H7 complex using Desmond
(Bowers et al., 2006). Protein structure in the simulated systems remained stable with
a protein Cα root mean square deviation (RMSD) under 3.5 Å (Figure 48A). Per
residue level root mean square fluctuation (RMSF) highlighted that intracellular
loops (ICL) ICL1, ICL2 and ICL3 and extracellular loop (ECL) ECL2 were more
flexible while membrane-embedded regions exhibited limited fluctuations (Figure
48D). The decapeptide interacted consistently with ICL2, and ICL3, while its
interactions with TM3 and TM6 were considerably weak. The N-terminus residues
(Val2 and Val3) formed intermittent interactions with His132 and Ala221 of ICL2
and ICL3, respectively (Figure 52). Tyr4 formed intermittent interactions with
Val131 and Lys135 of ICL2. Pro5 showed an intermittent hydrogen bond with
Met134 of ICL2. Trp6 of the peptide formed an intermittent hydrophobic interaction
with Arg126 and a consistent hydrophobic interaction with Pro133 and Arg234 of
ICL2 and ICL3. Gln8 exhibited sustained hydrophobic interactions with Ile130 and
Pro233. Arg9 also intermittently interacted with Ala129 of ICL2. These ICL2
residues have been reported to form an allosteric site in other GPCRs (Luderman et
al., 2018; P. Zhang et al.,2015).

Table 7: AT1R residues that interacted with the best docked pose of LVV-H7 and AngII.
Peptide

AT1R
PBD ID

Glide docking MM-GBSA
score
binding free
energy
(kcal/mol)

Residues forming
hydrogen bonds

Residues forming hydrophobic
interactions

(kcal/mol)

LVV-H7

Residues
forming π-π
stacking or
cation-π
interactions

4ZUD

-11.05

-125.05 Lys60, Arg126,
Val131, His132,
Lys135

Val62, Tyr127, Ile130, Pro133,
Arg234
Met134, Leu138, Met142, Ala221,
Ala225, Pro233, Ile238

4ZUD

-12.01

-129.31 Arg167, Tyr184,
Glu185, Ser186,
Thr260, Asp263,
Asp281

Leu13, Cys18, Ala21, Ile31,
Tyr35, Trp84, Tyr87, Tyr92,
Val108, Leu112, Pro162, Ala163,
Phe182, Ile172, Val179, Ala181,
Trp253, Ile266, Ala277, Val280,
Met284, Pro285

AngII
4ZUD
together
with LVVH7

-13.51

-160.71 Ser15, Lys20, Tyr87,
Arg167, Lys199,
Asp263, Gln267,
Asp281

Leu13, Pro19, Ala21, Tyr35,
Phe77, Trp84, Val108, Leu112,
Tyr113, Ala159, Pro162, Ala163,
Ile172, Cys180, Ala181, Phe182,
Tyr184, Leu195, Phe204, Ile266,
Met284, Pro285, Ile288, Tyr292

(IC)

AngII

Tyr9, Tyr87
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Figure 46: Structure of AT1R with the docked peptide. AT1R structure is shown in
purple cartoon representation while its interacting residues are shown in green stick
representation. Docked peptide is shown in orange stick representation. Black dotted
lines represent hydrogen bonds and blue lines represent and π- π interactions. (A)
Structure of AT1R. (B) AT1R with AngII docked in the orthosteric site and LVVH7 docked to the intracellular site shown in space-filling representation. (C) Closer
view of the docked pose of LVV-H7 and the hydrogen bond it forms with AT1R
shown as black dashed lines. (D) Image in (C) shown with interacting residues
labelled.
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Figure 47: 2D ligand interaction diagram of LVV-hemorphin-7 with AT1R. LVVhemorphin-7 interacting residues with intracellular binding pocket of AT1R (PDB:
4ZUD). Colored circles represent amino acids that form interaction with bound
ligand. Red circles indicate negatively charged amino acids, dark blue colors indicate
positively charged amino acids, light blue circles indicate polar amino acids, and
green circles indicate hydrophobic amino. Hydrogen bonds are shown with purple
arrows–dashed arrows for hydrogen bonds involving amino acid side chain and
regular arrows for hydrogen bonds involving amino acid backbone. π–π interactions
are represented with green lines.
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Figure 48: Plots of RMSD and RMSF of protein Cα atoms extracted from three
independent 500 ns simulations of AT1R complexes. Data of three independent runs
are plotted with blue, green and red colors. (A) RMSD of AT1R-LVV-H7 complex;
(B) RMSD of AT1R-AngII complex; (C) RMSD of AT1R-LVV-H7-AngII complex;
(D) RMSF of AT1R-LVV-H7 complex; (E) RMSF of AT1R-AngII complex; (F)
RMSF of AT1R-LVV-H7-AngII complex.
5.1.8 Binding of LVV-H7 to AT1R potentiated the binding of AngII

The effect of intracellular binding of LVV-H7 on AngII binding affinity was
evaluated. AngII was first docked in the orthosteric site of AT1R. In the docked
pose, the C-terminus of AngII was embedded deep in the active site and the Nterminus was extended towards the lid (Figure 49A). The best binding pose of Ang II
had a GScore of -12.01 kcal/mol. The calculated MM-GBSA binding energy for this
pose was -129.31 kcal/mol (Table 7). AngII formed multiple hydrogen bonds,
hydrophobic, electrostatic and polar interactions that was consistent with previous
studies (Fillion et al., 2013; Singh, Unal, Desnoyer, & Karnik, 2019) (Figure 50).
Interactions between AngII and AT1R are provided in Table 7.
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Next, the last frame from a 500 ns simulation of LVV-H7 docked to AT1R
intracellularly was taken and AngII was docked to the orthosteric binding site in this
complex. Interestingly, the binding of AngII was improved. The best binding pose of
AngII produced a GScore of -13.51 kcal/mol and MM-GBSA binding free energy of
-160.71 kcal/mol (Table 7). This suggested that intracellular binding of LVV-H7
allosterically enhanced the binding affinity of AngII in extracellular orthosteric
binding site. This observation is consistent with the BRET data obtained in HEK293
cells (Figure 41, 42 and 43). Notably, Asp1, Tyr4 and Phe8 residues of AngII were
positioned differently when LVV-H7 was bound to AT1R (Figure 49). The Cterminus of AngII bound slightly deeper inside the binding pocket in the presence of
LVV-H7 (Figure 49B). This allowed Phe8 of AngII to form a hydrogen bond with
Lys199. Pro7 of AngII showed hydrogen bond with Arg167 both in the presence and
absence of LVV-H7 (Figure 49). Tyr4 of AngII, without LVV-H7 formed a π–π
stacking with Tyr184 (Figure 49A). The sidechains amino groups of Arg2 of AngII
formed hydrogen bonds with Asp263 and Asp281 of AT1R with and without LVVH7 bound. Lastly, Asp1 of AngII, in the presence of LVV-H7, formed a hydrogen
bond with Gln267 (Figures 49A and 49B). In the absence of LVV-H7, Asp1 was
observed to form hydrogen bonds with Ser16, and Asp17 (Figure 37A and 37B).
Overall, AngII was able to form more hydrogen, hydrophobic and polar interactions
with AT1R when bound to LVV-H7 (Figures 50 and 51).

Figure 49: Binding pose of AngII with AT1R in the presence and absence of LVV-H7. AT1R structure is shown in purple cartoon representation
while its interacting residues are shown in green stick representation. Docked peptide is shown in orange stick representation. Black dotted lines
represent hydrogen bonds and blue lines represent and π- π interactions. (A) Interaction of the docked pose of AngII in the absence of LVV-H7
and hydrogen bonds it forms with AT1R shown as black dashed lines. (B) Interaction of the docked pose of AngII in the presence of LVV-H7
and hydrogen bonds (black dashed lines) and π- π interactions (green dashed lines) it forms with the AT1R.
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Figure 50: 2D ligand interaction diagram of AngII with AT1R. A) AngII interacting residues with orthosteric binding site of AT1R (PDB:
4ZUD). Colored circles represent amino acids that form interaction with bound ligand. Red circles indicate negatively charged amino acids, dark
blue colors indicate positively charged amino acids, light blue circles indicate polar amino acids, and green circles indicate hydrophobic amino.
Hydrogen bonds are shown with purple arrows–dashed arrows for hydrogen bonds involving amino acid side chain and regular arrows for
hydrogen bonds involving amino acid backbone. π–π interactions are represented with green lines.
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Figure 51: 2D ligand interaction diagram of AngII with AT1R-LVV-hemorphin-7. AngII interacting residues with orthosteric binding site of
AT1R docked with LVV-H7. Colored circles represent amino acids that form interaction with bound ligand. Red circles indicate negatively
charged amino acids, dark blue colors indicate positively charged amino acids, light blue circles indicate polar amino acids, and green circles
indicate hydrophobic amino. Hydrogen bonds are shown with purple arrows–dashed arrows for hydrogen bonds involving amino acid side chain
and regular arrows for hydrogen bonds involving amino acid backbone. π–π interactions are represented with green line.
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The best binding pose of AT1R-Ang II and AT1R-LVV-H7-Ang II
complexes were extracted, and the complexes were simulated for 500 ns in triplicates
to assess the binding stability and dynamics of AngII with AT1R in the presence and
absence of LVV-H7. The membrane embedded AT1R structures remained stable
when AngII and LVV-H7 were bound with a Cα RMSD that was under 4 Å (Figures
48B and 48C). RMSF of AT1R, where both LVV-H7 and Ang II were bound,
showed that ICL2 (residues 131-137) and ECL2 (residues 180-191) fluctuated more
compared to AT1R bound to AngII only (Figures 48E and 48F).

Figure 52: Average percentage of simulation time from three 500 ns runs during which AT1R residues maintain contact with LVV-H7. The
average percentage of simulation time is shown next to the dotted line. Charged, hydrophobic, and polar residues are represented with orange,
green and blue color respectively.
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Figure 53: Average percentage of simulation time from three 500 ns runs during which AT1R residues maintain contact with AngII in the
absence of LVV-H7. The average percentage of simulation time is shown next to the dotted line. Charged, hydrophobic, and polar residues are
represented with orange, green and blue color respectively.
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Figure 54: Average percentage of simulation time from three 500 ns runs during which AT1R residues maintain contact with AngII in the
presence of LVV-H7. The average percentage of simulation time is shown next to the dotted line. Charged, hydrophobic, and polar residues are
represented with orange, green and blue color respectively.
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Figure 55: Histograms of the percentage of simulation time where an AT1R residue
maintained contact with a peptide. (A) AT1R-LVV-H7; (B) AT1R-AngII; (C)
AT1R-LVV-H7-AngII.
The stability of interactions between AT1R and the peptides were assessed
from the simulations of AT1R-AngII complex in the presence and absence of LVVH7 (Figures 53 and 54). AT1R residues Trp84, Val108, Leu112, Arg199 and Ile288,
located at the bottom of the orthosteric binding site, interacted with Pro7 and Phe8 of
AngII (Figures 49). Arg199 was observed to be close to Phe8 of AngII in the AT1R-
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LVV-H7-AngII complex, and this inward movement was linked to a more sustained
interaction of Arg199 with Phe8 during simulations when compared to the AT1RAng II complex (Figures 53 and 54). The interaction of Phe8 with Arg199 has been
demonstrated to be an essential contact associated with AT1R activation (Fillion et
al., 2013). Phe8 also formed consistent hydrophobic interactions with Ser109 and
intermittent interactions with Tyr113 when LVV-H7 was bound. This interaction was
observed in only one of the simulations when LVV-H7 was not bound to AT1R
(Figures 53 and 54). His6 showed consistent interactions with Trp84 of AT1R bound
with LVV-H7 in all runs of simulation, while the same interaction was formed in
only two runs in the absence of LVV-H7. Pro7 of AngII formed limited interactions
with Ser105 and Ile288 residues and which were better when LVV-H7 was bound to
AT1R. Ile5 maintained sustained interactions with Arg167 in both cases for the full
duration of the simulations. Arg167 is an important to AT1R when compared to
other structurally similar GPCRs and play a vital role in defining ligand binding
affinity. Tyr4 of AngII exhibited sustained interactions with Tyr92 of AT1R only
when LVV-H7 was bound (Figure 54). However, Tyr4 interacted with Tyr35 in both
cases. AngII residues Arg2 interacted with Asp263 and Asp281of AT1R with and
without LVV-H7 throughout the simulations. Such an interaction between AT1R and
AngII has been reported previously (Feng et al., 1995; Wingler, McMahon, Staus,
Lefkowitz, & Kruse, 2019). The interactions of Asp263 and Asp281 of AT1R with
Arg2 of AngII were slightly weaker in the absence of LVV-H7. Val3 formed
consistent interactions with Cys180 and Phe182 in the presence of LVV-H7. While,
without LVV-H7, these residues of AT1R interacted with Tyr4 of AngII (Figures 53
and 54). Asp1 of AngII formed sustained interaction with Ser15, Lys20 and Arg23 of
AT1R in the presence of LVV-H7. Overall, the docking and simulation data
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indicates that the N-terminus of AngII was firmly held by hydrogen bonds as well as
hydrophobic and polar interactions with Ile12, Leu13, Ser15, Lys20, Arg23, Asp263
and Asp281 residues of AT1R when LVV-H7 was bound. This permitted the Cterminus of AngII to bind stably deep inside the orthosteric site. However, in the
absence of LVV-H7, the N-terminus of AngII formed less stable interactions with
Ile12, Leu13, Ser15, Lys20 and Arg23 of AT1R (Figures 53 and 54). Such subtle
changes support the higher binding affinity of AngII in the presence of LVV-H7.

MM-GBSA based free energy of binding (ΔGbind) was estimated using frames
extracted every 50 ns from the MD simulations. AT1R-AngII simulations in the
presence of LVV-H7 exhibited

ΔGbind (-224.8 ± 7.6 kcal/mol, -206.1 ±

10.9

kcal/mol and -228.4 ± 8.1 kcal/mol) that were higher than AT1R-AngII simulations
without LVV-H7 (-193.0 ± 14.9 kcal/mol, -161.3 ± 25.2 kcal/mol and -189.9 ± 24.7
kcal/mol). There is a notable improvement in ΔGbind compared to the initially docked
structure indicating that AngII remained stably bound in the simulations.
Furthermore, this also indicates higher binding affinity of AngII in the presence of
LVV-H7.

5.2 Discussion
Here, the pharmacological action of LVV–hemorphin-7 on HEK293 cells
transiently expressing AT1R was observed. Interesting, a positive allosteric action on
AT1R activation and signaling was observed for the first time. This effect was
determined using multiple in vitro assays such as real-time BRET for AngIImediated AT1R-Gαq coupling and β-arrestin 2 recruitment. Their related
downstream signaling pathway was also determined via the estimation of IP1
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production. Additionally, extensive in silico studies indicate the allosteric
potentiation of AngII binding affinity by LVV-H7 through binding to intracellular
regions of AT1R. Results clearly showed that LVV–hemorphin-7 produced a
positive allosteric effects on the activation of AT1R and also enhanced the functional
coupling with Gαq and its interaction with β-arrestin 2. LVV-hemorphin-7 produced
substantial potentiation of AngII-induced BRET signals as indicated by both dose–
response and real-time kinetics experiments. The positive allosteric action of LVVhemorphin-7 was also found on AngII-mediated Gαq/IP1 generation. Therefore, the
findings reveal that LVV-hemorphin-7 produces a differential action on AT1Rmediated signaling. Furthermore, LVV-hemorphin-7 produce positive allosteric
modulation (PAM)-like effect on Gαq activation and β-arrestin 2 recruitment
(assessed by BRET).

Molecular docking and long (MD) simulations were performed to determine
the most suitable binding pose of LVV-H7 and its effect on AngII binding to AT1R.
Extensive molecular docking runs identified an intracellular location, previously
linked to allosteric modulation in other GPCRs, to be the most suitable binding site
of LVV-H7 (Wang et al., 2018) . Long MD simulations revealed that LVV-H7
binding in this IC site induced conformational changes in the orthosteric binding
pocket associated with AngII binding. Interestingly, the C-terminus of AngII was
embedded deeper in its binding site and formed sustained interaction with Trp84,
Ser105, Ser109, Lys199 and Ile288 of AT1R when compared to the structure without
LVV-H7 (Figures 49, 53 and 54).

These findings are of prime importance to pharmacology of GPCRs and
hemorphins and their involvement in human physiology. This body of work reports
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another member of the GPCR family - AT1R - that is a target of hemorphins with the
possible involvement in the pathophysiology and physiology of renal and vascular
systems, besides hemorphin’s direct effect on opioid receptors (Brantl et al., 1986;
Cheng et al., 2012; Davis et al., 1989; Glamsta et al., 1992). Additionally, the effect
of LVV-hemorphin-7 on AT1R is in agreement with the earlier studies indicating
LVV-hemorphin-7 acting on opioid receptors encompassing the fields of action of
hemorphins on GPCRs. A partial to full radioligand binding have been confirmed in
opioid receptors, with a competition with some opioids peptides such as endogenous
dynorphins and enkephalins but not nonpeptide ligands (Garreau, Zhao, Pejoan,
Cupo, & Piot, 1995; Zhao & Piot, 1997). Furthermore, an agonist like action of
LVV–hemorphin-6 has been reported in guinea-pig ileum and GTPγS binding
assays, respectively (Yukhananov et al., 1994). These studies clearly showed the
precise binding of hemorphins on the opioid receptors that elucidate the palliative
potentials of hemorphin found in vivo (Albiston et al., 2001; Cheng et al., 2012;
Hughes et al., 1975). Indeed, in vitro experiments reported here clearly demonstrated
the substantial PAM effects of LVV-hemorphin-7 on AT1R, as indicated by different
BRET and in IP1 assays, and to less extent BRET (100 µM), indicate such an
interaction between AT1R and LVV-hemorphin-7. Importantly, results of BRET
and IP1 dose–response curves are characteristic of PAM of LVV–hemorphin-7 on
AT1R with no noteworthy effects of LVV-hemorphin-7 were observed when used
alone. However, a left shift of the AngII dose curves were clearly observed in the
presence of different doses of LVV–hemorphin-7. Indeed, this suggests that AT1R
could exhibit an allosteric modulation in the presence of LVV-hemorphin-7 and may
harbor an allosteric binding site as indicated in several earlier studies.
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Positive allosteric binding site of GPCRs have been identified in the past
(Bruns & Fergus, 1990; Nemeth et al., 1998). However, recent studies have fully
characterized the potential of PAM in multiple GPCRs using in silico and in vitro
approaches (Congreve, Oswald, & Marshall, 2017; Kruse et al., 2013). Allosteric
binding sites located near the EC face and IC face in different GPCRs have been
documented (Bock et al., 2012; Kruse et al., 2013). Allosteric sites near the
orthosteric site in GPCRs often block the entry of other ligands (Proska & Tucek,
1994; Wang et al., 2018). However, this would not be a problem for allosteric
ligands that target the IC region. DETQ, an allosteric modulator of dopamine 1
receptor binds preferentially to ICL2 and significantly enhanced the potency of
dopamine (Wang et al., 2018). Interestingly, LVV-H7 binds to the IC face of AT1R
and predominantly targets the ICL2 (Figure 46). LVV-H7 targets ICL2 residues that
are not conserved in dopamine 1 receptor at AT1R such as Lys135 and Ser136 as
well as the conserved residues Arg126, Ile130 and Pro133 (Figures 46, and 47).
These residues are located near the binding site of DETQ on ICL2 of dopamine 1
receptor (Wang et al., 2018). Moreover, recent studies have shown that AT1R
stabilizing nanobodies target the intracellular side of AT1R, especially ICL2 residues
and enhanced the binding affinity of AngII for AT1R (Wingler et al., 2019). This
phenomenon shows complementary cooperativity anticipated for an allosteric
interaction. Interestingly, here, LVV-H7 binds to these ICL2 residues of AT1R and
could potentiate the binding affinity and potency of AngII. Moreover, the allosteric
binding of LVV-H7 in the intracellular regions of AT1R is consistent with the
allosteric modulation of GPCRs through the targeting of their intracellular surfaces
which has been well documented with the lipidated peptides known as pepducins and
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even small molecules (Covic, Gresser, Talavera, Swift, & Kuliopulos, 2002; P.
Zhang et al., 2015).

Evaluating the binding mode of AngII in the presence and absence of LVVH7 revealed that AngII bound deeper in the orthosteric binding pocket in the
presence of LVV-H7 (Figure 49). The interaction between Phe8 of AngII with
Lys199, located at the base of the orthosteric pocket of AT1R was improved in the
presence of LVV-H7 (Figures 53 and 54). Lys199 has been identified as a residue
critical for AT1R activation (H. Zhang et al., 2015a). Tyr35 and Trp84 are conserved
in other GPCRs such as angiotensin, chemokine and opioid receptors and mutating
these residues would abolish the binding of both peptide and synthetic ligands of
AT1R (H. Zhang et al., 2015b). In simulations, Tyr35 and Trp84 were observed to
form more sustained interactions with AngII in the presence of LVV-H7 (Figures 53
and 54). AT1R activation cascade has also been shown to be initiated by the van der
Waals interaction between Phe8 and Ile288 (Singh et al., 2019). Interestingly,
intracellular binding of LVV-H7 enhanced stability of the interaction between Phe8
with Ile288 (Figures 53 and 54). This could likely lead to a more robust disruption of
the Asn111-Asn295 interaction, and better AngII binding affinity and potency (Singh
et al., 2019). The existence of a stable hydrogen bond between Asn111 and Asn295
is characteristic of the inactive state of AT1R and its disruption is vital for AT1R
activation (H. Zhang et al., 2015a; H. Zhang et al., 2015b). Mutagenesis studies have
also reported that Tyr87, Arg167 and Tyr292 are important for AngII binding (Singh
et al., 2019). Interestingly, these residues formed more sustained interactions with
AngII in the presence of LVV-H7 (Figures 53 and 54).
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DRY, Yx7K, NPxxY, and helix-8 motifs are highly conserved among GPCRs
and are located in the cytoplasmic region. These motifs, initially reported in
rhodopsin, act as microswitches (Elgeti et al., 2011). Functional studies of AT1R
have illustrated the stability of these motifs in the inactive state (Elgeti et al., 2011;
Lin, Han, & Sakmar, 2000). ICL2 residues of AT1R, where LVV-H7 bound, are
associated with structural changes that induce a transition from an inactive to an
active conformation in GPCRs (Wang et al., 2018). Trajectory analysis of AT1RLVV-H7 complex indicated that the binding of LVV-H7 to ICL2 and ICL3 of AT1R
induced conformational changes in the DRY motif present at the cytoplasmic end of
TM3 that are important for GPCR activation (Singh et al., 2019; Wang et al., 2018).
GPCR activation involves the breakage of a stable interaction that exists between
Asp125 and Arg126 of the DRF motif in the inactive state (Matsoukas et al., 2013;
Singh et al., 2019). Interestingly, LVV-H7 binds to the DRF motif and forms an
intermittent interaction with Arg126 residue of AT1R throughout the simulations
(Figure 52). Additionally, the side chain of Arg126 was observed to slightly orient
itself towards TM6 in the presence of LVV-H7. These changes have been associated
with the opening of the groove where G-protein binds and could, therefore, enhance
the coupling of G-protein to AT1R (Rasmussen et al., 2011; Singh et al., 2019).

In the physiological context, the positive allosteric modulator effects of
LVV–hemorphin-7 on AT1R captivatingly indicate a hypertensive action. Such an
effect is somehow is not in agreement with the previous antihypertensive effects of
hemorphins demonstrated in several in vivo and in vitro studies (Ali et al., 2020;
Fruitier-Arnaudin, Cohen, Coitoux, & Piot, 2003; Lantz et al., 1991; Zhao & Piot,
1997). Previous study has shown that hemorphins produce hypotensive activities
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through the direct inhibition of ACE (Zhao & Piot, 1997). Additionally, hemorphins
have been reported to enhance the hypotensive and vasodilatory effect of bradykinin
(Ianzer et al., 2006). Lastly, studies have shown that serum hemorphin-7 levels after
long distance running were determined to be very high (Glamsta et al., 1992), while
they were observed quite low in diabetic and obese patients, which are associated to
high blood pressure and cardiovascular risks (Maraninchi et al., 2013). Thus,
conflicting activities of hemorphins on ACE (inhibition) and AT1R (activation) and
their

physiological

outcomes,

hypotensive

and

hypertensive,

respectively,

demonstrate the intricacy of hemorphin’s action on RAS. One possibility of
explaining these opposing effects is by assuming that the blockage of ACE which
results in a reduction of AngII levels can be compensated by the positive effect of
hemorphins on AT1R. This would suggest that low doses of AngII could be
sufficient to activate RAS in this condition.

In addition, it is possible that

hemorphins regulate water reabsorption and blood pressure under different
conditions by biasing RAS towards activation via their positive modulatory activities
on AT1R or inhibition of ACE effect and AngII levels. The data presented here can
be viewed and interpreted in both physiological and pathophysiological
circumstances. Certainly, it is not established yet if hemorphins release from the
hemoglobin is a normal or a pathogenic mechanism with an effect on blood pressure
and water balance. Additionally, it is also unknown that which part of hemorphin’s
action ACE, or AT1R is actually the determinant of the system and how it interacts
under physiological and pathophysiological conditions. In the physiological context,
the two contradictory action of hemorphins could be components of the precise
control of the blood pressure (and maybe even water balance) via the stimulatory and
the inhibitory effects on AT1R and ACE, respectively, to maintain the blood pressure
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in the normal range. For example, if elevated blood pressure occurs for some reason
and this could be correlated with high ACE expression and/or activity, in such
circumstances hemorphins could be released to counterbalance this condition so as to
prevent any risk of consistent or chronic hypertension. Similarly, if there is a
hypotensive/vasodilatation condition due to lower expression/activity of AT1R,
hemorphins could then be produce and released to raise blood pressure by
stimulating AT1R-dependent vasoconstriction. However, in pathological conditions,
the increased expression/activity of AT1R correlated with possible decrease in the
expression/activity of ACE and the enhanced release of hemorphins could be
indicative of the pathophysiology of hypertension and of RAS. In such a scenario,
hypertension may be either the cause or the outcomes of the action of hemorphins.
Therefore,

it

could

be

speculated

that

in

different

physiological

and

pathophysiological conditions, the biological system including all these components
(hemorphins, AT1R, or ACE) could rely on the circulating concentrations of
hemorphins along with the comparative expression levels of the two RAS targets,
ACE and AT1R. Until now, there is no reliable data available on the possible
relationship between the quantity of hemorphins released in blood and the expression
profiles of AT1R and ACE and their effects on the regulation of blood pressure and
hypertension. This indicates that the stoichiometry of hemorphins/AT1R versus
hemorphins/ACE in hypotensive and hypertensive situations remain elusive. A
previous study has revealed that the blood of long-distance running subjects
contained a higher concentration of hemorphins (Glamsta, Morkrid, Lantz, &
Nyberg, 1993). This could be true with either a positive modulator effect of
hemorphins (hypertensive) via action on AT1R due to exercise or their negative
regulatory action (hypotensive) via the binding and inhibition of ACE to prevent any
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unnecessary hypertension. Moreover, very low hemorphin levels have recently been
documented in diabetic and obese patients that are associated to hypertension and
cardiovascular risks indicating therapeutically beneficial effects of hemorphins on
ACE inhibition (Maraninchi et al., 2013). Thus, it would be important to explore the
possible effects of hemorphins on other primary RAS and kidney actor such as
bradykinin, adrenergic, and vasopressin receptors, identified to have functional
interactions with AT1R (Tóth, Turu, Hunyady, & Balla, 2018).
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Chapter 6: Structural and Genetic Changes of Camel Hemoglobin
6.1 Results
Genetic and in silico approaches were used to investigate the structural and
genetic changes of camel hemoglobin and were compared with human hemoglobin.
6.1.1 Hemoglobin α and β genes sequences
Hemoglobin α and β genes of 170 camel samples from different breeds were
amplified to determine the variation near the heme, ATP and 2,3-BPG binding sites.
PCR was first used to amplify hemoglobin α and β genes of all samples. These
samples were then purified and sent for DNA sequencing using the primers used for
PCR. Chromatograms obtained from sequencing were inspected using Finch TV
Viewer and the sequences were aligned using BioEdit Sequence Alignment Editor to
identify locations that harbor variations. One synonymous variation (Ser82) was
observed in hemoglobin α gene in all camel breeds. The frequency of this variation
in each breed is given in Table 8. The chromatogram showing the variation is given
in Figure 56. The coding regions of both genes were devoid of any other variation.
However, several non-coding variations were observed in both genes (Table 8).
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Figure 56: Chromatograms of camel samples. (A) Chromatogram of a wild camel;
(B) Chromatogram of a camel with synonymous variation. Arrow in red color shows
the position of variation.
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Table 8: List of coding and non-coding variations observed in hemoglobin genes of
different breeds of camel.
Gene Name

Bread Name

Variation

Exonic function

g.384G>T

Synonymous

Local

Hemoglobin α

g.454G>A

NA

g.384G>T

Synonymous

26/50
2/50

p.S82=
g.454G>A

NA

g.384G>T

Synonymous

Sudani

19/50
6/50

p.S82=
g.454G>A

NA

g.384G>T

Synonymous

Dairy

Local

5/50

p.S82=

Mixed

Hemoglobin 

Frequency

16/50
3/20

p.S82=
g.563C>T

NA

34/50

g.608C>T

NA

2/50

g.644C>T

NA

17/50

g.655A>C

NA

3/50

g.677C>T

NA

24/50

g.684C>T

NA

26/50

g.694C>T

NA

11/50

g.704C>T

NA

5/50

g.707C>T

NA

2/50

g.715C>T

NA

30/50

g.1033T>C

NA

44/50

g.1251T>C

NA

50/50
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Table 8: List of coding and non-coding variations observed in hemoglobin genes of
different breeds of camel (Continued).
Gene Name

Hemoglobin 

Hemoglobin 

Bread Name

Mixed

Sudani

Variation

Exonic function

Frequency

g.563C>T

NA

25/50

g.608C>T

NA

0/50

g.644C>T

NA

5/50

g.655A>C

NA

0/50

g.677C>T

NA

15/50

g.684C>T

NA

17/50

g.694C>T

NA

9/50

g.704C>T

NA

0/50

g.707C>T

NA

8/50

g.715C>T

NA

18/50

g.1033T>C

NA

48/50

g.1251T>C

NA

47/50

g.563C>T

NA

23/50

g.608C>T

NA

Nil

g.644C>T

NA

12/50

g.655A>C

NA

Nil

g.677C>T

NA

11/50

g.684C>T

NA

14/50

g.694C>T

NA

4/50

g.704C>T

NA

Nil

g.707C>T

NA

9/50

g.715C>T

NA

17/50

g.1033T>C

NA

46/50

g.1251T>C

NA

50/50
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Table 8: List of coding and non-coding variations observed in hemoglobin genes of
different breeds of camel (Continued).
Gene Name

Hemoglobin 

Bread Name

Dairy

Variation

Exonic function

Frequency

g.563C>T

NA

7/20

g.608C>T

NA

1/20

g.644C>T

NA

3/20

g.655A>C

NA

0/20

g.677C>T

NA

5/20

g.684C>T

NA

8/20

g.694C>T

NA

6/20

g.704C>T

NA

1/20

g.707C>T

NA

3/20

g.715C>T

NA

5/20

g.1033T>C

NA

16/20

6.1.2 Molecular dynamics (MD) simulation of camel and human hemoglobin

MD simulations were performed on camel and human hemoglobin at
different temperatures (27°C, 30°C, 34°C, and 41°C) and salt concentration (0 mM,
150 mM, 300 mM, and 600 mM) to investigate the structural stability and flexibility
of hemoglobin residues. The salt concentration of 150 mM was maintained in each
simulation when the effects of different temperature conditions were measured.
While, a temperature of 27°C was used in each simulation to assess the overall
impact of different salts concentrations on hemoglobin stability. Sixteen different
complex systems were prepared. The information of each prepared complex system
is given in Table 9. One microsecond MD simulations were performed for each
complex system to determine the dynamical features of the camel and human
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hemoglobin structure under different salt concentrations and temperature conditions.
The dynamical features were investigated by evaluating RMSD and RMSF.

Table 9: MD simulation conditions used for simulating complex systems of camel
and human hemoglobin.
PDB ID

Temperature
(°C)

Salt concentrations
(mM)

Run time
(ns)

3GDJ

27

0

1000

3GDJ

27

150

1000

3GDJ

27

300

1000

3GDJ

27

600

1000

3GDJ

27

150

1000

3GDJ

30

150

1000

3GDJ

34

150

1000

3GDJ

41

150

1000

2HHB

27

0

1000

2HHB

27

150

1000

2HHB

27

300

1000

2HHB

27

600

1000

2HHB

27

150

1000

2HHB

30

150

1000

2HHB

34

150

1000

2HHB

41

150

1000
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6.1.2.1 RMSD and RMSF of camel and human hemoglobin at different salt
concentration
RMSD of camel and human hemoglobin was measured at different salt
concentration (0 mM, 150 mM, 300 mM and 600 mM). Each simulation was
performed at a constant temperature of 27°C. RMSD of Hb from each simulation
system was computed and plotted to determine the dynamic features of camel and
human Hb throughout the simulation runs (Figure 57). The backbone Cα atoms of
camel Hb showed the RMSD of approximately 2 Å at all salt concentration except
600mM where the complex system stabilized under 3 Å. All systems reached
equilibrium after few nanoseconds of simulation except the complex system of 600
mM (Figure 57A). This system attained equilibrium after 500ns (Figure 57A). The
average calculated RMSD values were 1.97 Å, 1.82 Å, 1.83 Å and 2.42 Å for the salt
concentration of 0 mM, 150 mM, 300 mM and 600 mM respectively. Human Hb
showed higher RMSD values at all salt concentration (Figure 57B). The average
estimated RMSD values of human Hb were 3.56 Å, 4.07 Å, 3.23 Å, and 3.24 Å for
the salt concentrations of 0 mM, 150 mM, 300 mM and 600 mM, respectively.
Moreover, all human Hb complex systems required more time to reach equilibrium.
This indicates that camel hemoglobin structure showed more stability at different salt
concentrations, compared to human hemoglobin. The structural integrity of all
simulations of camel and human Hb were retained as indicated by their RMSD.

To evaluate the flexibility of camel hemoglobin at constant temperature,
T=27°C, with various salt concentrations (NaCl), the RMSF of Cα atoms on a
residue from the average structure obtained from the MD frames was calculated. The
RMSF of the hemoglobin structure exhibited similar pattern of fluctuations at
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different salt concentrations and high peaks were observed in some residues in the
loop or turn region (Figure 57C). The residue numbering used in RMSF plots of
hemoglobin shows the seuential combination of residues from the four chains (α1,
β1, α2, and β2) in the structure. Importantly, camel hemoglobin residues α2:46 -55
(represented by residues 330-342 in Figure 57C) showed more fluctuations at 600
mM NaCl concentration. α1:46-50 showed high fluctuations at 0 mM and 600 mM
salt concentrations (Figure 57C). β1:47-53 exhibited more fluctuations at only 0 mM.
However, the same region remained stable in all other simulations. β2:5-11 exhibited
higher fluctuations at 150 mM and 300 mM salt concentrations. However, the same
region in β1 showed more fluctuations at 0 mM only (Figure 57C). The residue
His87 of α1 subunit and His92 of β1 and β2 subunits showed more fluctuations at
higher salt concentrations. However, His87 of α2 showed more fluctuation at 0 mM
salt concentration. At 150 mM and 300 mM, Ser70-Phe71-Gly72 in the β1 and β2
subunits showed more fluctuations.

Residues of human hemoglobin compared to camel hemoglobin showed more
fluctuations at all salt concentrations (Figure 57D). Loop region residues 42-51, and
70-77 of α1 subunit exhibited more fluctuations particularly at 300 mM and 600 mM.
Helical residues 78-91 of α1 subunit also showed higher fluctuations at higher salt
concentrations. Interestingly, the same helical residues of camel α1 subunit
demonstrated extremely low fluctuations at all salt concentrations (Figure 57D).
However, such fluctuations were not observed in the same residues of both camel
and human α2 subunits. Moreover, residues 111-140 of α1 subunit of human Hb
showed higher fluctuations at higher salt concentrations especially at 300 mM.
However, the same residues in camel Hb demonstrated very limited variations at all
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salt concentrations. However, such a pattern was not observed in α2 subunits of both
camel and human Hb. Val2 of β1 and β2 subunits of human Hb showed more
fluctuations particularly at higher salt concentrations, compared to camel Hb (Figure
57D). Helical residues 11-15 of camel Hb showed slightly higher fluctuations at all
salt concentrations, particularly at 0 mM. However, the same residues in human β2
subunit showed slightly more fluctuations compared to camel Hb (Figure 57D). Loop
residues 39-59 of β1 subunit of human Hb exhibited higher variations at all salt
concentrations compared to camel β1 subunit. However, such a trend was observed
in only 39-45 residues of β2 subunits of both human and camel Hb (Figure 57D).
Residues 80-98, 84-98 which formed loops in β1 and β2 subunits showed higher
fluctuations in human Hb compared to camel Hb at all salt concentrations,
respectively (Figure 54D). Lys82 of both β1 and β2 chains is considered an essential
residue for the binding of 2,3-BPG and ATP (Chen et al., 2017). However, His92 is
an important residue of β1 and β2 subunits which form the binding sites for oxygen.
Interestingly, these residues fluctuated more in human Hb at all salt concentrations.
Residues 141-147 of β1and β2 chain of human Hb exhibited higher fluctuations
particularly at higher salt concentrations. However, camel Hb demonstrated limited
variations at all salt concentrations (Figure 57). His143 and His146 of β1 and β2
chains are also important for the binding of 2,3-BPG and ATP (Berg et al., 2002).
Overall, human Hb showed higher fluctuations at all salt concentrations, compared to
camel hemoglobin (Figure 57).

Figure 57: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 1000 ns
run of camel and human hemoglobin simulation at different salt conditions. Data from different salt conditions are shown in red, green, blue and
purple. (A) RMSD of camel hemoglobin; (B) RMSD of human hemoglobin; (C) RMSF of camel hemoglobin and, (D) RMSF of human
hemoglobin. Note that the residue number used in the RMSF plots uses a sequential combination of the α1, β1, α2, and β2 in the PDB structure.
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6.1.2.2 RMSD and RMSF of camel and human hemoglobin at different
temperature conditions
The camel and human hemoglobin protein was simulated separately for one
microsecond at four different temperature conditions (27°C, 30°C, 34°C, and 41°C).
The final salt concentration was kept constant (150 mM) for these simulations.
RMSD of main-chain atoms for the entire Hb was plotted to investigate the structural
changes of camel and human Hb (Figure 58). RMSD of the Cα atoms of camel Hb
with respect to the initial structure stabilized under 2 Å in all the simulations except
the one at 34°C. At 34°C the complex system of camel hemoglobin stabilized at
approximately 2.5 Å. This indicates that the structure of hemoglobin exhibited a
stable conformation from low to high temperature conditions. The average RMSD
values were 2.04 Å, 2.17 Å, 2.76 Å and 2.34 Å for the temperature, 27°C, 30°C,
34°C and 41°C respectively. In the case of 27°C and 30°C, the hemoglobin structure
reached equilibrium during the initial nanoseconds of the simulation, but the
structure required more time in the case of high temperature (34°C and 41°C). In
comparison to camel Hb, human Hb needed more time to reach equilibrium at all
temperature conditions. The RMSD of backbone Cα atoms of human Hb with respect
to the initial structure stabilized under 4.5 Å in all the simulations which were higher
compared to RMSD of camel Hb (Figure 58). The average RMSD values were 3.86
Å, 3.31 Å, 2.76 Å and 3.91 Å for the temperature, 27°C, 30°C, 34°C and 41°C
respectively.

In order to evaluate and compare flexibility in camel Hb at various
temperature conditions, the RMSF of Cα atoms on a residue, from the average
structure obtained from merged MD frames, was calculated. The camel Hb structure
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exhibited more fluctuations at higher temperature conditions especially in loop
regions (Figure 58C). The loop region residues 41-52 of α1, and α2 subunit showed
higher fluctuations compared to other residues particularly at higher temperature
conditions. The β1 helical residues 1-7 demonstrated higher fluctuations at lower
temperature conditions. However, the same residues of β2 subunits showed more
fluctuations at 34°C. Val2 and His3 of both β1 and β2 subunits are considered
important for the binding of 2,3-BPG and ATP (Chen et al., 2017). Higher
fluctuations were observed for residues near to the heme binding sites in each
subunit. The residues in these regions exhibited high RMSF values than the other
residues. The loop residues 44-55 of β1 and β2 showed higher fluctuations at 41°C.
Loop residues 72-82 of β1 exhibited higher fluctuations at only 34°C. The same
residues of β2 exhibited more fluctuations at higher temperature conditions (30°C,
34°C, and 41°C) (Figure 58C). The helical residues 2-7 and loop residues 15-19 of
α2 showed higher fluctuations 34°C and 41°C, respectively. However, the same
residues of α1 subunit exhibited limited fluctuations at all temperature conditions.
His87 of α subunits and His92 of β1 subunits demonstrated more fluctuations at
higher temperature conditions. These residues are essential for the binding of four
heme groups and served as oxygen binding sites. Importantly, conserved residues α1Phe43 and α1-Phe46 showed more fluctuations at higher temperature conditions
(Figure 58). These functional residues are present in the heme pocket distal to heme
where oxygen binds (Laberge et al., 2008). Moreover, α1 conserved residues Leu86
and Leu91 also exhibited higher fluctuations when the temperature was increased
(Figure 58C). These residues are part of the proximal heme pocket residues (Laberge
et al., 2008).
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The helical residues 1-10 and loop residues 11-17 of α1 of human Hb showed
higher fluctuations at higher temperature conditions when compared to camel Hb
(Figure 58D). The loop region residues 41-52 of α1 and α2 subunits showed higher
fluctuations at lower temperature conditions compared to camel Hb (Figure 58).
Moreover, the loop residues 44-55 of β1 of human Hb showed higher fluctuations at
higher temperature conditions compared to camel Hb.

Loop residues 72-82 of

human β1 and β2 exhibited higher fluctuations at lower temperature conditions
compared to camel Hb. Interestingly, at higher temperature conditions these residues
showed limited fluctuations in both camel and human Hb. Overall, in comparison to
camel Hb, human hemoglobin showed more fluctuations at different temperature
conditions.

Figure 58: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 1000 ns
run of camel and human hemoglobin simulation at different temperature conditions. Data from different temperature conditions are shown in red,
green, blue and purple. (A) RMSD of camel hemoglobin; (B) RMSD of human hemoglobin; (C) RMSF of camel hemoglobin and, (D) RMSF of
human hemoglobin. Note that the residue number used in the RMSF plots uses a sequential combination of the α1, β1, α2, and β2 in the PDB
structure.
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6.1.3 Molecular docking of 2,3-BPG and ATP with camel hemoglobin

The binding pose and binding affinity of 2,3-BPG and ATP was investigated
with camel deoxyhemoglobin structure (PDB ID: 3GDJ). 2,3-BPG and ATP
preferentially bind to deoxyhemoglobin and target the same binding site which is
located in the central cavity of hemoglobin molecule. The best binding pose of 2,3BPG had a GScore of -5.165 kcal/mol. The carbonyl and phosphate groups of 2,3BPG formed hydrogen bonds and salt bridges with Lys82 of β2 chain (Figure 59A).
Lys82 of β1 showed hydrogen bonds and salt bridge formation with carbonyl and
phosphate groups of 2,3-BPG. His146 residue of β2 formed hydrogen bond with
phosphate group. 2,3-BPG showed polar interactions with His143 of both β1 and β2
chains. Additionally, β1 chain formed hydrophobic interactions with Leu81 and
Ala140, electrostatic interaction with Asp79, and polar interactions with Asn80 and
Asn139 (Figure 59A).

GScore of the best binding pose of ATP with camel hemoglobin was -7.44
kcal/mol. Phosphate groups formed hydrogen bonds and a salt bridge with Lys82
residue of both β1 and β2 chains (Figure 59C). They also formed hydrogen bond and
polar interaction with His146 and His143 of β2 respectively. Additionally, Leu81
and Asp79 of β1 exhibited hydrophobic and electrostatic interactions with phosphate
groups of ATP. Hydroxyl group present on the ribose sugar of ATP formed hydrogen
bonds with Asp79 of β2 (Figure 59C). The β1 residues His143 and His146 were
involved in the formation of polar interactions with adenine group. Residues Arg144
and Tyr145 of β1 formed electrostatic and hydrophobic interactions with adenine.
Val2 and His3 of β2 showed hydrophobic and polar interactions with adenine (Figure
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59C). Overall, camel hemoglobin formed more interactions with ATP, compared to
human hemoglobin.

6.1.4 Molecular docking of 2,3-BPG and ATP with human hemoglobin

The binding pose and binding affinity of 2,3-BPG and ATP of camel
hemoglobin was compared with human deoxyhemoglobin structure (2HHB). The
best binding pose of 2,3-BPG showed GScore of -4.925 kcal/mol. These findings
were in agreement with previous studies performed to determine the binding affinity
of 2,3-BPG with hemoglobin (Chen et al., 2017). 2,3-BPG formed interactions with
critical residues of only β1 chain of hemoglobin as reported by previous studies.
Both phosphate groups of 2,3-BPG formed hydrogen bonds and salt formation with
Lys82 of β1 chain of hemoglobin (Figure 59B). The phosphate group of 2,3-BPG
showed electrostatic interaction with His143 of β1 chain. Additionally, phosphate
group also formed hydrogen bond with Val2, hydrophobic interaction with Leu81
and electrostatic interaction with Asn80 (Figure 59B). However, carbonyl group of
2,3-BPG showed hydrogen bond formation with Asn139.

The best binding pose of ATP exhibited GScore of -7.205 kcal/mol. All three
phosphate groups of ATP formed hydrogen bonds and salt formation with Lys82 of
β2 chain (Figure 59D). The third phosphate group also showed hydrogen bond and
hydrophobic interaction with Val2 and Leu81 of β2 chain respectively. The
phosphate groups also formed polar interactions with Asn79 and His143 of β1 and
β2 chains respectively (Figure 59D). The hydroxyl group of ribose sugar of ATP
formed hydrogen bonds with Asn79 of β1 subunit. The adenine group of ATP
formed a hydrogen bond and -cation interaction with Asp79 and Lys82 of β1 chain
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respectively. Adenine also formed hydrophobic and polar interactions with Val2 and
Asn80 of β1 (Figure 59D).

Figure 59: Docked pose of 2,3-BPG and ATP with camel and human hemoglobin. B)
Docked pose of 2,3-BPG with human hemoglobin. C) Docked pose of ATP with
camel hemoglobin. D) Docked pose of ATP with human hemoglobin. β1 and β2
subunits of camel and human hemoglobin are represented with blue and green
cartoons respectively. Interacting residues are shown in gray stick representation, the
docked ligands are represented as yellow stick, hydrogen bonds and salt bridges are
shown as black and blue dashed lines, respectively.
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Table 10: Interacting residues of camel and human hemoglobin with 2,3-BPG and
ATP.
Ligand

Residues
forming
hydrogen
bonds

Hemoglobin Glide
docking
PDB ID
Gscore
(kcal/mol)

Residues forming
hydrophobic and
polar interactions

Residues
forming π-π
stacking or
cation-π
interactions

2,3-BPG 3GDJ

-5.165 β1:Lys82, β1:Leu81,β1:Ala140 β1:Lys82,
β2:Lys82, β1:Asn139,β1:His14 β2:Lys82
β2:His146 3, β2:His143

2,3-BPG 2HHB

-4.925 β1:Lys82,
β1:Val2

β1:Asn80,β1:Leu81,β β1:Lys82
:1Asn139,
β1:Ala140,
β1:His143

-7.44 β2:Asp79,
β1:Lys82,
β2:Lys82,
β2:His146

β2:Val2,β2:His2,
β1:Lys82,
β1:Leu81,β1:Asn80, β2:Lys82
β1:His143,β2:His143
, β1:Tyr145
β1:His146

ATP

3GDJ

ATP

2HHB

-7.205 β1:Val2,
β1:Val2,β2:Val2,
β1:Lys82,
β2:Asp79, β1:Asn80,β1:Leu81, β2:Lys82
β2:Lys82, β2:Leu81,β2:Asn139,
β1:Asn139
β1:Ala140,
β1:His143
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6.1.5 Molecular dynamics (MD) simulations of 2,3-BPG and ATP bound to
camel and human hemoglobin
MD simulations were performed to determine the binding stability of 2,3BPG and ATP with camel and human hemoglobin in the presence of different salt
concentrations (0 mM, 150 mM, 300 mM, and 600 mM) and different temperature
conditions (27°C, 30°C, 34°C, 41°C). For measuring the impact of different
temperatures on the binding stability of 2,3-BPG-Hb and ATP-Hb complexes, a
single salt concentration of 150 mM was used for all simulations, whereas for
determining the effect of different salt concentrations, a single temperature of 27°C
was used for all simulations. Thirty two different complex systems were prepared.
The information of each prepared complex system is given in Table 11. For each
complex, two hundred nanosecond MD simulations were performed to determine the
binding stability of 2,3-BPG and ATP bound to camel and human hemoglobin.

Table 11: MD simulation conditions used for simulating complex systems of 2,3BPG and ATP with camel and human hemoglobin.
PDB ID

Ligand

Temperature
(°C)

Salt concentrations
(mM)

Run time
(ns)

3GDJ

2,3-BPG

27

0

200

3GDJ

2,3-BPG

27

150

200

3GDJ

2,3-BPG

27

300

200

3GDJ

2,3-BPG

27

600

200

3GDJ

2,3-BPG

27

150

200

3GDJ

2,3-BPG

30

150

200

3GDJ

2,3-BPG

34

150

200

3GDJ

2,3-BPG

41

150

200

3GDJ

ATP

27

0

200

3GD

ATP

27

150

200

3GDJ

ATP

27

300

200
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Table 11: MD simulation conditions used for simulating complex systems of 2,3BPG and ATP with camel and human hemoglobin (Continued).
PDB ID

Ligand

Temperature
(°C)

Salt concentrations
(mM)

Run time
(ns)

3GDJ

ATP

27

600

200

3GDJ

ATP

27

150

200

3GDJ

ATP

30

150

200

3GDJ

ATP

34

150

200

3GDJ

ATP

41

150

200

2HHB

2,3-BPG

27

0

200

2HHB

2,3-BPG

27

150

200

2HHB

2,3-BPG

27

300

200

2HHB

2,3-BPG

27

600

200

2HHB

2,3-BPG

27

150

200

2HHB

2,3-BPG

30

150

200

2HHB

2,3-BPG

34

150

200

2HHB

2,3-BPG

41

150

200

2HHB

ATP

27

0

200

2HHB

ATP

27

150

200

2HHB

ATP

27

300

200

2HHB

ATP

27

600

200

2HHB

ATP

27

150

200

2HHB

ATP

30

150

200

2HHB

ATP

34

150

200

2HHB

ATP

41

150

200

6.1.6 MD simulations of camel and human hemoglobin bound to 2,3-BPG at
different salt concentrations
2,3-BPG is an important co-factor present abundantly in erythrocytes and is
involved in binding with deoxyhemoglobin. Different salt concentrations were used
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to determine the effect of osmotic pressure on the structural stability, residual
flexibility and the binding stability of 2,3-BPG with camel and human hemoglobin.
The RMSD of both camel and human hemoglobin-2,3-BPG complexes at different
salt concentration remained stable throughout the simulation time. RMSD of the Cα
atoms of camel and Hb bound to 2,3-BPG with respect to the initial structure were
stabilized under 3.5Å in all the simulations (Figures 60A and 60B). However, human
hemoglobin bound to 2,3-BPG demonstrated higher RMSD at 600 mM. To
determine the effect of 2,3-BPG on the backbone stability and residual flexibility of
camel and human hemoglobin, the RMSF of backbone Cα atoms of both camel and
human hemoglobin were investigated (Figures 60C and 60D). Overall, camel
hemoglobin showed limited fluctuations compared to human hemoglobin. The loop
residues 44-52 and 45-52 of α1 and α2 subunits showed similar fluctuations at all
salt concentrations, in both camel and human hemoglobin bound to 2,3-BPG, except
150 mM, where camel Hb-2,3-BPG complex showed lower fluctuations (Figures
60C and 60D). The loop residues 78-93 of α1 subunit exhibited higher fluctuations
at higher salt concentrations in both camel and human Hb-2,3-BPG complexes.
However, the fluctuations of the same residues of α1 subunit were observed higher in
human Hb-2,3-BPG complex at 600 mM, compared to camel. The loop residues 111120, and the helical residues 120-132 of α1 exhibited higher fluctuations at higher
salt concentrations in human Hb-2,3-BPG complex, compared to camel complex
system. The helical residues 2-13 and loop residues 14-20 of β1 and β2 subunits of
camel Hb showed higher fluctuations at 300 mM. However, residues 1-32 of β1 and
β2 subunits of human Hb, composed of loops and helical regions exhibited higher
fluctuations at 600 mM, compared to camel. The loop residues 44-55 of β1 showed
higher fluctuations at lower salt concentrations (0 mM and 150 mM), while the same
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residues of β2 showed higher fluctuations at higher salt concentrations (300 mM and
600 mM) in camel Hb-2,3-BPG complex. However, the same residues showed
higher fluctuations at all salt concentrations in human Hb. Loop residues 80-100 of
β1 and β2 showed higher fluctuations at only 0 mM and 600 mM, (Figures 60C and
60D). While the same residues in human demonstrated higher fluctuations at higher
salt concentrations (300 mM and 600 mM). Importantly, residues 79 and 82 of β1 of
camel Hb showed higher fluctuations at higher salt concentrations, while the same
residues of β2 subunit showed higher fluctuations at only 300 mM. However, the
same residues in human Hb showed higher fluctuations at higher salt concentrations
(300 mM and 600 mM). Additionally, residues 139, 143 and 146 of both β1 and β2
subunits exhibited lower fluctuations at higher salt concentrations, compared to
human Hb. Overall, the fluctuations of these important residues of β1 and β2
subunits were observed higher in human compared to camel at all salt concentrations,
especially at 300 mM and 600 mM.

Figure 60: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 200 ns
run of 2,3-BPG bound camel and human hemoglobin simulations at different salt conditions. Data from different salt conditions are shown in red,
green, blue, and purple. (A) RMSD of camel Hb-2,3-BPG complex simulations; (B) RMSD of camel Hb-2,3-BPG complex simulations: (C)
RMSF of camel Hb-2,3-BPG complex simulations and, (D) RMSF of human Hb-2,3-BPG complex simulations. Note that the residue number
used in the RMSF plots uses a sequential combination of the α1, β1, α2, and β2 in the PDB structure.
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The contact duration of critically important residues of hemoglobin β subunits with
2,3-BPG were observed during the simulations. Several hydrogen bonds,
hydrophobic interactions, salt bridges, cation–π, and π–π and interactions were
observed to form, break, and reform throughout the simulation runs. Asp79 of both
β1 of β2 subunits of camel Hb exhibited consistent interactions at all salt
concentrations. While the same residue of β1 chain of human Hb formed intermittent
interaction at lower salt concentrations only. Lys82 of both β chains of human and
camel Hb formed sustained interactions for the full duration of the simulations at all
salt concentrations. Moreover, Asn139 of β1 chain of camel Hb exhibited sustained
interactions with 2,3-BPG at higher salt concentration. However, Asn139 of both β
chains of human Hb formed interactions with 2,3-BPG at lower salt concentrations
only. The residue His143 of β1 and β2 of camel hemoglobin formed more sustained
interactions with 2,3-BPG at higher salt concentrations, compared to human
hemoglobin. Similarly, His146 of camel β subunits formed more sustained
interactions with 2,3-BPG at higher salt concentrations (300 mM and 600 mM).
However, such interactions were not observed in human Hb. Additionally, Asn80 of
camel β2 subunit showed more sustained interactions at 300 mM, and 600 mM,
while, the same residue of β1 of human Hb showed interactions with 2,3-BPG at 0
mM and 150 mM only (Figures 61 and 62).
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Figure 61: The percentage of simulation time during which different residues of
camel hemoglobin interacted with 2,3-BPG. Orange, green, and blue colors represent
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of camel
hemoglobin-2,3-BPG complex at 0mM; (B) Simulations of camel hemoglobin-2,3BPG complex at 150 mM; (C) Simulations of camel hemoglobin-2,3-BPG complex
at 300 mM; and, (D) Simulations of camel hemoglobin-2,3-BPG complex at 600
mM.
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Figure 62: The percentage of simulation time during which different residues of
human hemoglobin interacted with 2,3-BPG. Orange, green, and blue colors
represent charged, hydrophobic and polar amino acids, respectively. (A) Simulations
of human hemoglobin-2,3-BPG complex at 0mM; (B) Simulations of human
hemoglobin-2,3-BPG complex at 150 mM; (C) Simulations of human hemoglobin2,3-BPG complex at 300 mM; and, (D) Simulations of human hemoglobin-2,3-BPG
complex at 600 mM.
6.1.7 MD simulations of camel and human hemoglobin bound to 2,3-BPG at
different temperature conditions
Next, the RMSD of both camel and human hemoglobin-2,3 BPG complexes
at different temperature conditions were determined. The structures of both camel
and human Hb remained stable during simulation runs. The RMSD of the Cα atoms
of camel and human Hb bound to 2,3-BPG with respect to the initial structure
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stabilized under 3.5 Å and 4 Å in all the simulations, respectively (Figures 63A and
63B). However, human hemoglobin bound to 2,3-BPG demonstrated higher RMSD
at 34°C. In order to measure the effect of 2,3-BPG on the backbone stability and
residual flexibility of camel and human hemoglobin, the RMSF of backbone Cα
atoms of both camel and human hemoglobin were investigated (Figures 63C and
63D). Overall, camel hemoglobin showed limited fluctuations compared to human
hemoglobin. The loop residues 41-52 of α1 of camel Hb showed limited fluctuation
at all temperature conditions, compared to human Hb when bound to 2,3-BPG.
Whereas, loop residues 46-52 of α2 subunit of both camel and human showed
similar fluctuations at all conditions, especially at 41°C. Additionally, fluctuations in
human Hb were observed to be higher at 34°C and 41°C, compared to camel Hb
(Figures 63C and 63D). The loop residues 78-87 of α1 subunit in camel Hb showed
higher fluctuations at lower temperature condition (27°C). However such an effect
was not observed in human Hb. The loop residues 44-55 of β1 demonstrated similar
fluctuations in both camel and human hemoglobin. However, these residues of β2
chain showed higher fluctuations at higher temperature conditions (34°C and 41°C)
in human Hb, compared to camel Hb (Figures 63C and 63D). The loop residues 8197 of β1 chain of camel Hb demonstrated more fluctuations at only 34°C, while the
same residues of human Hb showed higher fluctuations at all temperature conditions.
Additionally, the same residues of β2 chain of human Hb exhibited higher
fluctuations at higher temperature conditions when compared to camel Hb. More
importantly, residues 79, 82, 139, 143, and 146 of β1 and β2 subunits of camel Hb
showed limited fluctuations at higher temperature conditions, compared to human
Hb.

Figure 63: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 200 ns
run of 2,3-BPG bound camel and human hemoglobin simulations at different temperature conditions. Data from different temperature conditions
are shown in red, green, blue, and purple. (A) RMSD of camel Hb-2,3-BPG complex simulations; (B) RMSD of camel Hb-2,3-BPG complex
simulations: (C) RMSF of camel Hb-2,3-BPG complex simulations and, (D) RMSF of human Hb-2,3-BPG complex simulations. Note that the
residue number used in the RMSF plots uses a sequential combination of the α1, β1, α2, and β2 in the PDB structure.
178

179
The contact duration of important interacting residues of camel and human
Hb with 2,3-BPG at different temperature conditions were also determined. Asp79 of
both β1 of β2 subunits of camel Hb exhibited intermittent interactions at different
temperature conditions (Figure 64). However, such interactions were not observed in
human Hb. Lys82 of both β chains of human and camel Hb formed sustained
interactions for the full duration of the simulations at all temperature conditions
(Figures 64 and 65). Moreover, Asn139 of both β chains of human Hb exhibited
intermittent interactions with 2,3-BPG, especially at lower temperature conditions.
However, camel hemoglobin did not produce such interactions in any simulation run.
The residues His143, His146 of β1 and β2 of camel hemoglobin formed more
sustained interactions with 2,3-BPG at higher salt concentrations, compared to
human hemoglobin. However, such interactions were not observed in human Hb.
Additionally, Asn80 of camel β2 subunit showed more sustained interactions at 300
mM, and 600 mM, while, the same residue of β1 of human Hb showed interactions
with 2,3-BPG at 0 mM and 150 mM only.The contact duration of important
interacting residues of camel and human Hb with 2,3-BPG at different temperature
conditions were also determined. Asp79 of both β1 of β2 subunits of camel Hb
exhibited intermittent interactions at different temperature conditions. However, such
interactions were not observed in human Hb. Lys82 of both β chains of human and
camel Hb formed sustained interactions for the full duration of the simulations at all
temperature conditions. Moreover, Asn139 of both β chains of human Hb exhibited
intermittent interactions with 2,3-BPG, especially at lower temperature conditions.
However, camel hemoglobin did not produce such interactions in any simulation run.
The residues His143, His146 of β1 and β2 of camel hemoglobin formed more
sustained interactions with 2,3-BPG at higher salt concentrations, compared to
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human hemoglobin. However, such interactions were not observed in human Hb.
Additionally, Asn80 of camel β2 subunit showed more sustained interactions at 300
mM, and 600 mM, while, the same residue of β1 of human Hb showed interactions
with 2,3-BPG at 0 mM and 150 mM only (Figures 64 and 65).

Figure 64: The percentage of simulation time during which different residues of
camel hemoglobin interacted with 2,3-BPG. Orange, green, and blue colors represent
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of camel
hemoglobin-2,3-BPG complex at 27°C; (B) Simulations of camel hemoglobin-2,3BPG complex at 30°C ; (C) Simulations of camel hemoglobin-2,3-BPG complex at
34°C; and, (D) Simulations of camel hemoglobin-2,3-BPG complex at 41°C.
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Figure 65: The percentage of simulation time during which different residues of
human hemoglobin interacted with 2,3-BPG. Orange, green, and blue colors
represent charged, hydrophobic and polar amino acids, respectively. Orange, green,
and blue colors represent charged, hydrophobic and polar amino acids, respectively.
(A) Simulations of human hemoglobin-2,3-BPG complex at 27°C; (B) Simulations
of human hemoglobin-2,3-BPG complex at 30°C ; (C) Simulations of human
hemoglobin-2,3-BPG complex at 34°C; and, (D) Simulations of human hemoglobin2,3-BPG complex at 41°C.
6.1.8 MD simulations of ATP bound to camel and human hemoglobin at
different salt conditions
ATP is another important co-factor present in erythrocytes and is also
involved in binding with deoxyhemoglobin. However, its levels in erythrocytes are
significantly lower compared to 2,3-BPG. Camel and human hemoglobin bound to
ATP were simulated at different salt concentration. RMSD of Cα atoms of camel
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hemoglobin with respect to initial structure showed stability at 2.5 Å in all salt
concentrations except 150 mM (Figure 66A). Camel Hb-ATP complex systems were
observed more stabilized with lower RMSD at higher salt concentrations (300 mM
and 600 mM) compared to lower salt concentrations (Figure 66A). However, the
structural integrity of human Hb-ATP complex systems at different salt
concentrations were retained with a RMSD of Cα atoms from the initial structure that
was under 3.5 Å (Figure 66B). Moreover, to determine and compare backbone
stability and residual fluctuations of the camel and human Hb-ATP complex at
different salt concentrations, RMSF of backbone Cα atoms were measured and
plotted (Figures 66A and 66B). Overall, camel Hb showed lower fluctuations,
compared to human hemoglobin. Loop residues 45-51 of α1 subunit showed more
variations only at 150 mM, while the same region in human hemoglobin fluctuated
more at 150 mM and 300 mM. The similar residues of α2 subunits of both camel and
human Hb exhibited higher fluctuations at 300 mM and 600 mM (Figure 66). These
residues fluctuated more in camel Hb compared to human Hb. The Loops residues 15, and 16-20 of camel β1 chain exhibited more fluctuations at higher salt
concentrations (300 mM and 600 mM), compared to human Hb. Loop residues 44-55
and 80-100 residues of β1 of human Hb showed higher fluctuations at higher salt
concentrations, while the same residues of camel Hb exhibited more fluctuations at
lower salt concentrations. However, the same residues of β2 of camel and human Hb
showed higher fluctuations at higher and lower salt concentrations, respectively
(Figures 66C and 66D). Interestingly, these regions fluctuated more in human Hb,
compared to camel hemoglobin. Importantly, residues 79, 82, 139, 143, and 146 of
β1 and β2 subunits of camel Hb showed lower fluctuations at higher salt
concentrations, compared to human Hb.

Figure 66: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 200 ns
run of ATP bound camel and human hemoglobin simulations at salt conditions. Data from different salt conditions are shown in red, green and
blue. (A) RMSD of camel Hb-ATP complex; (B) RMSD of human Hb-ATP complex simulations (C) RMSF of camel Hb-ATP complex
simulations and, (D) RMSF of human Hb-ATP complex simulations. Note that the residue number used in the RMSF plots uses a sequential
combination of the α1, β1, α2, and β2 in the PDB structure.
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The contact duration of important interacting residues of camel and human
Hb with ATP were determined. Asp79 of both β1 of β2 subunits of camel Hb
exhibited intermittent interactions at lower salt concentrations (Figure 67). While the
same residue of β1 chain of human Hb formed intermittent interaction at 600 mM
only (Figure 67). Lys82 of both β chains of human and camel Hb formed sustained
interactions for the full duration of the simulations at all salt concentrations.
Moreover, Asn139 of both β chains of human Hb exhibited intermittent interactions
with ATP in all simulation runs. However, such interactions were not observed in
camel Hb. The residue His143 and His146 of β1 and β2 of camel hemoglobin formed
more sustained interactions at 300 mM, with ATP, respectively. However, His143 of
β1 chain in human hemoglobin produced consistent interaction at all salt
concentrations. His146 of camel β1 chain formed more sustained interactions with
ATP at 0 mM and 300 mM. However, such an interaction was not observed in
human Hb. Moreover, Arg144, a substituted residue in camel Hb β1 subunit formed
interactions with ATP at higher salt concentrations. Human Hb did not produce such
an interaction. Additionally, Asn80, and Leu81 of camel β2 subunit showed more
sustained interactions at 300 mM, compared to other salt concentrations. However,
Asn80 residue of β1 of human Hb showed interactions with ATP at 600 mM only
(Figures 67 and 68).
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Figure 67: The percentage of simulation time during which different residues of
camel hemoglobin interacted with ATP. Orange, green, and blue colors represent
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of camel
hemoglobin-ATP complex at 0 mM; (B) Simulations of camel hemoglobin-ATP
complex at 150 mM; (C) Simulations of camel hemoglobin-ATP complex at 300
mM; and, (D) Simulations of camel hemoglobin-ATP complex at 600 mM.
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Figure 68: The percentage of simulation time during which different residues of
human hemoglobin interacted with ATP. Orange, green, and blue colors represent
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of human
hemoglobin-ATP complex at 0 mM; (B) Simulations of human hemoglobin-ATP
complex at 150 mM; (C) Simulations of human hemoglobin-ATP complex at 300
mM; and, (D) Simulations of human hemoglobin-ATP complex at 600 mM.
6.1.9 MD simulations of ATP bound to camel and human hemoglobin at
different temperature conditions
Camel and human hemoglobin bound to ATP were simulated at different
temperature conditions. Camel and human Hb structures remained stable during
simulation runs. The RMSD of Cα atoms of both camel and human hemoglobin with
respect to initial structures showed stability under 3.5 Å in all simulations (Figures
69A, 69B). In order to determine and compare the backbone stability and residual
fluctuations of both camel and human Hb-ATP complexes at different temperature

187
conditions, RMSF of backbone Cα atoms were measured and plotted (Figures 69C
and 69D). Loop residues 12-18 of α1 exhibited more fluctuations in human Hb only,
especially at 30°C and 34°C. Loop residues 48-51 of α1 subunit of camel Hb
showed higher fluctuations at lower temperature condition (27°C), while α1 subunit
residues 44-54 of human Hb showed higher fluctuations at higher temperature
conditions (34°C and 41°C). However, similar residues of α2 subunits of both camel
and human Hb exhibited higher fluctuations at higher temperature conditions
(Figures 69C and 69D). These residues fluctuated more in camel Hb compared to
human Hb. The loop residues 74-94 of both α1 and α2 subunits of human Hb
exhibited more fluctuations at higher temperature conditions when compared to
camel Hb. The loop residues 113-118 of α1 chain of human Hb also demonstrated
higher fluctuations at 30°C and 41°C, compared to camel Hb. The loop residue 1-5
and helical residues 6-13 of β1 chain of camel Hb showed higher fluctuations at
41°C, compared to human Hb. While the loop residues of 1-5 of β2 subunit of only
human Hb exhibited higher fluctuations at 34°C. Loop residues 44-54 and 82-100 of
β1 and β2 of camel Hb showed higher fluctuations at higher temperature conditions
(34°C and 41°C). While in human Hb, the residues 44-54 β1 exhibited more
fluctuations at lower temperature conditions, and 87-100 residues of both β1 and β2
showed higher fluctuations at higher temperature conditions. Moreover, the residues
82-100 of β1 and β2 of camel Hb showed limited fluctuations at higher temperature
conditions, compared to human Hb (Figure 69). Importantly, residues 79, and 82 of
β1 and β2 subunits of camel Hb showed lower fluctuations, compared to human Hb.
However, 139, 143, and 146 of β1 and β2 subunits demonstrated higher fluctuations
in both camel and human Hb (Figures 69C and 69D).

Figure 69: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 200 ns
run of ATP bound camel and human hemoglobin simulations at different temperature conditions. Data from different temperature conditions are
shown in red, green, blue, and purple. (A) RMSD of camel Hb-ATP complex simulations; (B) RMSD of human Hb-ATP complex simulations;
(C) RMSF of camel Hb-ATP complex simulations and, (D) RMSF of human Hb-ATP complex simulations. Note that the residue number used in
the RMSF plots uses a sequential combination of the α1, β1, α2, and β2 in the PDB structure.
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The contact duration of important interacting residues of camel and human
Hb with ATP were determined. Asp79 of both β1 of β2 subunits of camel Hb
exhibited consistent interactions at all temperature conditions (Figure 70). However,
such interactions were not formed in human Hb (Figure 71). Lys82 of both β chains
of human and camel Hb formed sustained interactions throughout the simulations at
all temperature conditions. Asn139 of both β chains of human Hb exhibited
consistent interactions with ATP in all simulation runs. However, Asn139 of camel
Hb showed extremely weak interactions with ATP. The residue His143 of β1 of
human hemoglobin formed more sustained interactions with ATP at 34°C, and the
same residue β2 exhibited intermittent interactions at all temperature conditions,
except at 30°C. However, in camel only β1 chain produced intermittent interaction at
only 34°C and 41°C. His146 of human β chains also formed intermittent interactions
with ATP at only lower temperature conditions. However, such an interaction was
not observed in camel Hb. Moreover, Arg144, a substituted residue in camel Hb β1
subunit formed interactions with ATP at 34°C. Human Hb did not produce such an
interaction (Figures 70 and 71).
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Figure 70: The percentage of simulation time during which different residues of
camel hemoglobin interacted with ATP. Orange, green, and blue colors represent
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of camel
hemoglobin-ATP complex at 27°C; (B) Simulations of camel hemoglobin-ATP
complex at 30°C ; (C) Simulations of camel hemoglobin-ATP complex at 34°C; and,
(D) Simulations of camel hemoglobin-ATP complex at 41°C.
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Figure 71: The percentage of simulation time during which different residues of
human hemoglobin interacted with ATP. Orange, green, and blue colors represent
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of human
hemoglobin-ATP complex at 27°C; (B) Simulations of human hemoglobin-ATP
complex at 30°C ; (C) Simulations of human hemoglobin-ATP complex at 34°C;
and, (D) Simulations of human hemoglobin-ATP complex at 41°C.
6.2 Discussion
This study provide insights into the stability of camel and human hemoglobin
under various dehydrated conditions, as well as the stability of interaction of 2,3BPG and ATP, which are essential for the unloading of oxygen from hemoglobin,
with camel and human hemoglobin using several long MD simulations. Overall,
interestingly, extended MD simulations at different salt and temperature conditions
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revealed that camel hemoglobin structures showed more stability when compared to
human hemoglobin. Additionally, in camel hemoglobin, critical regions important
for the binding of heme, 2,3-BPG, and ATP molecules demonstrated limited
fluctuations in the studied conditions.

Molecular docking and MD simulations

indicated that 2,3-BPG, and ATP molecules, which are abundantly present in
erythrocytes, formed more stable interactions with essential residues with camel
hemoglobin when compared to human hemoglobin.

Generally, mammalian erythrocytes are highly sensitive to osmotic fragility
except camels (Bogner et al., 2005; Schmidt-Nielsen et al., 1956). Importantly,
camels RBCs are extremely resistant to osmotic fragility and are inherently adapted
to endure the sudden fluctuations in blood osmolarity without affecting its function
(Oyewale et al., 2011). In order to measure the changes resulting from different salt
concentrations, MD simulations were performed, since no prior attempt has been
made to look at the residue level fluctuations of this macromolecule. Indeed,
simulations are clearly representative of fluctuations being affected by different salt
concentrations (Figure 57). The natural capability of protein function is highly
dependent on the extent of the innate fluctuations of a macromolecule (Frauenfelder,
Parak, & Young, 1988; Steinbach et al., 1991). Here, simulations in the presence of
different salt concentrations demonstrated fluctuations of the important regions
essential for the oxygen binding (Figure 57). Interestingly, the high fluctuations were
observed in residues near to the heme binding sites in each subunit. The residues in
these regions exhibited high RMSF values than the other residues. Importantly,
His87 of α subunits and His92 of β subunits demonstrated more fluctuations at
higher salt concentrations. These residues are essential for the binding of four heme
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groups and served as oxygen binding sites.

Importantly, conserved residues

α1:Phe43 and α1:Phe46 showed more fluctuations at higher salt conditions (Figure
57). These functional residues are present in the heme pocket distal to heme where
oxygen binds (Laberge & Yonetani, 2008). Moreover, α1 conserved residues Leu86
and Leu91 also exhibited higher fluctuations when salt concentration was increased.
These residues are part of proximal heme pocket residues (Laberge & Yonetani,
2008). Interestingly, in comparison to human hemoglobin, camel hemoglobin
demonstrated lower fluctuations at all salt concentrations. Similarly, when different
temperature conditions were used camel hemoglobin showed lower fluctuations at
higher temperature conditions especially in the regions important for the binding of
heme groups and thus considered as oxygen binding sites, compared to human
hemoglobin (Figure 58). Therefore, these changes could affect the affinity of oxygen
molecule with camel hemoglobin.

2,3-BPG and ATP are two important co-factors present abundantly in the
erythrocytes that bind to hemoglobin (Castilho, Glass, & Manco, 2003). Prior studies
have demonstrated that both these co-factors preferentially bind to deoxyhemoglobin
(Chen et al., 2017; Chu et al., 2008). Additionally, their binding with
deoxyhemoglobin is responsible for stabilizing the deoxyhemoglobin or tense (T)
state of the hemoglobin. Generally, oxygen is unloaded from hemoglobin to tissue
cells during the deoxyhemoglobin state. Therefore, these two co-factors have
significant role in the unloading of oxygen molecules and also in the regulation of
transition from oxyhemoglobin (relaxed state) to deoxyhemoglobin (tensed state).
During the transition from deoxyhemoglobin to oxyhemoglobin, the binding pocket
present in the center of hemoglobin or more precisely at the entrance of the β1/β2
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cavity, is disrupted and therefore not available for these co-factors to bind in
oxyhemoglobin state (Berg et al., 2002). Thus, only deoxyhemoglobin or tensed state
of Hb was selected for the molecular docking and MD simulations of 2,3-BPG and
ATP with camel and human Hb. The molecular docking of 2,3-BPG and ATP
identified the active site residues of Hb and were situated at the entrance of β1/β2
cavity. These findings are in agreement with previous studies (Arnone, 1972; Chen et
al., 2017). Importantly, both 2,3-BPG and ATP share the same binding site on Hb. In
comparison to ATP, 2,3-BPG is the more abundant co-factor present in erythrocytes
of most mammals present at a concentration 4-13 mmol/l. While, observed ATP
concentration in the mammal’s RBCs is 1.3 mmol/l. Additionally, ATP is mostly
present as ATP-Mg2+ in the erythrocytes, which binds weakly to hemoglobin. Thus,
this suggests that ATP has minimal effect on oxygen affinity, while 2,3-BPG
predominantly binds with deoxyhemoglobin and play a major role in the regulation
of oxygen affinity and unloading of oxygen to tissue cells. Importantly, the levels
and precise functions of these co-factors in the erythrocytes of camel have not been
reported so far. Therefore, extensive computational modeling approaches were used
to determine the binding mode, and stability of critical interactions between camel
deoxyhemoglobin and 2,3-BPG or ATP. Several stresses such as different salt
concentrations and different temperature conditions were used to determine the
impact of these conditions on the binding stability of 2,3-BPG and ATP with camel
Hb. Additionally, these results were compared with human Hb. Previous studies have
reported that Lys82 and His143 residues of both β subunits are highly essential for
the binding of 2,3-BPG and ATP with deoxyhemoglobin subunit. However, Asp79,
Asn139 and His146 residues are also considered vital for the binding of these cofactors. However, 2,3-BPG produced interactions with only β1 chain residues of
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human Hb and were in agreement with prior studies (Chen et al., 2017).
Additionally, ATP formed similar interactions with human Hb, except His143 of β2,
and His146 of both β subunits. MD simulations indicated that 2,3-BPG formed more
sustained interactions with essential residues Lys82, His143, and His146 of camel
hemoglobin at higher salt concentrations (Figure 61). However, 2,3-BPG only
maintained interactions with His143 at lower salt concentrations and with Lys82 of
human Hb at all salt concentrations (Figure 62). This indicate that at higher osmotic
pressure induced by increased concentrations of NaCl, camel Hb formed stronger
interactions with 2,3-BPG and support the release of oxygen to tissue cells. The
effect of different temperature conditions on the binding stability of 2,3-BPG with
camel and human Hb indicated that 2,3-BPG maintained intermittent interactions
with critical residues of both camel and human Hb at lower temperatures (Figures 64
and 65). These findings are in agreement with previous studies which mentioned that
lower temperature favored the binding of 2,3-BPG with Hb (Benesch, Benesch, &
Yu, 1969). Human Hb residues (Asn139, His143) also showed more consistent
interactions at lower temperature conditions, compared to camel. However, Lys82
formed sustained interactions with both camel and human Hb at all temperature
conditions. Importantly, Asp79, Asn80 residues of camel Hb exhibited more
consistent interactions with 2,3-BPG even at higher temperature conditions,
compared to human Hb (Figures 64 and 65).

The binding stability of ATP with camel and human Hb residues at different
temperature and salt conditions exhibited similar results. ATP formed more sustained
interactions with Asp79, Asn80, His143, and His146 residues of camel Hb at higher
salt concentrations, compared to human Hb (Figures 70 and 71). Lys82 of both camel
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and human Hb exhibited consistent interactions throughout the simulations at all salt
concentrations (Figure 70). However, the binding stability of camel residues His143,
and His146 with ATP were weaker when compared to 2,3-BPG at higher salt
concentrations. However, at different temperature conditions, human Hb residues
His143, and His146 produced more consistent interactions with ATP, especially at
lower temperature conditions, compared to camel Hb (Figures 70 and 71). While,
Asp79, Asn80, and Arg144 of camel Hb showed more consistent interactions with
ATP at higher temperature conditions, compared to human Hb (Figures 70 and 71).
Hb Lys82 residue formed interactions with ATP for the full duration of simulation
time at all temperature conditions in both camel and human.

The findings of this study are of significant importance in understanding the
behaviour of camel hemoglobin under different dehydrated conditions, particularly
the involvement of erythrocytes co-factors during dehydrated conditions. Indeed,
hemoglobin is the most well studied protein both genetically, and biochemically
(Oyewale et al., 2011). However, from structural prospective, the behavior of
hemoglobin under different stresses have not been greatly explored. This study
provided useful insights into the interactions of 2,3-BPG and ATP with camel and
human Hb with implications in the physiology of these mammals under dehydrated
conditions. Interestingly, camels can fluctuate their body temperature from
approximately 34°C to 40°C during daytime (Oyewale et al., 2011; Schmidt-Nielsen
et al., 1956). Moreover, camels have an exceptional ability to live without drinking
water for longer period of time. These two conditions in combination produces a
severe dehydrated environment in camels. Other mammals cannot withstand such
drastic conditions any significant period of time. More importantly, severe
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dehydration and high temperature conditions are significantly associated with
increased respiratory rate in mammals (Barcroft & Izquierdo, 1931; Gaalaas, 1945;
Rubini & Bosco, 2013). Higher temperature conditions decrease the overall binding
affinity of oxygen molecules with hemoglobin and is also involved in an increased
production of 2,3-BPG as a result of hyperventilation. These phenomena support
more unloading of oxygen into tissues to meet their oxygen demand during high
temperature and hyperventilation. It is also important to mention that these effects
are due to Bohr effect (Yonetani et al., 2002). It states that hemoglobin’s lower
affinity for oxygen is associated with an increase in partial pressure of carbon
dioxide and a decrease in blood pH. For instance, higher temperature, and
hyperventilation enhances the metabolic activities within tissues lead in the
generation of more carbon dioxide. As a result of high CO2, more hydrogen ion (H+)
will be produced which ultimately lead to lower pH and the production of more 2,3BPG.

These effects ultimately reduce the affinity of hemoglobin for oxygen.

However, hyperventilation for longer period of time or chronic hyperventilation
blocks the potential of Bohr effects and increases the hemoglobin binding affinity for
oxygen with lesser release to peripheral tissues, including important organs such as
brain, liver, kidney, and heart (Benner, Patel, Singh, & Dua, 2020). Importantly,
more stable interactions of 2,3-BPG especially with camel hemoglobin at higher
dehydrated conditions support these arguments and are vital to fulfill the oxygen
demands of the peripheral tissues. This could be the reason why a camel’s vital
organs and peripheral tissues remain functional for longer period of time during
severe environmental conditions.
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Chapter 7: Conclusion
This study looked at a number of aspects related to structural, genetic and
pharmacological properties of camel hemoglobin and hemoglobin-derived peptides.
First, the work presented here provides structural insights into the binding of camel
and human hemorphins with MOR, IRAP and ACE. Importantly, camel hemorphins
demonstrated more stable interactions with these drug targets and also produced
more potent ACE inhibitory activity, compared to human hemorphins. This study
also identified, for the first time, a G protein-coupled receptor, angiotensin II type 1
receptor (AT1R) that is a target of hemorphins. In silico and in vitro data indicated
that LVV-hemorphin-7 binds to the intracellular side of AT1R and allosterically
potentiated the potency of AngII as well as its downstream signaling. Additionally,
this study explored the genetic and structural variations of camel hemoglobin and
how these variations could contribute to the overall stability and residue-level
flexibility in camel hemoglobin in response to dehydrated conditions when compared
to human hemoglobin. The study helped in determining the stability of crucial
residues important for the binding of co-factors like heme, 2,3-BPG and ATP.
Several critical residues of camel hemoglobin α and  subunits exhibited fluctuations
that were notably different when compared to humans. This study also showed that
camel hemoglobin exhibited more stability in severe dehydrated conditions when
compared to human hemoglobin. Additionally, in silico data indicated a more stable
binding of 2,3-BPG and ATP with  subunits of camel hemoglobin when compared
to human hemoglobin when severe dehydrated conditions were used. These results
illustrate that under extreme dehydrated conditions, especially with high salt
concentrations, 2,3-BPG could bind more strongly to camel hemoglobin and help
with the unloading of oxygen in peripheral tissues.
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Chapter 8: Future Prospects
The synthesis, metabolism and therapeutic potential of hemoglobin-derived peptides
(hemorphins) continue to be both fascinating and challenging. The tissue-specific
release and its ability to bind diverse targets are yet to be clearly elucidated.
Hemorphins have been studied for the last three or four decades. Even though
hemorphins are endogenous peptides with several therapeutic and pharmacological
activities, astonishingly, these peptides have not been actively explored in the last
decade. Moreover, a huge gap still exists between in vitro and in vivo data using
human subjects and animal models and mechanistic basis at the cellular and
molecular level. Indeed, different aspects of hemoglobin-derived peptides discussed
in this study clearly demonstrate the direct pharmacological and biological action of
hemorphins on key receptors and enzymes. However, a big gap still exists in our
understanding of the precise mode of action and the specific binding sites on the
targets. Future studies should aim specifically toward dissecting the cellular and
molecular pathways and to investigate the critical residues of hemorphins that
interact with a target. Additionally, in depth structure activity relationship and
binding assays involving hemorphins and putative targets should be considered using
both in vitro and in silico studies. A lot is known about hemorphins. However, the
story is still enormously incomplete and further studies are needed to understand and
to unlock the true potential of hemoglobin derived peptides for therapeutic and
diagnostic purposes.
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